

2021

INTERIM REPORT

中報

蒼生為念
厚德載醫



廣東康華醫療股份有限公司
Guangdong Kanghua Healthcare Co., Ltd.*

(於中華人民共和國註冊成立的股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)

股份代號 Stock Code : 3689

*僅供識別 For identification purposes only

Contents

目錄

- 2 Corporate Information
公司資料
- 4 Financial Highlights
財務概覽
- 6 Management Discussion and Analysis
管理層討論及分析
- 45 Corporate Governance Highlights
企業管治概覽
- 47 Other Information
其他資料
- 55 Report on Review of Condensed Consolidated
Financial Statements
簡明綜合財務報表之審閱報告
- 57 Condensed Consolidated Statement of Profit or
Loss and Other Comprehensive Income
簡明綜合損益及其他全面收益表
- 58 Condensed Consolidated Statement of Financial Position
簡明綜合財務狀況表
- 60 Condensed Consolidated Statement of Changes in Equity
簡明綜合權益變動表
- 61 Condensed Consolidated Statement of Cash Flows
簡明綜合現金流量表
- 62 Notes to the Condensed Consolidated Financial Statements
簡明綜合財務報表附註
- 84 Definitions
釋義



Corporate Information

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. Wang Junyang (*Chairman*)
Mr. Chen Wangzhi (*Chief Executive Officer*)
Mr. Wong Wai Hung Simon (*Vice Chairman*)
Ms. Wang Ai Qin

Non-executive Director

Mr. Lv Yubo

Independent Non-executive Directors

Mr. Yeung Ming Lai
Dr. Chen Keji
Mr. Chan Sing Nun

Audit Committee

Mr. Chan Sing Nun (*Chairman*)
Dr. Chen Keji
Mr. Yeung Ming Lai

Remuneration Committee

Mr. Chan Sing Nun (*Chairman*)
Ms. Wang Ai Qin
Mr. Yeung Ming Lai

Nomination Committee

Mr. Wang Junyang (*Chairman*)
Dr. Chen Keji
Mr. Yeung Ming Lai

SUPERVISORY COMMITTEE

Mr. Chen Shaoming (*Chairman*)
Mr. Wang Shaofeng
Mr. Yue Chunyang

JOINT COMPANY SECRETARIES

Mr. Wong Wai Hang Ricky
Ms. Chau Hing Ling

SECRETARY TO THE BOARD

Ms. Wang Yingda

董事會

執行董事

王君揚先生 (*主席*)
陳旺枝先生 (*行政總裁*)
王偉雄先生 (*副主席*)
王愛勤女士

非執行董事

呂玉波先生

獨立非執行董事

楊銘澧先生
陳可冀醫生
陳星能先生

審核委員會

陳星能先生 (*主席*)
陳可冀醫生
楊銘澧先生

薪酬委員會

陳星能先生 (*主席*)
王愛勤女士
楊銘澧先生

提名委員會

王君揚先生 (*主席*)
陳可冀醫生
楊銘澧先生

監事會

陳少明先生 (*主席*)
王少鋒先生
岳春陽先生

聯席公司秘書

黃偉恒先生
周慶齡女士

董事會秘書

王櫻達女士



AUTHORISED REPRESENTATIVES

Mr. Wong Wai Hung Simon
Mr. Wong Wai Hang Ricky

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditors

LEGAL ADVISERS AS TO HONG KONG LAWS

Allen & Overy

LEGAL ADVISERS AS TO PRC LAWS

Commerce & Finance Law Offices

REGISTERED OFFICE

3/F, Outpatient Zone One
Dongguan Kanghua Hospital
Nancheng Street Road
Dongguan
Guangdong Province
PRC

HEAD OFFICE IN THE PRC

1000 Dongguan Avenue
Dongguan
Guangdong Province
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 3207, Metroplaza Tower 2
223 Hing Fong Road
Kwai Fong, New Territories
Hong Kong

H SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712–1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

STOCK CODE

3689

COMPANY'S WEBSITE

<http://www.kanghuagp.com>

授權代表

王偉雄先生
黃偉恒先生

核數師

德勤•關黃陳方會計師行
註冊公眾利益實體核數師

香港法律顧問

安理國際律師事務所

中國法律顧問

通商律師事務所

註冊辦事處

中國
廣東省
東莞市
南城街道
東莞康華醫院
門診一區3樓

中國總部

中國
廣東省
東莞市
東莞大道1000號

香港主要營業地點

香港
新界葵芳
興芳路223號
新都會廣場第二座3207室

H股證券登記處

香港中央證券登記有限公司
香港
灣仔
皇后大道東183號
合和中心
17樓1712–1716號舖

股份代號

3689

公司網站

<http://www.kanghuagp.com>

Financial Highlights

財務概覽

KEY FINANCIAL PERFORMANCE 主要財務表現

		For the six months ended 30 June 截至六月三十日止六個月		
			2021 二零二一年	2020 二零二零年
		PoP Change 按期變動	RMB'000 人民幣千元	RMB'000 人民幣千元
Revenue	收益	+14.5%	871,485	760,987
Gross profit	毛利	+77.4%	129,845	73,174
Gross profit margin	毛利率		14.9%	9.6%
Profit (loss) before taxation	除稅前溢利(虧損)	+128.8%	35,843	(124,446)
Profit (loss) for the period	期內溢利(虧損)	+111.7%	14,799	(126,219)
Profit (loss) for the period attributable to owners of the Company	本公司擁有人應佔期內溢利(虧損)	+129.0%	30,875	(106,324)
Adjusted EBITDA [#]	經調整EBITDA [#]	+283.9%	111,097	28,936
Earnings (loss) per share – basic (RMB cents)	每股盈利(虧損) – 基本 (人民幣分)	+128.9%	9.2	(31.8)

[#] Adjusted EBITDA is earnings before accounting for bank and other interest income, interest expenses, taxes, depreciation and amortisation, fair value gain (loss) and investment income from financial assets at FVTPL, net exchange gain (loss) and impairment loss on goodwill.

[#] 經調整EBITDA為除銀行及其他利息收入、利息支出、稅項、折舊及攤銷、公平值收益(虧損)及按公平值計入損益的金融資產投資收入、匯兌收益(虧損)淨額及商譽減值虧損前的盈利。



PATIENT VISITS

病人人次

Thousand Visits 千人次


No. of inpatient

住院人次



No. of outpatient

門診人次




No. of physical examination

體檢人次



REVENUE PROPORTION BY MAJOR HEALTHCARE DISCIPLINES*

主要科室收益佔比*




REVENUE PoP OF MAJOR HEALTHCARE DISCIPLINES*

主要科室期內收益同比*

RMB'000 人民幣千元

2021 | 2020



* The amount does not include revenue from rehabilitation and other healthcare services, sale of pharmaceutical products and elderly healthcare services.

* 該金額不包括提供康復及其他醫療服務、銷售藥品及老年醫療服務。

Management Discussion and Analysis

管理層討論及分析

BUSINESS REVIEW AND OUTLOOK

Business Overview for the six months ended 30 June 2021

In the first half of 2021, the novel coronavirus disease 2019 ("COVID-19") pandemic continued. However, with vaccination programs rolled out across the PRC and the continuous implementation of pandemic prevention policies in many parts of the country, the PRC economy, in particular, the healthcare market and hospital operation sector, demonstrated signs of stabilisation and gradually recovered from the effects of the pandemic. The PRC economy, especially in the Guangdong Province, generally maintained stable with positive favourable momentum due to the outstanding performance in the COVID-19 pandemic control and prevention, and healthcare market recovery has been driven by government support and the effective implementation of in-depth reform carried forward from year 2020.



In the first half of 2021, the Group's consolidated revenue amounted to RMB871.5 million (six months ended 30 June 2020: RMB761.0 million), representing a period-on-period increase of 14.5%, mainly attributable to the increase in revenue from our hospital services segment and an increase in the overall patient visits of our owned-hospital operations. The Group's owned-hospitals (making up our hospital services segment), namely Kanghua Hospital, Renkang Hospital have both recorded increases in revenue of 9.7% and 45.8%, respectively. However, our Kangxin Hospital, continued to be dampened by the effects from prior year and its revenue recorded a mild decline of 1.7% as compared with the first half of year 2020.

業務回顧和展望

截至二零二一年六月三十日止六個月的業務概覽

二零二一年上半年，二零一九年新型冠狀病毒病（「COVID-19」）疫情仍在繼續。然而，隨著疫苗接種計劃在中國全面展開，以及全國多地疫情防控政策的持續實施，中國經濟，尤其是醫療市場及醫院運營部門出現企穩跡象，並逐漸從疫情的影響中恢復過來。中國經濟，特別是廣東省，由於在 COVID-19 疫情防控工作中表現突出，總體保持穩定及向好勢頭，自二零二零年開始，在政府的支持和深入改革的有效實施推動下，醫療市場得益復甦。



於二零二一年上半年，本集團的綜合收入為人民幣 871.5 百萬元（截至二零二零年六月三十日止六個月：人民幣 761.0 百萬元），同比增長 14.5%，主要由於我們的醫院服務部門的收入增加，以及我們自有醫院運營的患者整體就診次數增加。本集團擁有的醫院（構成我們的醫院服務部門），即康華醫院、仁康醫院均錄得收益分別增加 9.7% 及 45.8%。然而，我們的康心醫院繼續受到前一年的影響，其收入較二零二零年上半年溫和下降 1.7%。



Management Discussion and Analysis

管理層討論及分析

Our rehabilitation and other related healthcare services segment, through our ownership of 57% equity interest in Anhui Hualin (Anhui Hualin directly and indirectly (through its wholly-owned subsidiary) holds sponsor interests in the managed and controlled entities, all of which are private non-enterprise entities in Anhui Province, the PRC), has recorded a revenue of RMB44.2 million for the Reporting Period (six months ended 30 June 2020: RMB31.5 million), representing a period-on-period increase of 40.7%, primarily due to recovery from the pandemic, and in particular, the strong growth in revenue from our children rehabilitation and other healthcare services.

The Group's consolidated profit for the six months ended 30 June 2021 amounted to RMB14.8 million (six months ended 30 June 2020: consolidated loss of RMB126.2 million). The turnaround from loss in the corresponding period last year to profit for the Reporting Period is mainly attributable to: (i) the increase in revenue and profit recorded at Kanghua Hospital and Renkang Hospital primarily as a result of the increase in the number of patient visits across all its service offerings. Our revenue from hospital services segment recorded an increase in revenue of 13.8% from RMB721.6 million for the first half of year 2020 to RMB821.3 million for the Reporting Period; (ii) no further impairment loss on goodwill in respect of the cash generating unit of Kangxin Hospital ("Kangxin Hospital CGU") and Anhui Hualin ("Anhui Hualin CGU") for the Reporting Period (six months ended 30 June 2020: the Group recognised an impairment loss on goodwill in respect of the Kangxin Hospital CGU and Anhui Hualin CGU in aggregate of RMB76.0 million), and (iii) however, our performance has continued to be affected by the significant loss incurred at Kangxin Hospital (which commenced operation in March 2017 and was acquired by the Group in August 2018), in the current interim period, Kangxin Hospital recorded a decline in revenue of 1.7% as compared with the prior interim period, primarily due to the residual impact of the COVID-19 pandemic from year 2020 and other ongoing challenges including huge burden on professional headcounts, overhead expenditure and fixed costs.

於報告期，我們的康復及其他相關醫療服務分部通過我們擁有安徽樺霖57%的股權（其直接及間接（透過其全資附屬公司）持有受管理及控制實體的舉辦者權益（均為中國安徽省的民辦非企業單位）），已錄得收益人民幣44.2百萬元（截至二零二零年六月三十日止六個月：人民幣31.5百萬元），同比增長40.7%，乃主要由於在經歷疫情後的復甦，特別是來自兒童康復及其他醫療服務的收益強勁增長。

本集團截至二零二一年六月三十日止六個月的綜合溢利為人民幣14.8百萬元（截至二零二零年六月三十日止六個月：綜合虧損人民幣126.2百萬元）。去年同期虧損轉為報告期的溢利乃主要由於：(i)康華醫院及仁康醫院的收益及溢利增長，主要因為其所有服務項目的患者就診次數增加。我們來自醫院服務部門的收益由二零二零年上半年的人民幣721.6百萬元增加13.8%至報告期的人民幣821.3百萬元；(ii)報告期內康心醫院的現金產生單位（「康心醫院現金產生單位」）及安徽樺霖的現金產生單位（「安徽樺霖現金產生單位」）的商譽無進一步減值虧損（截至二零二零年六月三十日止六個月：本集團就康心醫院現金產生單位及安徽樺霖現金產生單位確認商譽減值虧損合共人民幣76.0百萬元）；及(iii)然而，我們的業績繼續受到康心醫院（於二零一七年三月開始營運，而於二零一八年八月被本集團收購）所產生重大虧損的影響，於本中期期間，康心醫院的收益較上個中期期間減少1.7%，主要乃由於受二零二零年COVID-19疫情的後續影響以及其他一系列持續的挑戰，包括專業人員人數、間接費用及固定成本的巨大負擔。

Management Discussion and Analysis

管理層討論及分析

The Group's Adjusted EBITDA (Adjusted EBITDA is earnings before accounting for bank and other interest income, finance costs, taxes, depreciation and amortisation, fair value gain (loss) and investment income from financial assets at FVTPL, net exchange gain (loss) and impairment loss on goodwill) has recorded a period-on-period increase of 284.4% to RMB111.1 million (six months ended 30 June 2020: RMB28.9 million), which demonstrated that the Group's core operation rebounded solidly from prior interim period and remained profitable, after eliminating the effects of financing, investment-related income, effects of exchange rates, capital expenditures and extraordinary non-cash related losses.

Hospital Services

The Group's owned hospitals, namely, Kanghua Hospital, Renkang Hospital and Kangxin Hospital, represent our Group's hospital services segment. During the Reporting Period, the Group sees a solid recovery from effects of COVID-19 outbreak in year 2020, with our key operating performance indicators as follows: (i) the total number of inpatient visits increased to 31,308 (for six months ended 30 June 2020: 26,030), representing a period-on-period increase of 20.3%; (ii) the overall average spending per inpatient visit amounted to RMB15,567.7 (six months ended 30 June 2020: RMB17,977.6), representing a period-on-period decrease of 13.4% (however, representing an increase of 4.6% from RMB14,883.7 for the six months ended 30 June 2019); (iii) the overall bed utilisation rate increased to 69.1% (six months ended 30 June 2020: 60.8%), mainly affected by the low bed utilisation at Kangxin Hospital; (iv) the average length of stay remained relatively stable at 7.2 days (six months ended 30 June 2020: 7.6 days); (v) the total number of outpatient visits increased to 698,486 (six months ended 30 June 2020: 566,568), representing a period-on-period increase of 23.3%; (vi) the overall average spending per outpatient amounted to RMB403.2 (six months ended 30 June 2020: RMB399.7), representing a period-on-period increase of 0.9%; and (vii) the total number of surgical operations increased to 19,416 (six months ended 30 June 2020: 17,991), representing a period-on-period increase of 8.0%.

本集團的經調整EBITDA（經調整EBITDA為除銀行及其他利息收入、融資成本、稅項、折舊及攤銷、公平值收益（虧損）及按公平值計入損益的金融資產投資收入、匯兌收益（虧損）淨額及商譽減值虧損前的盈利）同比增長284.4%至人民幣111.1百萬元（截至二零二零年六月三十日止六個月：人民幣28.9百萬元），表明本集團的核心業務於撇除融資、投資相關收入、匯率影響、資本支出及重大非現金相關虧損後，從上一中期間強勁反彈並保持盈利。

醫院服務

本集團擁有的醫院（即康華醫院、仁康醫院及康心醫院）代表本集團的醫院服務部門。於報告期內，本集團認為二零二零年COVID-19疫情的影響將穩步復甦，我們的主要運營績效指標如下：(i) 住院人次總數增加至31,308名（截至二零二零年六月三十日止六個月：26,030名），同比增長20.3%；(ii) 每名住院病人的整體平均支出為人民幣15,567.7元（截至二零二零年六月三十日止六個月：人民幣17,977.6元），同比下降13.4%（然而，相當於較截至二零一九年六月三十日止六個月的人民幣14,883.7元增加4.6%）；(iii) 主要因康心醫院病床利用率低導致病床的整體利用率增加至69.1%（截至二零二零年六月三十日止六個月：60.8%）；(iv) 平均住院時間相對穩定於7.2天（截至二零二零年六月三十日止六個月：7.6天）；(v) 門診人次總數增加至698,486名（截至二零二零年六月三十日止六個月：566,568名），同比增長23.3%；(vi) 每名門診病人的整體平均支出為人民幣403.2元（截至二零二零年六月三十日止六個月：人民幣399.7元），同比增長0.9%；及(vii) 外科手術總數增加至19,416宗（截至二零二零年六月三十日止六個月：17,991宗），同比增長8.0%。



Management Discussion and Analysis

管理層討論及分析

The table below sets forth certain key operational data of the Group's owned hospitals of our hospital services segment for the periods indicated:

下表載列本集團擁有的醫院服務分部的醫院於所示期間的若干主要營運數據：

		For the six months ended 30 June 截至六月三十日止六個月		
		Change 變動	2021 二零二一年	2020 二零二零年
Inpatient healthcare services	住院醫療服務			
Inpatient visits	住院人次	+20.3%	31,308	26,030
Average length of stay (days)	平均住院日數(天)	-0.4	7.2	7.6
Average spending per visit (RMB)	每人次平均開支(人民幣元)	-13.4%	15,567.7	17,977.6
Outpatient healthcare services	門診醫療服務			
Outpatient visits	門診人次	+23.3%	698,486	566,568
Average spending per visit (RMB)	每人次平均開支(人民幣元)	+0.9%	403.2	399.7
Physical examination services	體檢服務			
Physical examination visits	體檢人次	+26.0%	56,726	45,035
Average spending per visit (RMB)	每人次平均開支(人民幣元)	+52.9%	922.3	603.1

Kanghua Hospital

In the first half of 2021, Kanghua Hospital continued to (i) strengthen media linkage and improve the quality of publicity; (ii) recruit talents and retain talents through performance management reform; and (iii) tighten cost control and deepen quality services. During the first half of the year, Kanghua Hospital strengthened its linkage with more media to increase the positive exposure rate of Kanghua Hospital and improve the quality of publicity. In February 2021, Kanghua Hospital was awarded the "Five-star" Party Organisation in Dongguan City. In May 2021, it was awarded the Dongguan City Excellent League (General) Branch, and Kanghua Hospital was the only medical service provider awarded in the evaluation. In July 2021, Kanghua Hospital was rated as a demonstration site for the "Four Haves" project of party building in private hospitals in Guangdong Province. Of the seven hospitals in Dongguan, Kanghua Hospital was one of the three private hospitals being awarded this rating. In order to fully respond to the normalisation of the pandemic, Kanghua Hospital has strengthened the storage and response capabilities of various epidemic prevention materials. At the same time, the hospital has actively followed up the centralised procurement work of the national and provincial platforms to reduce the proportion of pharmaceutical and the proportion of consumable consumption. In the first half of the year, Kanghua Hospital and the Social Health Centre strengthened cooperation in many aspects. For example, the newly added endocrinology department provided expert outpatient clinics in Nancheng Social Health Centre, and the cardiovascular centre visited Dongkeng Social Health Centre for strengthening cooperation and exchanges of skills. At present, Kanghua Hospital will increase the attraction of talents, deepen the medical discipline construction, in order to meet the needs of the core talents of our hospital's Fourth-Five Plan, and vigorously promote and assist the hospital's performance reform and further retain talents.

康華醫院

二零二一年上半年，康華醫院繼續(i)加強媒體聯動，提升宣傳品質；(ii)招才引才，績效改革留用人才；及(iii)持續成本管控，深化優質服務。上半年，康華醫院與更多媒體加強聯動，增加康華醫院的正面曝光率，提升宣傳品質。二零二一年二月，康華醫院獲評東莞市「五星級」黨組織，二零二一年五月，獲評東莞市優秀團(總)支部，全市僅康華醫院唯一一家醫療單位獲此評。二零二一年七月，獲評廣東省民營醫院黨建「四有」工程示範點。在東莞市七家醫院中，康華醫院是獲得該評級的三家民營醫院之一。為全力應對疫情常態化工作，康華醫院已加強各項防疫物資的儲備及應對能力。同時，醫院積極跟進國家及省平台的集採工作，降低醫院藥佔比和耗佔比。上半年，康華醫院與社衛中心加強多方面合作，如新增內分泌科在南城社衛出專家門診，及心血管中心在東坑社衛出診，以加強合作及技能交流。現時，康華醫院將加大人才引進力度，深化醫學學科建設，滿足醫院四五計劃的核心人才需求，大力推進和協助醫院績效改革，進一步留用人才。

Management Discussion and Analysis

管理層討論及分析

During the Reporting Period, Kanghua Hospital has recorded revenue of RMB672.2 million (six months ended 30 June 2020: RMB613.0 million), representing a period-on-period increase of 9.7%. Up to 30 June 2021, Kanghua Hospital has outpatient visits of 512,460 with an increase of 18.9% as compared with the corresponding period last year and inpatient visits of 24,191 with an increase of 16.0% as compared with the corresponding period last year.

Renkang Hospital

In the first half of 2021, in accordance with the unified deployment of the Health Bureau of Dongguan City and Houjie Town, Renkang Hospital has actively carried out normalised prevention and control of COVID-19 and the business operation and performance of the hospital have steadily improved. Renkang Hospital has also launched business skills competitions to improve the quality of the medical care it provides. In 2021, the Department of Medical Education and the Department of Nursing jointly launched cardiopulmonary resuscitation, tracheal intubation and medical record writing competitions at Renkang Hospital to improve the technical standards of the medical staff. At the same time, Renkang Hospital strengthened its in-depth cooperation with Kanghua Hospital. In order to transfer the strength of Kanghua Hospital's medical technology and assist Renkang Hospital in developing steadily in the medical standards of various disciplines, Kanghua Hospital dispatched experts for outpatient visits, surgical guidance and business operations, discussions about thorny cases, and gradually strengthened the establishment of a unified management model. In addition, Renkang Hospital has made preliminary progress in the Class II grading evaluation work, and carried out counselling and training work for second-level general hospitals. At present, Renkang Hospital has established a work leadership group to clarify the division of labour and strive to obtain the evaluation qualification.

During the Reporting Period, Renkang Hospital has recorded revenue of RMB130.1 million (six months ended 30 June 2020: RMB89.2 million), representing a period-on-period increase of 45.8%. Up to 30 June 2021, Renkang Hospital has outpatient visits of 175,782 with an increase of 37.1% as compared with the corresponding period last year and inpatient visits of 6,285 with an increase of 39.7% as compared with the corresponding period last year.

於報告期內，康華醫院錄得收益人民幣672.2百萬元（截至二零二零年六月三十日止六個月：人民幣613.0百萬元），同比增長9.7%。截至二零二一年六月三十日，康華醫院門診人次為512,460次，較去年同期增加18.9%；住院人次為24,191次，較去年同期增加16.0%。

仁康醫院

二零二一年上半年，仁康醫院按照東莞市和厚街鎮衛健局的統一部署，積極做好COVID-19疫情常態化防控工作，醫院經濟效益和社會效益穩步提高。仁康醫院亦開展業務技能競賽，提高其所提供的醫療品質水準。於二零二一年，醫教部與護理部聯合在仁康醫院開展了心肺復蘇、氣管插管和病歷書寫競賽活動，提高了醫務人員的技術水準。同時，仁康醫院加強與康華醫院的深度合作，為充分發揮康華醫院醫療技術的整體實力，協助仁康醫院各學科醫療水準穩步發展，康華醫院派出專家進行門診出診、手術指導、業務查房、疑難病例討論等，逐步加強建立統一管理模式。仁康醫院二甲評審工作取得初步進展，開展二級綜合醫院輔導培訓工作，目前仁康醫院已成立工作領導小組，明確了分工，力爭取得評審資格。

於報告期內，仁康醫院錄得收益人民幣130.1百萬元（截至二零二零年六月三十日止六個月：人民幣89.2百萬元），同比增長45.8%。截至二零二一年六月三十日，仁康醫院門診人次為175,782次，較去年同期增加37.1%；住院人次為6,285次，較去年同期增加39.7%。



Management Discussion and Analysis

管理層討論及分析

Kangxin Hospital

In the first half of 2021, the revenue of Kangxin Hospital has slightly declined as compared to the corresponding period in 2020. Despite facing numerous challenges, Kangxin Hospital seized the opportunities for vaccination and actively expanded its admission of patients, with the number of outpatients, discharged patients and number of performed surgeries significantly increasing as compared to the corresponding period in 2020. The overall standard of equipment and peripheral influences have also increased significantly. In the first half of 2021, with the approval of the Jiangbei District Health Commission of Chongqing City, Kangxin Hospital officially became a spot for COVID-19 vaccination. Expanding its business in an all-rounded way, Kangxin Hospital has built a strategic partnership with a physical examination centre in Chongqing, giving full play to the advantages of both parties in the field of medical services and further improving the channelling of various sources of diseases. In the first half of 2021, Kangxin Hospital also vigorously strengthened its market promotion. The charity event for patients with supraventricular tachycardia ("SVT"), under which Kangxin Hospital performed radiofrequency ablation surgeries for 100 SVT patients, has been officially completed. Moreover, cardiology experts from Kangxin Hospital, together with teachers and students of the School of Medicine of Chongqing Energy Vocational College, went to a community centre of Xiangrui Xicheng, Jiangjin District, Chongqing, the PRC to carry out a free cardiac consultation and rehabilitation event with the theme of "Strengthening Professional Skills, Protecting People's Health", which further spread the influence of Kangxin Hospital to the vicinity.

During the Reporting Period, Kangxin Hospital has recorded revenue of RMB19.0 million (six months ended 30 June 2020: RMB19.3 million), representing a period-on-period decrease of 1.7%. Up to 30 June 2021, Kangxin Hospital has outpatient visits of 10,244 with an increase of 43.1% as compared with the corresponding period last year; inpatient visits of 832 with an increase of 24.6% as compared with the corresponding period last year; and 280 (six months ended 30 June 2020: 240) performed cardiovascular surgeries with an increase of 16.7% as compared with the corresponding period last year.

Despite its operational potentials, Kangxin Hospital has continued to face many ongoing challenges, including huge burden on professional headcounts, overhead expenditure and fixed costs, as well as the inadequacy of certain key professional healthcare talents. The competition for healthcare professionals and experts remained intense in the local Chongqing market. The loss of certain key medical experts in year 2020 caused lagging patient visits at Kangxin Hospital during the current interim period. However, the Group will continue to step up its recruitment of experienced medical experts and improvement of our medical capabilities to regain and attract local patients.

康心醫院

二零二一年上半年，康心醫院收入相較二零二零年同期略有下滑，面臨多項挑戰，抓住疫苗接種機遇，積極擴大收治，門診病人量、出院病人量、手術臺次較二零二零年同期均顯著增加，醫院整體設備水準和周邊影響力明顯提升。二零二一年上半年，經重慶市江北區衛健委批准，康心醫院正式成為COVID-19疫苗接種點。全面拓展業務建設康心醫院與重慶一所體檢中心達成戰略合作關係，發揮雙方在醫療服務領域的優勢，進一步擴大病源管道。二零二一年上半年，康心醫院亦大力加強市場推廣，醫院舉行的室上速患者（「室上速患者」）公益救助活動正式結束，活動期間，醫院幫助100名室上速患者成功完成射頻消融手術。此外，康心醫院心內科專家攜手重慶市能源職業學院醫藥學院師生，赴中國重慶市江津區祥瑞西城中心社區開展了以「強專業技能、護百姓健康」為主題的心臟康復義診社區活動，進一步將醫院影響力向周邊區縣擴散。

於報告期內，康心醫院錄得收益人民幣19.0百萬元（截至二零二零年六月三十日止六個月：人民幣19.3百萬元），同比減少1.7%。截至二零二一年六月三十日，康心醫院門診人次為10,244次，較去年同期增加43.1%；住院人次為832次，較去年同期增加24.6%；及進行280宗（截至二零二零年六月三十日止六個月：240宗）心血管手術，較去年同期增加16.7%。

儘管具有營運潛力，康心醫院繼續面臨著一系列持續的挑戰，包括專業人員人數、間接費用及固定成本的巨大負擔，以及部分主要專業醫療人才不足。重慶本地市場對醫療專業人員及專家的競爭仍激烈。二零二零年若干主要專業醫療專家的流失導致了本中期間康心醫院的就診人次滯後。然而，本集團將繼續加大聘請經驗豐富的醫療專家及改善醫療能力的力度以重新獲得並吸引本地病患。

Management Discussion and Analysis

管理層討論及分析

The table below sets forth the revenue contribution by healthcare disciplines of our hospital services segment for the periods indicated:

下表載列於所示期間按醫院服務分部的醫學專科劃分的收益貢獻：

		For the six months ended 30 June 截至六月三十日止六個月				
		2021 二零二一年		2020 二零二零年		
		Change	RMB'000	% of	RMB'000	% of
Healthcare disciplines	醫學專科	變動	人民幣千元	revenue of the Group's owned hospitals 分佔本集團 擁有醫院的	人民幣千元	revenue of the Group's owned hospitals 分佔本集團 擁有醫院的
				收益百分比		收益百分比
O&G-related disciplines	婦產科有關科室	+4.0%	122,077	14.9	117,382	16.3
Internal medicine-related disciplines	內科有關科室	+6.4%	95,367	11.6	89,633	12.4
Cardiovascular-related disciplines	心血管有關科室	-6.8%	92,703	11.3	99,458	13.8
General surgery-related disciplines	普通外科有關科室	-8.3%	57,457	7.0	62,628	8.7
Neurology-related disciplines	神經醫學有關科室	+9.3%	56,605	6.9	51,776	7.2
Emergency medicine-related disciplines	急診有關科室	+2.1%	53,610	6.5	52,512	7.3
Orthopaedics-related disciplines	骨科有關科室	+13.0%	50,717	6.2	44,899	6.2
Oncology-related disciplines	腫瘤有關科室	+14.0%	29,394	3.6	25,782	3.6
Nephrology-related disciplines	腎臟科有關科室	+16.7%	29,232	3.5	25,049	3.5
Medical aesthetic-related disciplines	醫學美容有關科室	+49.4%	24,062	2.9	16,105	2.1
Paediatrics-related disciplines	兒童醫學有關科室	+81.2%	19,700	2.4	10,869	1.5
Physical examination	體檢科	+92.6%	52,321	6.4	27,162	3.8
Other disciplines	其他臨床科室	+40.4%	138,101	16.8	98,336	13.6
Total			821,346	100.0	721,591	100.0

Note: The Group's healthcare disciplines can generally be classified into clinical disciplines and medical technology disciplines. Medical technology disciplines provide diagnostic and treatment support according to the requirements of clinical disciplines from time to time. Revenue derived from services delivered through medical technology disciplines is generally recognised in the relevant clinical disciplines that utilised such services.

附註：本集團的醫學專科一般可分為臨床專科和醫療技術專科。醫療技術專科根據臨床專科的要求不時提供診斷和治療支援。通過醫療技術專科提供服務產生的收益通常在使用該等服務的相關臨床專科中確認。



Management Discussion and Analysis

管理層討論及分析

In the first half of 2021, the Group performed a total of 19,416 surgeries (six months ended 30 June 2020: 17,991), including 7,218 surgeries (six months ended 30 June 2020: 7,084) with level 3 or level 4 complexities, representing a period-on-period increase of 8.0% and 1.9%, respectively. The increase is primarily attributable to the gradual normalisation over scheduling of surgeries in the Group's hospitals operations after the COVID-19 pandemic. The Board believes that the impact of the pandemic on our hospital operations is temporary, despite occasional operational disturbance in the business operations due to isolated cases identified in Guangzhou and other regions of the PRC, and medical service operations have substantially returned to the normal level.

Obstetrics and gynaecology ("O&G") disciplines, internal medicine disciplines, cardiovascular disciplines, general surgery disciplines and neurology disciplines (six months ended 30 June 2020: O&G disciplines, cardiovascular disciplines, internal medicine disciplines, general surgery disciplines and emergency medicine disciplines) were the top five revenue-generating disciplines of the Group for the first half of 2021, accounting for approximately 51.7% of the Group's total revenue in the same period (six months ended 30 June 2020: 58.4%).

During the six months ended 30 June 2021, except for cardiovascular disciplines and general surgery disciplines (which recorded a decline in revenue), revenue from all our major disciplines of our owned hospitals has increased as compared with the corresponding period last year, which is mainly due to an increase in patient visits after gradual recovery in our hospital operations from the COVID-19 pandemic. Our O&G-related disciplines remained to be our largest medical discipline and recorded a period-on-period increase in revenue of 4.0%. However, revenue from O&G-related disciplines has not returned to our normal level in 2019, primarily due to the continued impact resulting from low patient visits and pregnancy level during the period of the COVID-19 pandemic in year 2020.

Revenue from cardiovascular-related disciplines recorded a period-on-period decrease of 6.8%, primarily attributable to the decline in revenue from Kangxin Hospital and deceleration in the growth of our surgeries in this discipline. However, our revenue from paediatrics-related disciplines, medical aesthetic-related disciplines and physical examination has recorded considerable growth, with a period-on-period increase of 81.2%, 49.4% and 92.6%, respectively. Patient visits and revenue rebounded substantially over these disciplines, demonstrating strong demand for our services as soon as the condition of the pandemic has eased starting from the second half of year 2020.

於二零二一年上半年，本集團已施行合共19,416例（截至二零二零年六月三十日止六個月：17,991例）手術，包括7,218例（截至二零二零年六月三十日止六個月：7,084例）三、四級複雜手術，同比分別增加8.0%及1.9%。該增加主要是由於COVID-19疫情後本集團醫院運營中的手術安排逐漸正常化。董事會認為，疫情對我們醫院運營的影響屬暫時。儘管由於在廣州及中國其他地區發現個別病例導致業務運營中偶爾出現運營中斷，但醫療服務運營已基本恢復至正常水平。

婦產科（「婦產科」）、內科、心血管科、普通外科及神經科（截至二零二零年六月三十日止六個月：婦產科、心血管科、內科、普通外科及急診科）為二零二一年上半年本集團產生五大收益的專科，佔本集團同期總收益約51.7%（截至二零二零年六月三十日止六個月：58.4%）。

截至二零二一年六月三十日止六個月，除心血管科及普通外科（錄得收益下降）外，我們所屬醫院的所有主要專科的收益較去年同期有所增加，主要乃由於我們醫院的業務自COVID-19疫情中逐漸恢復後，患者就診次數有所增加。婦產科有關科室仍然為我們最大的醫學專科，錄得收益同比增長4.0%。然而，婦產科有關科室的收益於二零一九年並未恢復至我們的正常化水平，這主要是由於二零二零年COVID-19疫情期間患者就診次數及懷孕水平的持續影響。

心血管有關科室錄得同比下降6.8%，主要是由於康心醫院收益下降以及我們於科室的手術增長放緩。然而，兒童醫學有關科室、醫學美容有關科室及體檢科的收益均錄得可觀的增長，分別同比增長81.2%、49.4%及92.6%。該等科室的患者就診次數及收益大幅反彈，表明自二零二零年下半年開始，疫情狀況有所緩解後，對我們的服務需求強勁。

Management Discussion and Analysis

管理層討論及分析

VIP Special Services

The Group's special services are high-end healthcare services that extend beyond basic medical services and are specifically catered for more affluent patients who are willing to pay a premium for higher quality and customised services that are not generally available in public hospitals. The Group's special services consist of VIP healthcare services, reproductive medicine, plastic and aesthetic surgery and laser treatment. In the first half of 2021, the total revenue derived from special services amounted to RMB85.8 million (six months ended 30 June 2020: RMB78.3 million), representing a period-on-period increase of 9.6%.

Our revenue from VIP inpatient services recorded RMB30.1 million for the Reporting Period (six months ended 30 June 2020: RMB30.8 million), representing a period-on-period decrease of 2.3%, primarily caused by a decline in the average spending of our inpatients. Revenue from VIP outpatient service amounted to RMB22.8 million for the Reporting Period (for the six months ended 30 June 2020: RMB21.6 million), representing a period-on-period increase of 5.9%. In the first half of 2021, the numbers of both VIP inpatient and outpatient visits have increased as compared with prior interim period, primarily due to recovery from the pandemic. However, the average spending per inpatient visit of our VIP healthcare services amounted to RMB36,378.5 (six months ended 30 June 2020: RMB43,437.2), representing a period-on-period decrease of 16.3%, and the average spending per outpatient visit of our VIP healthcare services amounted to RMB1,159.6 (six months ended 30 June 2020: RMB1,413.1), representing a period-on-period decrease of 17.9%. The demand for our service offerings from Huaxin Building (a complex in Kanghua Hospital dedicated to VIP healthcare services) has maintained stable. The decrease in patients average spending is primarily due to a more diverse patient base which visited Kanghua Hospital after the pandemic in various different disciplines, whereas, there were a more focused group of customers from O&G discipline during the earlier time of the pandemic in year 2020.

Our revenue from reproductive medicine increased to RMB20.0 million (six months ended 30 June 2020: RMB17.8 million) with a period-on-period increase of 11.8%. The increase in revenue of reproductive medicine is again due to recovery of our reproductive medicine service after the pandemic and at the same time, Kanghua Hospital has increased investment and deployed more resources in its business development team over the discipline.

VIP特殊服務

本集團的特殊服務是超出基本醫療服務的高端化醫療服務，主要針對高收入患者，彼等願意為普通公立醫院難以提供的高品質及定制化服務支付額外費用。本集團的特殊服務包括貴賓醫療服務、生殖醫學、整形及美容手術及激光治療。於二零二一年上半年，來自特殊服務的總收益為人民幣85.8百萬元（截至二零二零年六月三十日止六個月：人民幣78.3百萬元），同比增長9.6%。

於報告期，我們的貴賓住院服務收益錄得人民幣30.1百萬元（截至二零二零年六月三十日止六個月：人民幣30.8百萬元），同比減少2.3%，主要原因是我們住院病人的平均支出下降。我們的貴賓門診服務收入為人民幣22.8百萬元（截至二零二零年六月三十日止六個月：人民幣21.6百萬元），同比增加5.9%。二零二一年上半年，貴賓住院及門診人次與上一中期間相比均有所增加，主要是由於疫情的恢復。然而，我們貴賓醫療服務的名住院病人的平均支出為人民幣36,378.5元（截至二零二零年六月三十日止六個月：人民幣43,437.2元），同比下降16.3%及我們貴賓醫療服務的名門診病人的平均支出為人民幣1,159.6元（截至二零二零年六月三十日止六個月：人民幣1,413.1元），同比下降17.9%。華心樓（康華醫院專門用於貴賓醫療服務的綜合大樓）提供的服務需求保持穩定。患者平均支出下降主要是由於疫情後康華醫院不同科室的就診患者群體更加多樣化，而在二零二零年疫情初期，婦產科的客戶群體更加集中。

我們的生殖醫學收益增加至人民幣20.0百萬元（截至二零二零年六月三十日止六個月：人民幣17.8百萬元），同比增長11.8%。生殖醫學的收益增加再次得益於疫情後我們生殖醫學服務的恢復，同時康華醫院加大了投資，並在該科室的業務發展團隊中投入更多資源。



Management Discussion and Analysis

管理層討論及分析

The table below sets forth some key operating data and revenue for the Group's special services:

下表列出本集團特殊服務的若干主要營運數據及收益：

Special Services	特殊服務	Change 變動	For the six months ended 30 June 截至六月三十日止六個月	
			2021 二零二一年	2020 二零二零年
VIP healthcare services	貴賓醫療服務			
Inpatient visits	住院人次	+16.6%	827	709
Outpatient visits	門診人次	+29.0%	19,675	15,251
Revenue (RMB'000)	收益(人民幣千元)	+1.1%	52,900	52,348
Reproductive medicine	生殖醫學			
Number of outpatient visits	門診人次	+32.2%	21,173	16,017
Revenue (RMB'000)	收益(人民幣千元)	+11.8%	19,963	17,849
Plastic and aesthetic surgery	整形美容外科			
Revenue (RMB'000)	收益(人民幣千元)	+0.5%	2,053	2,042
Laser treatment	激光治療			
Revenue (RMB'000)	收益(人民幣千元)	+79.2%	10,872	6,066
Total revenue from special services (RMB'000)	特殊服務的總收益 (人民幣千元)	+9.6%	85,788	78,305

Rehabilitation and other Healthcare Services

During the Reporting Period, the Group's rehabilitation and other related healthcare services segments, through its ownership of 57% equity interest in Anhui Hualin, have recorded a revenue of RMB44.2 million (six months ended 30 June 2020: RMB31.5 million), representing a period-on-period increase of 40.7%. Anhui Hualin directly and indirectly (through its wholly-owned subsidiary) holds sponsor interests in certain private non-enterprise entities in Anhui Province, the PRC. It mainly operates two rehabilitation hospitals, a general hospital, an outpatient centre, twelve rehabilitation centres and one vocational training school (collectively referred to as "Anhui Hualin Group"). Anhui Hualin Group has generated significant synergies to the Group and expanded our presence in the rehabilitation healthcare sector in the PRC. Since its acquisition, Anhui Hualin Group has developed steadily, with its network of medical institutions and rehabilitation centres constantly expanding.

康復及其他醫療服務

於報告期內，本集團的康復及其他相關醫療服務分部（透過其擁有安徽樺霖57%的股本權益）錄得收益人民幣44.2百萬元（截至二零二零年六月三十日止六個月：人民幣31.5百萬元），同比增長40.7%。安徽樺霖透過其全資附屬公司直接及間接在中國安徽省若干民辦非企業單位持有舉辦者權益。其主要運營兩間康復醫院、一間綜合醫院、一個門診中心、十二間康復中心及一間職業培訓學校（統稱「安徽樺霖集團」）。安徽樺霖集團已為本集團帶來巨大的協同效應，並拓展我們於中國康復醫療行業之版圖。自收購以來，安徽樺霖集團穩步發展，其醫療機構及康復中心網絡不斷擴大。

Management Discussion and Analysis

管理層討論及分析

Anhui Hualin Group currently employs more than 800 members of staff and has a stable cooperation with the Anhui Disabled Persons Federation and local governments in the provision of training services for the disabled. Anhui Hualin Group is also a major organisation offering children rehabilitation services in Anhui Province, the PRC. As at 30 June 2021, the three hospitals operated by Anhui Hualin Group have a total of 220 registered beds. During the Reporting Period, Anhui Hualin Group has 8,084 (six months ended 30 June 2020: 20,666) outpatient visits, 331 (six months ended 30 June 2020: 1,430) inpatient visits and served 169,560 (six months ended 30 June 2020: 62,083) rehabilitation patient visits.

In the first half of 2021, although revenue from this segment has recorded a substantial increase of 40.7%, revenue from rehabilitation hospital services has recorded a period-on-period decline of 10.9% to RMB19.7 million (six months ended 30 June 2020: RMB22.1 million). Revenue from rehabilitation centres services and other healthcare service (in particular our children rehabilitation operation) has recorded a period-on-period increase of 163.3% to RMB24.5 million (six months ended 30 June 2020: RMB9.3 million). During the Reporting Period, our Hefei Jingu Hospital and Hefei Kanghua Rehabilitation Hospital (合肥康華康復醫院) were under periodical investigation by the relevant authority, and were required to be temporarily closed for two months before its reopening later in June 2021. This temporary closure has caused to certain extent in operational disturbance and loss of patient visits.

Sale of Pharmaceutical Products

The Group's sale of pharmaceutical products segment includes a pharmaceuticals and medical consumables trading company established for the purpose of streamlining pharmaceuticals and medical consumables sales directly to the patients at the Group's hospitals and walk-in customers who may not be the patients of the Group's hospitals. Revenue from sale of pharmaceutical products for the Reporting Period amounted to RMB0.7 million (six months ended 30 June 2020: RMB6.3 million), representing a period-on-period decrease of 88.5%. From the beginning of the pandemic in year 2020, the operation of our pharmaceutical stores within our hospitals has been difficult, mainly as a result of the decline in patient visits and various pharmaceutical reform policies and measures being implemented at the national level. Going forward, the Group has plans to reduce and retrench the operation of this segment and gradually integrate with our hospital services segment in later half of year 2021.

安徽樺霖集團目前擁有800多名員工，且與安徽省殘疾人聯合會及當地政府在提供殘疾人培訓服務方面有著穩定的合作關係。安徽樺霖集團亦為中國安徽省提供兒童康復服務的主要機構。於二零二一年六月三十日，安徽樺霖集團經營的三間醫院共有220張註冊床位。於報告期內，安徽樺霖集團的門診人次、住院人次及康復服務接待人數分別達8,084名(截至二零二零年六月三十日止六個月：20,666名)、331名(截至二零二零年六月三十日止六個月：1,430名)及169,560名(截至二零二零年六月三十日止六個月：62,083名)。

二零二一年上半年，雖然該部門收入大幅增長40.7%，但康復醫院服務收入同比下降10.9%至人民幣19.7百萬元(截至二零二零年六月三十日止六個月：人民幣22.1百萬元)。康復中心服務及其他醫療服務(尤其是我們的兒童康復業務)的收入錄得同比增長163.3%至人民幣24.5百萬元(截至二零二零年六月三十日止六個月：人民幣9.3百萬元)。於報告期內，我們的合肥金谷醫院及合肥康華康復醫院正在接受有關部門的定期調查，並被要求暫時關閉兩個月後於二零二一年六月下旬重新開放。此次暫時關閉在一定程度上造成了運營中斷及就診次數的損失。

銷售藥品

本集團銷售藥品分部包括為將藥品及醫療耗材直接銷售予本集團醫院的患者以及非本集團醫院患者的步入式客戶而設立的藥品及醫療耗材貿易公司。報告期內銷售藥品的收益為人民幣0.7百萬元(截至二零二零年六月三十日止六個月：人民幣6.3百萬元)，同比減少88.5%。自二零二零年疫情開始，醫院內的藥店經營困難重重，主要是由於患者就診次數下降以及國家層面正在實施的各項藥學改革政策及措施。展望未來，本集團計劃於二零二一年下半年減少及縮減該分部的營運，並逐步與我們的醫院服務分部整合。



Management Discussion and Analysis

管理層討論及分析

Elderly Healthcare Services

The Group's elderly healthcare services segment commenced in 2018, with the strategy to establish a comprehensive elderly healthcare centre located inside Renkang Hospital, namely, Renkang Elderly Care Centre, initially with 60 registered beds to explore the potential of providing quality high-end elderly care services to local residents in Houjie Town, Dongguan City, the PRC. In view of the accelerating aging population problem in the PRC that leads to the high development potential of the healthcare and elderly care industry, the establishment of the Renkang Elderly Care Centre was the Group's first presence and extension of our big health concept business development.

In the first half of 2021, Renkang Elderly Care Centre continued to upgrade and achieved outstanding performance. Up to June 2021, the centre has a total of 108 beds with 104 elderly patients, achieving a bed utilisation rate of 96%. Revenue from provision of elderly healthcare services for the Reporting Period amounted to RMB5.2 million (six months ended 30 June 2020: RMB1.6 million), representing a period-on-period increase of 215.8%, primarily due to an increase in intake of patients during the current interim period. As the operation matures, as well as the centre became a designated medical institution covered by the social insurance system in Dongguan, the PRC in 2020, Renkang Elderly Care Centre has gradually gained reputation in the local area with bed utilisation close to 100% and received more enquiry from local potential patients. In the current period, the development of the third phase elderly centre building has commenced inside Renkang Hospital (construction cost will be provided by the landlord of Renkang Hospital), aiming to provide the best in the class elderly healthcare services and satisfy the overwhelming demand for elderly healthcare service in the district.

With respect to the land use rights of a land parcel acquired in year 2020, the management expects that the construction of the main facilities will commence in later half of year 2021. The land use rights of the land parcel were to develop a comprehensive elderly healthcare medical facility with a particular focus on geriatric patients and rehabilitation. The Board expects that such development will further enhance the Group's capability in providing high-end integrated medical care to meet the increasing demand for such services in Guangdong Province, the PRC (and in particular Dongguan City, the PRC).

老年醫療服務

本集團的老年醫療服務，始於二零一八年，其戰略是在仁康醫院內部建立一個綜合性的老年保健中心，即仁康護理院，初步擁有60張註冊床位，以開拓向中國東莞市厚街鎮的當地居民提供優質高端養老服務的潛力。鑑於中國人口加速老齡化問題導致醫療保健及老年護理行業的巨大發展潛力，成立仁康護理院為本集團首次亮相及擴展我們的大型保健概念業務發展。

二零二一年上半年，仁康護理院持續升級，並取得驕人的業績。截至二零二一年六月，中心共有床位108張、老年患者104人、床位利用率達到96%。報告期內提供老年醫療服務的收入為人民幣5.2百萬元（截至二零二零年六月三十日止六個月：人民幣1.6百萬元），同比增長215.8%，主要由於中期間接收量的增加。隨著運營的成熟，以及二零二零年成為中國東莞市社會保險定點醫療機構，仁康護理院在當地逐漸享有盛譽，床位利用率接近100%，並獲得更多來自當地潛在患者的諮詢。於中期期間，仁康醫院內三期老年中心大樓已開始動工（建設費用由仁康醫院業主承擔），旨在提供一流的老年醫療服務，滿足該地區對老年醫療服務的巨大需求。

就於二零二零年收購的地塊的土地使用權而言，管理層預計主要設施的建設將於二零二一年下半年開始。該地塊的土地使用權將用於開發綜合老年醫療設施，尤其專注於老年患者及康復。董事會預期有關發展項目將進一步提升本集團提供高端綜合醫療服務的能力，以滿足中國廣東省（尤其是中國東莞市）對相關服務不斷增長的需求。

Management Discussion and Analysis

管理層討論及分析

Industry Outlook and Strategy

Year 2021 is the first year after the healthcare industry withstood the challenges brought by the COVID-19 pandemic in the PRC. The continuous raging of the COVID-19 pandemic continued to affect the PRC as well as the global economies. In this new era, the healthcare industry in the PRC faces both challenges and opportunities with the rise of online medical consultation, smart hospitals and the advancement of communication technology, all of which have enabled patients to choose alternative online medical treatments. The implementation of the COVID-19 pandemic prevention and control measures by the PRC government across the country has led to an upsurge of online medical treatments. Various hospitals have broken through the limitations of traditional face-to-face medical treatments and have provided patients with more options of various forms of medical treatments.

Prevention and Control of the COVID-19 Pandemic, and Deepening the Reform of the Disease Prevention and Control System

In the first half of 2021, the impact of the COVID-19 pandemic on the medical industry continued. Although the COVID-19 pandemic in the PRC was sporadic and locally clustered, it continued to consume a lot of social resources. Hospitals also had to tighten the COVID-19 pandemic prevention and control measures at all times. The Group therefore had to carry out a procurement plan under the normalisation of the COVID-19 pandemic, pay attention to market changes in a timely manner, and respond quickly. At the same time, in the first half of 2021, the health-related needs of the people were also stimulated, and medical institutions with strong comprehensive service capabilities, wide coverage, and good technical standards won the trust of patients. After the COVID-19 pandemic becomes effectively controlled, we believe that the Group's business will further continue to grow significantly.

行業前景及策略

二零二一年是中國醫療行業經受住COVID-19疫情帶來的挑戰後的第一年。COVID-19疫情的持續肆虐繼續影響中國和全球經濟。在這個新時代，隨著網上就診、智慧醫院的興起及通訊技術的進步，讓患者能夠選擇替代線上就醫，中國醫療行業挑戰與機遇並存。中國政府在全國範圍內實施COVID-19疫情防控措施，引發線上就醫的熱潮。各醫院突破了傳統面對面就醫的局限性，為患者提供更多的多種就醫形式的選擇。

防控COVID-19疫情，深化疾病防控體制改革

二零二一年上半年，COVID-19疫情對醫療行業的影響仍在持續。雖然中國的COVID-19疫情呈零星散發狀態，但仍然消耗大量的社會資源。醫院亦需時刻加強對COVID-19疫情的防控措施。因此，本集團需在COVID-19疫情常態化形勢下執行採購計劃，及時關注市場變化，並迅速作出應對。與此同時，二零二一年上半年，民眾的健康相關需求亦被激發，綜合服務能力強、覆蓋面廣、技術水平優異的醫療機構贏得患者的信賴。在COVID-19疫情得到有效控制後，我們相信本集團的業務將進一步持續大幅增長。



Management Discussion and Analysis

管理層討論及分析

Reform of Medical Insurance Payment Methods

In 2021, the reform of medical insurance payment methods continued. The competition between medical institutions and medical insurance management departments has become a competition between medical institutions, prompting medical institutions to carry out refined management, improve their service quality, and offer better development for medical institutions. In view of the reform, the market has promoted pilot projects, including the payment depending on the type or the group of diseases diagnosed, in order to refine the management.

Procurement of Pharmaceutical Consumables

In 2021, centralised procurement of pharmaceuticals and high-value consumables was normalised. The centralised procurement put forward new requirements for hospital operations, which will change the profit model of hospitals. While further reducing the operating costs of medical institutions, the centralised procurement also led to higher requirements for the improvement of medical technology and core competitiveness of medical institutions. The Group normalised and institutionalised the centralised procurement of drugs, and gradually expanded the scope of centralised procurement of drugs and high-value medical consumables.

醫保支付方式改革

二零二一年，醫保支付方式改革持續推進。醫療機構與醫保管理部門的競爭已經變成醫療機構之間的競爭，促使醫療機構進行精細化管理，提高服務質量，為醫療機構提供更好的發展。針對該項改革，市場推動了試點項目，包括按疾病診斷類型或分組進行支付，以細化管理。

採購醫藥耗材

二零二一年，藥品及高價值耗材集中採購實現常態化。集中採購對醫院運營提出新的要求，將改變醫院的盈利模式。在進一步降低醫療機構運營成本的同時，集中採購亦對醫療機構提升醫療技術和核心競爭力提出更高的要求。本集團將藥品集中採購常態化、制度化，並逐步擴大藥品和高價值醫療耗材的集中採購範圍。

Management Discussion and Analysis

管理層討論及分析

Online Healthcare Development

Online healthcare and digitalisation continued to develop rapidly in 2021. The medical and healthcare industry will continue to accelerate and upgrade by virtue of digitalisation, and provide patients with “Internet + hospital + out-of-hospital services”. Products and solutions will be extended to the closed-loop service of “treatment, medicine, insurance, and health management”. New technologies, such as digital therapy, are combined with the Internet to provide patients with greater value. The “Notice of the General Office of the State Council on Issuing the Key Tasks for Deepening the Reform of the Medical and Health System in 2021”, which was issued in May 2021, clearly and actively supports the development of social medical services. Medical institutions can take the lead in establishing or participating in county medical communities and urban medical groups and promote the balanced distribution of high-quality medical resources. In addition, the COVID-19 pandemic has promoted the rapid development of online medical care and the further implementation of intelligent payment models, all of which have put forward higher requirements for the construction of the informatisation of the medical services, especially for private medical institutions. With the continuously deepening of medical reform measures and the continuous implementation of supportive governmental policies, the operation of medical services has ushered in a new period of opportunities. The relevant letters issued by the National Health Commission of the People’s Republic of China on appointments for diagnosis and treatment and the construction of online hospitals have pointed out the path for the upgrading and transforming the hospital services in the PRC. The Company has fully accelerated the construction of online hospitals in response to rising social needs. Since 2020, the Group has officially deployed online medical services, and established an online medical platform to contribute to the online and offline integration and development of Kanghua Hospital.

Deepening the Reform of the Pricing of the Medical Services

In view of the reform of the pricing of the medical services, the PRC government will establish a sound and sensitive price adjustment mechanism, regularly carry out price adjustment evaluations, increase the price of medical services that reflect the value of the technique and labour involved, and increase guidance and supervision in areas where progress is lagging. The PRC government will also speed up the review of pricing of new medical service projects, guide local governments in reforming and optimising their rules that regulate the pricing of medical services, and allow the relevant authorities to conduct cost investigations in an easy and efficient manner. The Group will increase the cost-effectiveness of its operation and continue to implement measures with regard to cost management and control. The Group will also strive to increase the rate of use of the inpatient bedside settlement function and online settlement of fees.

線上醫療發展

二零二一年，線上醫療和數字化繼續快速發展。醫療保健行業將繼續藉助數字化加速升級，為患者提供「互聯網+醫院+院外服務」。產品和解決方案將拓展至「治療、醫藥、保險和健康管理」的閉環服務。數字治療等新技術與互聯網相結合，為患者提供更大價值。二零二一年五月發佈的《國務院辦公廳關於印發深化醫藥衛生體制改革二零二一年重點工作任務的通知》明確積極支持社會辦醫發展。醫療機構可牽頭組建或參加縣域醫共體和城市醫療集團，推動優質醫療資源均衡佈局。此外，COVID-19疫情推動線上醫療的快速發展和智慧支付模式的進一步落實，對醫療服務的信息化建設（特別是對民營醫療機構）提出了更高的要求。隨著醫改措施的不斷深化和政府扶持政策的不斷落實，醫療服務運作迎來了新的機遇期。中華人民共和國國家衛生健康委員會發佈的關於預約診療和線上醫院建設的相關函件，為中國醫院服務的升級轉型指明了道路。為應對日益增長的社會需求，本公司全面加快線上醫院的建設。自二零二零年起，本集團正式部署線上醫療服務，並建立線上醫療平台，助力康華醫院線上線下一體化發展。

深化醫療服務價格改革

針對醫療服務價格改革，中國政府將建立健全靈敏有度的價格動態調整機制，定期開展調價評估，提高反映所涉技術及勞動價值的醫療服務價格，並對進展滯後的地區加大指導督促力度。中國政府亦將加快審核新增醫療服務價格項目，指導地方改革優化政府制定醫療服務價格的行為規則，允許定價部門採取簡明易行的方式開展成本調查。本集團將提高運營的成本效益，並繼續實施成本管理和控制措施。本集團亦將努力提高住院患者床邊結算功能和費用線上結算的使用率。



Management Discussion and Analysis

管理層討論及分析

In the second half of 2021, the entire pharmaceutical industry will continue to face both challenges and opportunities. The Group will strive to optimise its medical services, improve the operational efficiency of its medical service business, accelerate the construction of disciplines over which the Group has competitive advantages, strengthen its quality management, accelerate the online transformation of the healthcare industry, promote breakthroughs in the consumer medical segment, and expand the scale of its operations. At the same time, the Group will continue to pay attention to the opportunities for carrying out mergers and acquisitions in the domestic market. In addition, the Group will continue to monitor the progress of the COVID-19 pandemic and adopt corresponding prevention and control measures to ensure the stability and orderliness of its business activities.

Future Plans for Material Investments and Capital Assets

Save as disclosed in this report, the Group did not have other plans for material investments or capital assets as at the date of this report.

FINANCIAL REVIEW

Segment Revenue

The Group generates revenue primarily from: (i) hospital services – providing healthcare services through its owned hospitals, namely Kanghua Hospital, Renkang Hospital and Kangxin Hospital (since August 2018), comprising inpatient healthcare services, outpatient healthcare services and physical examination services; (ii) rehabilitation and other healthcare services – providing rehabilitation services to patients with physical or mental disabilities and other healthcare-related services including elderly care and training service for the disabled; (iii) sale of pharmaceutical products and medical consumables to patients of the Group's hospitals and walk-in customers who may not be patients of the Group's hospitals; and (iv) elderly healthcare services – provision of elderly healthcare services, including assisted living, adult daycare, long-term care, residential care and hospice care to the aged patients.

二零二一年下半年，整個醫藥行業將繼續面臨挑戰與機遇並存的局面。本集團將努力優化醫療服務，提高醫療服務業務的運營效率，加快本集團有競爭優勢科室的建設，加強質量管理，加快醫療行業的線上轉型，推動醫療消費分部取得突破，及擴大經營規模。與此同時，本集團將繼續關注國內市場進行併購的機會。此外，本集團將繼續監察COVID-19疫情的進展，並採取相應的防控措施，以確保其業務活動穩定有序。

重大投資及資本資產之未來計劃

除本報告披露者外，於本報告日期，本集團並無其他重大投資計劃或資本資產計劃。

財務回顧

分部收益

本集團主要從以下各項賺取收益：(i) 醫院服務—通過其本身擁有的醫院（即康華醫院、仁康醫院及康心醫院（自二零一八年八月起）提供醫療服務，包括住院醫療服務、門診醫療服務及體檢服務；(ii) 康復及其他醫療服務—為身體或精神殘疾病人提供康復服務及其他醫療相關服務，包括老年護理及殘疾人訓練服務；(iii) 向本集團醫院的病人及未必為本集團醫院病人的步入式客戶銷售藥品及醫療耗材；及(iv) 老年醫療服務，提供老年醫療服務，包括生活輔助、成人日托、長期護理、住院護理及老年病人的臨終關懷。

Management Discussion and Analysis

管理層討論及分析

The following tables set forth the revenue, costs of revenue, gross profit and gross profit margin of the Group by segment for the periods indicated:

下表載列所示期間本集團按分部劃分的收益、收益成本、毛利及毛利率：

For the six months ended 30 June 2021 (unaudited)

截至二零二一年六月三十日止六個月(未經審核)

		Hospital services	Rehabilitation and other healthcare services	Sale of pharmaceutical products	Elderly healthcare services	Total
		醫院服務	康復及其他醫療服務	銷售藥品	老年醫療服務	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收益	821,346	44,247	726	5,166	871,485
Cost of revenue	收益成本	(693,560)	(43,266)	(610)	(4,204)	(741,640)
Gross profit	毛利	127,786	981	116	962	129,845
Gross profit margin	毛利率	15.6%	2.2%	16.0%	18.6%	14.9%

For the six months ended 30 June 2020 (unaudited)

截至二零二零年六月三十日止六個月(未經審核)

		Hospital services	Rehabilitation and other healthcare services	Sale of pharmaceutical products	Elderly healthcare services	Total
		醫院服務	康復及其他醫療服務	銷售藥品	老年醫療服務	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收益	721,591	31,458	6,302	1,636	760,987
Cost of revenue	收益成本	(652,347)	(27,865)	(4,930)	(2,671)	(687,813)
Gross profit (loss)	毛利(毛損)	69,244	3,593	1,372	(1,035)	73,174
Gross profit margin	毛利率	9.6%	11.4%	21.8%	-63.3%	9.6%

Revenue from the Group's hospital services amounted to RMB821.3 million for the Reporting Period (six months ended 30 June 2020: RMB721.6 million), representing a period-on-period increase of 13.8%, accounting for 94.2% (six months ended 30 June 2020: 94.8%) of the total revenue of the Group.

於報告期內，本集團醫院服務的收益為人民幣821.3百萬元(截至二零二零年六月三十日止六個月：人民幣721.6百萬元)，同比增加13.8%，佔本集團總收益94.2%(截至二零二零年六月三十日止六個月：94.8%)。



Management Discussion and Analysis

管理層討論及分析

Revenue from hospital services comprised (i) revenue from inpatient healthcare services, which amounted to RMB487.4 million (six months ended 30 June 2020: RMB468.0 million), representing a period-on-period increase of 4.2% and accounting for 55.9% (six months ended 30 June 2020: 61.5%) of the total revenue of the Group; (ii) revenue from outpatient healthcare services, which amounted to RMB281.6 million (six months ended 30 June 2020: RMB226.5 million), representing a period-on-period increase of 24.4% and accounting for 32.3% (six months ended 30 June 2020: 29.8%) of the total revenue of the Group; and (iii) revenue from physical examination services, which amounted to RMB52.3 million (six months ended 30 June 2020: RMB27.2 million), representing a period-on-period increase of 92.6% and accounting for 6.0% (six months ended 30 June 2020: 3.6%) of the total revenue of the Group. The increase in revenue from hospital services is mainly due to (i) an increase in the number of inpatient, outpatient and physical examination visits during the period across all of our owned-hospitals due to recovery from the pandemic; (ii) the growth in revenue across all of our major medical disciplines and our VIP special services; and (iii) overall increase public health safety awareness since the pandemic and economic recovery in Guangdong region. Revenue from physical examination has significantly increased to RMB52.3 million (six months ended 30 June 2020: RMB27.2 million), which is primarily due to increase the number of physical examination visits and the number of COVID-19 tests performed at our hospital during the current interim period. During the Reporting Period, the revenue from our VIP special services accounted for approximately 9.8% of the Group's total revenue (six months ended 30 June 2020: 10.3%) and 10.4% of the Group's revenue from our hospital services segment (six months ended 30 June 2020: 10.8%). The growth in revenue from our hospital services has demonstrated that the demand for our service continued to remain strong and the overall recovery in both economic activities and hospital operations in the Guangdong region ever since the outbreak of the COVID-19 pandemic in year 2020.

Revenue from rehabilitation and other healthcare services amounted to RMB44.2 million (six months ended 30 June 2020: RMB31.5 million), representing a period-on-period increase of 40.7%, accounting for 5.1% (six months ended 30 June 2020: 4.1%) of the total revenue of the Group. Anhui Hualin Group is principally engaged in provision of rehabilitation services to the patients with physical or mental disabilities and other healthcare-related services, including care services for elderly and training service for the disabled. The increase in revenue is mainly attributable to the recovery of patient visits after the pandemic and the significant improvement in business operation of our rehabilitation services in the Anhui region, in particular, our children rehabilitation and other healthcare services during the period.

醫院服務的收益包括(i)住院醫療服務的收益人民幣487.4百萬元(截至二零二零年六月三十日止六個月:人民幣468.0百萬元),同比增長4.2%,佔本集團總收益55.9%(截至二零二零年六月三十日止六個月:61.5%);(ii)門診醫療服務的收益人民幣281.6百萬元(截至二零二零年六月三十日止六個月:人民幣226.5百萬元),同比增長24.4%,佔本集團總收益32.3%(截至二零二零年六月三十日止六個月:29.8%);及(iii)體檢服務的收益人民幣52.3百萬元(截至二零二零年六月三十日止六個月:人民幣27.2百萬元),同比增長92.6%,佔本集團總收益6.0%(截至二零二零年六月三十日止六個月:3.6%)。醫院服務收益增加主要是由於(i)因在經歷疫情恢復後,期內我們擁有的所有醫院的住院、門診及體檢人次增加;(ii)所有主要科室及貴賓特殊服務的收益增長;及(iii)廣東地區疫情及經濟復甦以來公共衛生安全意識全面提升。體檢收益顯著增加至人民幣52.3百萬元(截至二零二零年六月三十日止六個月:人民幣27.2百萬元),主要是由於本中期期間我們醫院的體檢人次及COVID-19檢測次數有所增加。於報告期,貴賓特殊服務收益佔本集團總收益的約9.8%(截至二零二零年六月三十日止六個月:10.3%),佔本集團醫院服務分部收益的10.4%(截至二零二零年六月三十日止六個月:10.8%)。醫院服務收益的增長顯示,自二零二零年COVID-19疫情爆發以來,我們的服務需求持續強勁,而廣東地區的經濟活動及醫院運作亦全面復甦。

康復及其他醫療服務的收益為人民幣44.2百萬元(截至二零二零年六月三十日止六個月:人民幣31.5百萬元),同比增長40.7%,佔本集團總收益的5.1%(截至二零二零年六月三十日止六個月:4.1%)。安徽樺霖集團主要從事為身體或精神殘疾的患者提供康復服務及其他醫療相關服務,包括老年護理及殘疾人訓練服務。收益增加主要是由於疫情後患者就診次數有所恢復,以及期內我們在安徽地區的康復服務,尤其是兒童康復及其他醫療服務的業務運營顯著改善。

Management Discussion and Analysis

管理層討論及分析

Revenue from sale of pharmaceutical products and medical consumables amounted to RMB0.7 million (six months ended 30 June 2020: RMB6.3 million), representing a period-on-period decrease of 88.5%, accounting for 0.1% (six months ended 30 June 2020: 0.8%) of the total revenue of the Group. The decrease in revenue is mainly attributable to the decrease in the demand for pharmaceutical and medical consumables inside our hospitals and effects of pharmaceutical market reforms since year 2020.

Revenue from elderly healthcare services represented the provision of elderly healthcare services at our Renkang Elderly Care Centre, which amounted to RMB5.2 million (six months ended 30 June 2020: RMB1.6 million), representing a period-on-period increase of 215.8% and accounting for 0.6% (six months ended 30 June 2020: 0.2%) of the total revenue of the Group. In August 2020, the centre became a designated medical institution covered by the social insurance system in Dongguan, the PRC. The increase in revenue is mainly attributable to the increase in intake of patients during the current interim period and rising demand for elderly healthcare service in the local district.

Cost of Revenue

Cost of revenue of the Group's hospital services segment (consisting of inpatient healthcare services, outpatient healthcare services and physical examination services) primarily consisted of pharmaceuticals, medical consumables, staff cost, depreciation, service expenses, utilities expenses, rental expenses and other costs. Cost of revenue of the Group's hospital services segment increased to RMB693.6 million (six months ended 30 June 2020: RMB652.3 million), representing a period-on-period increase of 6.3%. The increase in cost of revenue of our hospital services segment is mainly attributable to the increase in business operations of our hospitals and the increase in the number of patients across all medical disciplines during the Reporting Period. Our Kangxin Hospital is still at its stage of ramping up its operation, it is running at negative gross margin during the Reporting Period.

銷售藥品及醫療耗材的收益為人民幣0.7百萬元(截至二零二零年六月三十日止六個月: 人民幣6.3百萬元), 同比減少88.5%, 佔本集團的總收益0.1%(截至二零二零年六月三十日止六個月: 0.8%)。收益減少主要由於自二零二零年以來醫院內部對藥品及醫療耗材的需求減少以及藥品市場改革的影響。

來自老年醫療服務的收益指在仁康護理院提供老年醫療服務的收益人民幣5.2百萬元(截至二零二零年六月三十日止六個月: 人民幣1.6百萬元), 同比增長215.8%, 佔本集團總收益的0.6%(截至二零二零年六月三十日止六個月: 0.2%)。二零二零年八月, 該護理院成為中國東莞市社會保險定點醫療機構。收益增加主要是由於本中期期間患者的接量增加及該地區老年醫療服務需求上升。

收益成本

本集團醫院服務分部(包括住院醫療服務、門診醫療服務及體檢服務)的收益成本主要包括藥品、醫療耗材、員工成本、折舊、服務開支、水電費、租金開支和其他成本。本集團醫院服務分部的收益成本增加至人民幣693.6百萬元(截至二零二零年六月三十日止六個月: 人民幣652.3百萬元), 同比增加6.3%。我們醫院服務分部的收益成本增加乃主要由於報告期, 醫院業務運營增加以及所有醫學專科患者人數增加所致。我們的康心醫院仍處於擴大運營階段, 於報告期內, 其毛利率為負。



Management Discussion and Analysis

管理層討論及分析

Cost of revenue of the Group's rehabilitation and other healthcare services segment amounted to RMB43.3 million (six months ended 30 June 2020: RMB27.9 million), representing a period-on-period increase of 55.3%, and primarily consisted of staff costs, medical consumables, depreciation, utilities and rental expenses. The increase in cost of revenue of our rehabilitation and other healthcare services segment is mainly attributable to the increase in operation of our rehabilitation centres, in particular in our number of direct staff headcounts during the Reporting Period.

Cost of revenue of the Group's sales of pharmaceutical products segment amounted to RMB0.6 million (six months ended 30 June 2020: RMB4.9 million), representing a period-on-period decrease of 87.6%. This is mainly attributable to the decreased cost of purchase of pharmaceutical and medical consumable products.

Cost of revenue of the Group's elderly healthcare services represented the cost of revenue at Renkang Elderly Care Centre, which amounted to RMB4.2 million (six months ended 30 June 2020: RMB2.7 million) and representing a period-on-period increase of 57.4%. This mainly represented the cost of services including direct staff cost and consumables incurred at the elderly care centre. The increase is due to the full operation of the centre with substantial increase in staff headcounts and full deployment of its services in 2020.

For the six months ended 30 June 2021, pharmaceuticals, medical consumables and staff cost accounted for approximately 25.7% (six months ended 30 June 2020: 28.0%), 27.9% (six months ended 30 June 2020: 26.1%) and 31.1% (six months ended 30 June 2020: 32.3%), respectively, of the total cost of revenue of the Group. The proportion of cost of pharmaceuticals and medical consumables as percentage of total cost of revenue has declined during the Reporting period, which is mainly attributable to the continuing adjustment on cost control and in line with medical reforms at the national level. Our total staff-related costs including salary, bonus and other benefits have increased by 3.7% as compared with the corresponding period last year, mainly attributable to an increase in general salary level with more competitive salary and bonus packages being offered to healthcare professionals.

本集團的康復及其他醫療服務的收益成本為人民幣43.3百萬元(截至二零二零年六月三十日止六個月:人民幣27.9百萬元), 同比增長55.3%, 主要包括員工成本、醫療耗材、折舊、水電費及租金開支。我們康復及其他醫療服務部門收益成本的增加主要是由於我們康復中心的運營增加, 特別是在報告期內我們的直接員工人數增加。

本集團銷售藥品分部的收益成本為人民幣0.6百萬元(截至二零二零年六月三十日止六個月:人民幣4.9百萬元), 同比減少87.6%, 該減少主要指藥品及醫療耗材採購成本減少。

本集團老年醫療服務的收益成本指仁康護理院收益的成本人民幣4.2百萬元(截至二零二零年六月三十日止六個月:人民幣2.7百萬元), 同比增長57.4%, 主要指服務成本, 包括直接員工成本及老年護理中心的消耗品。該增加乃由於該護理院於二零二零年全面運營, 其員工人數大幅增加及全面開展服務。

截至二零二一年六月三十日止六個月, 藥品、醫療耗材及員工成本分別佔本集團總收益成本約25.7%(截至二零二零年六月三十日止六個月:28.0%)、27.9%(截至二零二零年六月三十日止六個月:26.1%)及31.1%(截至二零二零年六月三十日止六個月:32.3%)。於報告期, 藥品及醫療耗材成本佔總收益成本的比例有所下降, 這主要是由於繼續調整成本控制, 並與國家一級的醫療改革保持一致。我們的總員工相關成本(包括薪金、花紅及其他福利), 較去年同期上升3.7%, 主要是由於總體工資水平提高並向醫療專業人員提供更具競爭力的工資及獎金。

Management Discussion and Analysis

管理層討論及分析

Gross Profit and Gross Profit Margin

Total gross profit of the Group amounted to RMB129.8 million (six months ended 30 June 2020: RMB73.2 million), representing a period-on-period increase of 77.45%. The overall gross profit margin increased to 14.9% (six months ended 30 June 2020: 9.6%), primarily due to:

- (i) our significant growth in medical aesthetic-related disciplines, paediatrics-related disciplines and physical examination during the current period. These medical disciplines usually require treatments that are typically least advanced and diagnostics support, and are capable of absorbing higher growth in patient visits without substantial adjustments to medical staff level or increase in costs than other medical services;
- (ii) the growth in our VIP centres that targeted at high-end patients and typically command higher margin than basic healthcare services (VIP services-related revenue recorded a period-on-period growth of 9.8%);
- (iii) the increase in the average spending of our outpatients and physical examination services and an increase healthcare consultation price leveraging the reputation of the “Kanghua” brand that is gaining wider recognition in the Guangdong region; and
- (iv) however, the above impact has been considerably offset by the loss incurred at Kangxin Hospital, which is currently running at negative gross margin. Kangxin Hospital has incurred significant amount of fixed staff costs and other fixed costs at its initial stage of operation since its commencement. In addition, there is an increase in overall direct staff costs and depreciation expenses of 3.7% and 6.6%, respectively, mainly caused by the impact of purchase of various new medical equipment and rights-of-use assets relating to operating leases.

毛利及毛利率

本集團總毛利為人民幣129.8百萬元(截至二零二零年六月三十日止六個月:人民幣73.2百萬元),同比增加77.45%。整體毛利率增加至14.9%(截至二零二零年六月三十日止六個月:9.6%),主要原因是:

- (i) 於本中期期間,我們於醫學美容有關科室、兒童醫學有關科室及體檢科方面的大幅增長。該等醫學科室通常需要最先進的治療及診斷支援,並且能夠吸收比其他醫療服務更高的就診增長,而不會大幅調整醫務人員水平或增加成本;
- (ii) 我們針對高端病人的貴賓中心增長,通常比基本醫療服務的利潤率更高(貴賓服務相關收入錄得同期增長9.8%);
- (iii) 增加門診及體檢服務的平均開支,以及利用「康華」品牌在廣東地區獲得更廣泛認可的聲譽提高醫療諮詢價格;及
- (iv) 然而,上述影響已被目前毛利率為負的康心醫院產生的虧損大幅抵銷。康心醫院自開業以來,在運營初期產生大量固定員工成本及其他固定成本。此外,整體直接員工成本及折舊開支分別增長3.7%及6.6%,主要是由於購買各種新醫療設備及與經營租賃相關的使用權資產的影響。



Management Discussion and Analysis

管理層討論及分析

Key Operational Information of our Owned Hospitals

我們擁有的醫院的主要營運資料

The following table sets forth certain key operational information of each of the hospitals owned by the Group for the periods indicated:

下表列出於所示期間本集團擁有的每間醫院的若干主要營運資料：

		For the six months ended 30 June 截至六月三十日止六個月		
		Change 變動	2021 二零二一年	2020 二零二零年
Inpatient healthcare services	住院醫療服務			
Inpatient visits:	住院人次：			
Kanghua Hospital	康華醫院	+16.0%	24,191	20,862
Renkang Hospital	仁康醫院	+39.7%	6,285	4,500
Kangxin Hospital	康心醫院	+24.6%	832	668
Total inpatient visits	住院總人次	+20.3%	31,308	26,030
Average spending per visit (RMB)	每人次平均開支(人民幣元)			
Kanghua Hospital	康華醫院	-14.3%	16,525.3	19,292.8
Renkang Hospital	仁康醫院	+4.9%	11,492.4	10,959.8
Kangxin Hospital	康心醫院	-23.5%	18,507.2	24,178.1
Outpatient healthcare services	門診醫療服務			
Outpatient visits:	門診人次：			
Kanghua Hospital	康華醫院	+18.9%	512,460	431,161
Renkang Hospital	仁康醫院	+37.1%	175,782	128,248
Kangxin Hospital	康心醫院	+43.1%	10,244	7,159
Total outpatient visits	門診總人次	+23.3%	698,486	566,568
Average spending per visit (RMB)	每人次平均開支(人民幣元)			
Kanghua Hospital	康華醫院	+3.3%	447.3	432.9
Renkang Hospital	仁康醫院	-2.9%	277.7	286.1
Kangxin Hospital	康心醫院	-20.7%	349.1	440.3
Physical examination services	體檢服務			
Physical examination visits:	體檢人次：			
Kanghua Hospital	康華醫院	+31.5%	28,388	21,582
Renkang Hospital	仁康醫院	+20.8%	28,338	23,453
Total physical examination visits	體檢總人次	+26.0%	56,726	45,035
Average spending per visit (RMB)	每人次平均開支(人民幣元)			
Kanghua Hospital	康華醫院	+37.3%	1,522.9	1,108.8
Renkang Hospital	仁康醫院	+132.7%	320.7	137.8

Management Discussion and Analysis

管理層討論及分析

Other Income

The other income of the Group primarily consisted of bank and other interest income, investment income, government subsidies, rental income and others. In the first half of 2021, other income amounted to RMB15.8 million (six months ended 30 June 2020: RMB15.8 million), representing a period-on-period decrease of approximately 0.3%, primarily attributable to (i) a decrease in bank and other interest income to RMB0.9 million (six months ended 30 June 2020: RMB2.6 million) mainly due to a decrease average bank balance and the lack of fixed deposits placed with banks with higher interest returns during the current interim period; (ii) an increase in investment income from financial assets at FVTPL to RMB4.7 million (six months ended 30 June 2020: RMB3.1 million) primarily due to higher return achieved with certain principal-protected structured deposit made during the current interim period; and (iii) a decrease in rental income to RMB1.8 million (six months ended 30 June 2020: RMB2.9 million) due to more rental concession given to staff during the current interim period.

As part of the Group's cash management to maximise return on idle cash, the Group invested in certain principal-protected structured deposit products issued by a PRC commercial bank and portfolio investment fund (all classified as financial assets at FVTPL) to achieve higher interest income and capital gain return without interfering with business operations or capital expenditures to earn better return on our excess cash balance, which is consistent with our cash management policy.

Other Expenses, Gains and Losses

The other expenses, gains and losses of the Group primarily consisted of fair value gain (loss) on financial assets at FVTPL, net exchange gain(loss), donations and loss on disposals of property, plant and equipment. In the first half of 2021, other expenses, gains and losses amounted to a net gain of RMB2.6 million (six months ended 30 June 2020: net loss of RMB2.9 million), primarily attributable to (i) a recorded fair value gain on financial assets at FVTPL of RMB3.7 million (six months ended 30 June 2020: fair value loss of RMB2.6 million) during the current interim period; (ii) a recorded net exchange loss of RMB1.0 million (six months ended 30 June 2020: net exchange gain of RMB1.3 million) mainly arising from our Hong Kong dollar denominated financial assets; and (iii) donations made during the Reporting Period of RMB0.1 million (six months ended 30 June 2020: RMB1.4 million).

其他收入

本集團的其他收入主要包括銀行及其他利息收入、投資收入、政府補貼、租金收入及其他。於二零二一年上半年，其他收入為人民幣15.8百萬元（截至二零二零年六月三十日止六個月：人民幣15.8百萬元），同比下降約0.3%，主要是由於(i)銀行及其他利息收入減少至人民幣0.9百萬元（截至二零二零年六月三十日止六個月：人民幣2.6百萬元），主要是由於本中期間平均銀行結餘減少，且缺少存放可獲得較高利息回報的銀行定期存款；(ii)按公平值計入損益的金融資產的投資收入增加至人民幣4.7百萬元（截至二零二零年六月三十日止六個月：人民幣3.1百萬元），主要是由於本中期間已作出若干保本結構性存款以取得較高回報；及(iii)由於本中期間授予員工更多租金優惠，租金收入減少至人民幣1.8百萬元（截至二零二零年六月三十日止六個月：人民幣2.9百萬元）。

作為本集團為盡量提高閒置現金回報的現金管理的一部份，本集團投資於一家中國商業銀行發行的若干保本結構性存款產品以及投資組合基金（全部分類為按公平值計入損益的金融資產）以獲取更高利息收入及資本收益回報，以便在不影響業務營運或資本開支的情況下利用剩餘資金賺取更高的回報率，這與我們的現金管理政策一致。

其他開支、收益及虧損

本集團的其他開支、收益及虧損主要包括按公平值計入損益的金融資產的公平值收益（虧損）、淨匯兌收益（虧損）、捐贈以及出售物業、廠房及設備的虧損。於二零二一年上半年，其他開支、收益及虧損為收益淨額人民幣2.6百萬元（截至二零二零年六月三十日止六個月：虧損淨額人民幣2.9百萬元），主要歸因於(i)於本中期間錄得按公平值計入損益的金融資產的公平值收益為人民幣3.7百萬元（截至二零二零年六月三十日止六個月：公平值虧損人民幣2.6百萬元）；(ii)錄得淨匯兌虧損人民幣1.0百萬元（截至二零二零年六月三十日止六個月：淨匯兌收益人民幣1.3百萬元），主要來自以港元計值的金融資產；及(iii)於報告期作出的捐贈為人民幣0.1百萬元（截至二零二零年六月三十日止六個月：人民幣1.4百萬元）。



Management Discussion and Analysis

管理層討論及分析

Net Reversal of Impairment Losses under Expected Credit Loss Model (ECL)

During the Reporting Period, impairment losses under expected credit loss model recorded a net reversal of provision of RMB1.3 million (six months ended 30 June 2020: nil). Over the past few years, the Group has increased its efforts to recover overdue debts, including recovering receivables from patients through legal actions, as well as tightening credit reviews given to corporate customers. The net reversal of provision is mainly attributable to an improved aging of the Group's accounts receivables and certain long outstanding debts which have been recovered by the Group during the current interim period.

The Group collectively assesses ECL for the accounts receivables, except for accounts receivables from the PRC government's social insurance scheme and certain credit-impaired debtors which are assessed for ECL individually. The provision rates are based on internal credit ratings as groupings of various receivables that have similar loss patterns. The collective assessment is based on the Group's historical default rates taking into consideration forward-looking information that is reasonable and available without undue costs or effort. At every reporting date, the historically observed default rates are reassessed and changes in the forward-looking information are considered.

The management of the Group closely monitors the credit quality of accounts receivables and considers the debts that are neither past due nor impaired to be of a good credit quality. Receivables that were neither past due nor impaired related to the customers for whom there was no history of default. As part of the Group's credit risk management, the Group uses accounts receivables' aging to assess the impairment for its accounts receivables except for accounts receivables from the PRC government's social insurance schemes and certain credit-impaired debtors of which ECL are assessed individually. These receivables consist of a large number of small patients with common risk characteristics that are representative of the patients' abilities to pay all amounts due in accordance with the contractual terms.

預期信貸虧損(預期信貸虧損)模式項下之減值虧損撥回淨額

於報告期，預期信貸虧損模式項下減值虧損錄得撥備撥回淨額人民幣1.3百萬元(截至二零二零年六月三十日止六個月：零)。於過往數年，本集團加大力度收回逾期債務，包括透過法律行動收回患者的應收款項，以及收緊對企業客戶的信貸審查。撥備撥回淨額主要由於本集團應收賬款的賬齡獲得改善及本集團於本中期期間已收回若干長期未償還債務所致。

本集團就應收賬款共同評估預期信貸虧損，惟中國政府社會保險計劃及若干獨立評估預期信貸虧損的信貸減值債務人的應收賬款除外。撥備率以內部信貸評級為基礎，作為具有類似虧損模式之各類應收款項的分組。共同評估以本集團的歷史違約率為基礎，並考慮合理且無需不必要的成本或努力即可獲得之前瞻性資料而作出。在各報告日期，重新評估歷史可觀察的違約率，並考慮前瞻性資料的變動。

本集團管理層密切監察應收賬款的信貸質素，並認為無逾期亦無減值的債項具有良好的信貸質素。無逾期亦無減值的應收款項與並無違約記錄的客戶有關。作為本集團信貸風險管理的一部分，本集團使用應收賬款的賬齡評估其應收賬款的減值情況，惟中國政府的社會保險計劃及若干獨立評估預期信貸虧損的信貸減值債務人的應收賬款除外。該等應收款項由大量具有共同風險特徵的小病患組成，該等病患代表病患按照合約條款支付所有應付金額的能力。

Management Discussion and Analysis

管理層討論及分析

Impairment of Goodwill

During the year ended 31 December 2018, the Group recognised (i) goodwill of RMB56.6 million arising from the acquisition of Anhui Hualin Group, which has been allocated to the CGU of rehabilitation and other healthcare services business (the Anhui Hualin CGU); and (ii) goodwill of RMB125.4 million arising from the acquisition of Kangxin Hospital, which has been allocated to the CGU of hospital services business (the Kangxin Hospital CGU). As at 30 June 2021 (the Group's interim reporting date), the Board conducted a review of the carrying values of the aforementioned CGUs.

The recoverable amounts of the Anhui Hualin CGU and Kangxin Hospital CGU have been determined based on a value in use calculation with reference to valuation reports prepared by an independent professional valuer. The calculations use the respective cash flow projections of Anhui Hualin Group and Kangxin Hospital based on their financial budgets approved by the management of the Group. The key assumptions are growth rates and pre-tax discount rates, which are estimated based on past practices and expectations of future changes in the market. As at 30 June 2021, after taking into consideration of the historical performances and most recent actual performances of the Anhui Hualin CGU and Kangxin Hospital CGU, the Board believe that any reasonably possible changes in any of these assumptions would not cause the carrying amount of each cash generating unit to exceed its recoverable amount and considers that no further impairment is required in respect of the goodwill allocated to the Anhui Hualin CGU and Kangxin Hospital CGU.

As at 30 June 2021, the carrying amount of goodwill relating to the Anhui Hualin CGU is approximately RMB29.1 million (31 December 2020: RMB29.1 million) and the Kangxin Hospital CGU is approximately RMB15.5 million (31 December 2020: RMB15.5 million).

商譽減值

截至二零一八年十二月三十一日止年度，本集團已確認(i)收購安徽樺霖集團產生的商譽人民幣56.6百萬元，該商譽已分配至康復及其他醫療服務業務的現金產生單位(安徽樺霖現金產生單位)；及(ii)收購康心醫院產生的商譽人民幣125.4百萬元已分配至醫院服務業務的現金產生單位(康心醫院現金產生單位)。於二零二一年六月三十日(本集團中期報告日期)，董事會已對上述現金產生單位的賬面值進行審閱。

安徽樺霖現金產生單位及康心醫院現金產生單位的可收回金額乃根據使用價值計算方法並經參考獨立專業估值師編製的估值報告後釐定。該計算方法使用基於本集團管理層所批准的財務預算的安徽樺霖集團及康心醫院各自的現金流量預測。關鍵假設指根據市場過往常規及未來變動預期所估計的增長率及稅前折現率。於二零二一年六月三十日，經考慮到安徽樺霖現金產生單位及康心醫院現金產生單位的歷史表現及最近期實際表現後，董事會相信該等假設的任何合理可能變動將不會導致各現金產生單位的賬面值超出其可收回金額，並認為分配至安徽樺霖現金產生單位及康心醫院現金產生單位之商譽毋須進一步減值。

於二零二一年六月三十日，與安徽樺霖現金產生單位有關的商譽賬面值約為人民幣29.1百萬元(二零二零年十二月三十一日：人民幣29.1百萬元)，而康心醫院現金產生單位的商譽賬面值則約為人民幣15.5百萬元(二零二零年十二月三十一日：人民幣15.5百萬元)。



Management Discussion and Analysis

管理層討論及分析

As disclosed in this report, the COVID-19 pandemic beginning in year 2020 and up to the present has affected almost all industries and sectors. The situation has caused some businesses to temporarily cease operations for a significant amount of time during the year of 2020. At present, our hospitals and rehabilitation centres have resumed normal operation and are largely operating as usual with stringent and restrictive policies and controls being implemented. The Board is of the view that the operations and adverse financial conditions of the Group as a whole for the current interim period are largely temporary. The effects of the COVID-19 pandemic are less likely to be permanent, primarily because the majority of our revenue from healthcare services is not directly correlated to the economic cycles and the overall demand for the Group's healthcare services (particularly those that are essential to health and well-being) is likely to remain strong in the medium to long term.

Administrative Expenses

The administrative expenses of the Group primarily consisted of staff costs, repairs and maintenance expenses, office expenses, depreciation and amortisation, rental expenses, utilities expenses, entertainment and travelling expenses and other expenses. In the first half of 2021, administrative expenses amounted to RMB103.4 million (six months ended 30 June 2020: RMB123.2 million), representing a period-on-period decrease of approximately 16.1%, primarily due to (i) a significant decrease in administrative staff-related costs to RMB36.9 million (six months ended 30 June 2020: RMB54.9 million) as a result of the decline in number of administrative staff headcounts and deduction in bonus payment and related staff benefits expenditure during the current interim period following a more tightened cost control; (ii) a decrease in depreciation and amortisation to RMB18.0 million (six months ended 30 June 2020: RMB18.4 million); and (iii) an increase in overall repair and maintenance expenditure to RMB9.7 million (six months ended 30 June 2020: RMB6.4 million) as more upgrades and maintenance were carried out during the current interim period when business operation capacity remained low and anticipated a higher and faster recovery in later half of the year.

如本報告所披露，於二零二零年開始直到現在，COVID-19 疫情已近乎對各行各業造成影響。該情況引致部分企業於二零二零年大量時間暫時停業。目前，我們的醫院及康復中心已恢復正常營運且在很大程度上照常營運，並實施嚴格的限制性措施及防控。董事會認為，本集團於本中中期期間的整體運營及不利財務狀況很大程度上為暫時狀況。COVID-19 疫情的影響不太可能永遠存在，主要因為我們自醫療服務所得的大部分收益與經濟週期並非直接相關，及於中長期內對本集團醫療服務（尤其是對健康及安康至關重要的服務）的整體需求仍有可能保持強勁。

行政開支

本集團的行政開支主要包括員工成本、維修及保養成本、辦公室開支、折舊及攤銷、租金開支、水電開支、交際及交通開支以及其他開支。於二零二一年上半年，行政開支為人民幣103.4百萬元（截至二零二零年六月三十日止六個月：人民幣123.2百萬元），同比減少約16.1%，主要由於(i)行政人員相關成本大幅下降至人民幣36.9百萬元（截至二零二零年六月三十日止六個月：人民幣54.9百萬元），由於成本控制更加嚴格，於本中中期期間行政員工人數減少、花紅支付及相關員工福利開支減少；(ii)折舊及攤銷減少至人民幣18.0百萬元（截至二零二零年六月三十日止六個月：人民幣18.4百萬元）；及(iii)整體維修及保養開支增至人民幣9.7百萬元（截至二零二零年六月三十日止六個月：人民幣6.4百萬元），由於在業務運營能力仍然較低的本中中期期間內進行更多的升級及維護，預計下半年將出現更高更快的復甦。

Management Discussion and Analysis

管理層討論及分析

Finance Costs

Finance costs for Reporting Period amounted to RMB10.2 million (six months ended 30 June 2020: RMB11.3 million), representing a period-on-period decrease of 9.6%. Finance costs for the Reporting Period represented (i) interest on bank loans raised of RMB8.7 million (six months ended 30 June 2020: RMB7.2 million); (ii) the interest element relating to lease liabilities charged to profit or loss during the current interim period due to application of IFRS 16 relating to leases of RMB5.9 million (six months ended 30 June 2020: RMB6.4 million); and (iii) adjustment by amount of interest capitalised in the cost of qualifying assets of RMB4.4 million (six months ended 30 June 2020: RMB2.5 million).

Income Tax Expenses

The income tax expenses of the Group primarily consisted of PRC enterprise income tax and Hong Kong Profits Tax. In the first half of 2021, income tax expenses amounted to RMB21.0 million (six months ended 30 June 2020: RMB1.8 million), representing a period-on-period increase of approximately 1,086.9%. The subsidiaries of the Group in the PRC are generally subject to income tax rate of 25% of their respective taxable income. Our effective tax rate for the Reporting Period was 58.7% (six months ended 30 June 2020: -1.4%). The increase in income tax expenses was primarily due to the increase in profits generated at Kanghua Hospital and Renkang Hospital during the Reporting Period, as well as, the tax effect that tax losses are not recognised for losses incurred of Kangxin Hospital.

Profit (Loss) for the Period

In the first half of 2021, the Group recorded profit for the Reporting Period amounting to RMB14.8 million (six months ended 30 June 2020: loss for the period of RMB126.2 million), and profit attributable to the shareholders amounted to RMB30.9 million (six months ended 30 June 2020: loss attributable to the shareholders of RMB106.3 million).

融資成本

報告期的融資成本為人民幣10.2百萬元(截至二零二零年六月三十日止六個月:人民幣11.3百萬元), 同比下降9.6%。報告期的融資成本為(i)所籌借銀行貸款的利息人民幣8.7百萬元(截至二零二零年六月三十日止六個月:人民幣7.2百萬元); (ii)由於應用與租賃人民幣5.9百萬元(截至二零二零年六月三十日止六個月:人民幣6.4百萬元)相關的國際財務報告準則第16號, 故指與本中期間期自損益扣除的租賃負債相關的利息要素; 及(iii)按於合資格資產成本人民幣4.4百萬元(截至二零二零年六月三十日止六個月:人民幣2.5百萬元)內資本化的利息金額調整。

所得稅開支

本集團的所得稅開支主要包括中國企業所得稅及香港利得稅。於二零二一年上半年, 所得稅開支為人民幣21.0百萬元(截至二零二零年六月三十日止六個月:人民幣1.8百萬元), 同比增加約1,086.9%。本集團於中國之附屬公司一般須就其應課稅所得收入按25%之所得稅稅率繳納稅項。我們於報告期的實際稅率為58.7%(截至二零二零年六月三十日止六個月:-1.4%)。所得稅開支增加主要由於報告期康華醫院及仁康醫院所產生溢利增加以及未就康心醫院所產生虧損確認稅項虧損的稅收影響。

期內溢利(虧損)

於二零二一年上半年, 本集團於報告期錄得溢利人民幣14.8百萬元(截至二零二零年六月三十日止六個月:期內虧損人民幣126.2百萬元), 及股東應佔溢利為人民幣30.9百萬元(截至二零二零年六月三十日止六個月:股東應佔虧損人民幣106.3百萬元)。



Management Discussion and Analysis

管理層討論及分析

FINANCIAL POSITION

Property, Plant and Equipment, Right-of-use assets and Deposits Paid for Acquisition of Property, Plant and Equipment

During the Reporting Period, the Group acquired property, plant and equipment and incurred expenditure on construction in progress of RMB32.7 million (six months ended 30 June 2020: RMB26.1 million) and RMB44.4 million (six months ended 30 June 2020: RMB35.1 million), respectively, mainly for the purpose of upgrading and expanding the service capacity of our hospital operations and construction cost incurred at Phase II medical facility at our Kangxin Hospital.

As at 30 June 2021, the Group had right-of-use assets of RMB371.7 million (31 December 2020: RMB382.8 million), which included leasehold lands of RMB229.0 million (31 December 2020: RMB231.5 million) and leasehold land and buildings relating to leases of RMB142.7 million (31 December 2020: RMB151.3 million) recognised in accordance with IFRS 16. During the Reporting Period, the Group entered into new lease agreements for the use of properties in the PRC ranging from 2 to 5 years. The Group is required to make fixed monthly payments. On the commencement of the lease, the Group recognised right-of-use assets and lease liabilities of RMB6.7 million (six months ended 30 June 2020: RMB1.0 million) each relating to those new leases.

As at 30 June 2021, the Group had deposits paid for acquisition of property, plant and equipment amounting to RMB94.5 million (31 December 2020: RMB91.2 million). The deposits mainly represented deposits paid for construction cost of Phase II medical facility at our Kangxin Hospital and amount paid for acquisition of new medical equipment and other new facilities as the Group continued to upgrade its medical facilities and expand its operation capacity.

財務狀況

物業、廠房及設備、使用權資產以及就收購物業、廠房及設備支付的按金

於報告期內，本集團購買物業、廠房及設備以及就在建工程產生支出分別為人民幣32.7百萬元及人民幣44.4百萬元（截至二零二零年六月三十日止六個月：分別為人民幣26.1百萬元及人民幣35.1百萬元），主要用於升級及擴大我們醫院營運的服務能力以及我們康心醫院二期醫療設施產生的建設成本。

於二零二一年六月三十日，本集團的使用權資產為人民幣371.7百萬元（二零二零年十二月三十一日：人民幣382.8百萬元），包括租賃土地人民幣229.0百萬元（二零二零年十二月三十一日：人民幣231.5百萬元）及根據國際財務報告準則第16號確認與租賃有關的租賃土地及樓宇人民幣142.7百萬元（二零二零年十二月三十一日：人民幣151.3百萬元）。於報告期內，本集團訂立新租賃協議，以在中國使用物業介乎2至5年。本集團須按月支付固定費用。於租賃開始時，本集團就該等新租賃確認各自使用權資產及租賃負債人民幣6.7百萬元（截至二零二零年六月三十日止六個月：人民幣1.0百萬元）。

於二零二一年六月三十日，本集團就收購物業、廠房及設備支付按金人民幣94.5百萬元（二零二零年十二月三十一日：人民幣91.2百萬元）。按金主要指就康心醫院二期醫療設施建設成本支付的按金及就購買新的醫療設備及其他新設施支付的款項，是由於本集團繼續升級醫療設施並增強經營能力。

Management Discussion and Analysis

管理層討論及分析

Accounts and Other Receivables

The account receivables of the Group primarily consisted of balances due from social insurance funds, certain corporate customers and individual patients. As at 30 June 2021, accounts receivables increased to RMB230.4 million (31 December 2020: RMB204.7 million), of which 78.9% (31 December 2020: 76.9%) were aged within 90 days. Average accounts receivables turnover days for the current period is 45.2 days (31 December 2020: 49.0 days). The increase in accounts receivables and decrease in accounts receivable turnover days are primarily due to (i) the increase in revenue of our hospitals operations and rehabilitation and other healthcare services operations during the current interim period; and (ii) the accelerated settlement from Dongguan social insurance funds and other government authorities, and certain corporate customers as the overall economic environment and business environment recovered from the COVID-19 pandemic in year 2020.

The other receivables of the Group primarily consisted of prepayments to suppliers, interest receivables and others. As at 30 June 2021, other receivables increased to RMB47.8 million (31 December 2020: RMB44.0 million), primarily due to (i) a decrease in prepayments to suppliers to RMB13.1 million (31 December 2020: RMB16.4 million); and (ii) an increase in other receivables mainly due to improvement in the Group's overall business operation during the current interim period and expansion of the Group's operations of our rehabilitation and other healthcare services segment and elderly healthcare services.

Accounts and Other Payables and Provision

The accounts and other payables and provision of the Group primarily consisted of accounts payables, accrued expenses, receipts in advance, payables for acquisition of property, plant and equipment, provision for medical dispute claims, other tax payables and others. As at 30 June 2021, accounts and other payables and provision increased to RMB625.9 million (31 December 2020: RMB516.9 million) primarily attributable to: (i) an increase in accounts payable to RMB281.2 million (31 December 2020: RMB256.8 million) as a result of increases in our hospital services operations and purchases of supplies during the current interim period; (ii) a decrease of accrued expenses to RMB85.1 million (31 December 2020: RMB94.0 million) mainly because of decreases in operational and administrative costs such as staff costs; and (iii) an increase in receipt in advance to RMB182.9 million (31 December 2020: RMB100.7 million) due to an increase in temporary funds received from social security insurance fund.

應收賬款及其他應收款項

本集團的應收賬款主要包括應收社保基金、若干公司客戶和個人病人的結餘。於二零二一年六月三十日，應收賬款增加至人民幣230.4百萬元（二零二零年十二月三十一日：人民幣204.7百萬元），其中78.9%（二零二零年十二月三十一日：76.9%）的賬齡為90天內。本期間平均應收賬款周轉天數為45.2天（二零二零年十二月三十一日：49.0天）。應收賬款增加及應收賬款周轉天數減少主要由於(i)本中中期期間我們的醫院營運以及康復及其他醫療服務營運收益增加；及(ii)隨著整體經濟環境及商業環境自二零二零年COVID-19疫情中恢復，東莞社會保險基金及其他政府部門以及部分企業客戶加速結算。

本集團的其他應收款項主要包括對供應商的預付款、應收利息及其他。於二零二一年六月三十日，其他應收款項增至人民幣47.8百萬元（二零二零年十二月三十一日：人民幣44.0百萬元），主要由於(i)對供應商的預付款減少至人民幣13.1百萬元（二零二零年十二月三十一日：人民幣16.4百萬元）；及(ii)其他應收款項增加，主要是由於本中中期期間內本集團整體業務運營的改善以及本集團康復及其他醫療服務部門以及老年人醫療服務業務的擴大。

應付賬款及其他應付款項以及撥備

本集團的應付賬款及其他應付款項以及撥備主要包括應付賬款、應計開支、預收款項、收購物業、廠房及設備應付款項、醫療糾紛索賠撥備、其他應付稅項及其他。於二零二一年六月三十日，應付賬款及其他應付款項以及撥備增加至人民幣625.9百萬元（二零二零年十二月三十一日：人民幣516.9百萬元），主要由於：(i)本中中期期間醫院服務業務及物資採購增加導致應付賬款增加至人民幣281.2百萬元（二零二零年十二月三十一日：人民幣256.8百萬元）；(ii)應計開支減少至人民幣85.1百萬元（二零二零年十二月三十一日：人民幣94.0百萬元），主要由於營運及行政費用（如員工成本）減少；(iii)自社保基金獲得的臨時資金增加使得預收款項增加至人民幣182.9百萬元（二零二零年十二月三十一日：人民幣100.7百萬元）。



Management Discussion and Analysis

管理層討論及分析

Net Current Assets and Net Assets

As at 30 June 2021, the Group recorded net current assets of RMB298.6 million (31 December 2020: RMB294.4 million) and net assets position of RMB1,422.3 million (31 December 2020: RMB1,407.5 million).

LIQUIDITY AND CAPITAL RESOURCES

Financial Resources

The Group continued to maintain a strong financial position with cash and cash equivalents of RMB213.4 million (31 December 2020: RMB179.7 million) as at 30 June 2021. The Group continues to generate steady cash inflow from operations and coupled with sufficient cash and bank balances, in the opinion of the Directors, the Group will have adequate and sufficient liquidity and financial resources to meet the working capital requirement of the Group for at least the next twelve months following the end of the Reporting Period.

As at 30 June 2021, as part of the Group's cash management activities, the Group had investments (classified as financial assets at FVTPL) in aggregate of RMB570.5 million (31 December 2020: RMB467.7 million), primarily consisting of (i) portfolio investment fund of RMB70.5 million (31 December 2020: RMB67.7 million), representing a portfolio investment fund, the underlying portfolio of which included a mixture of cash and shares that are primarily listed in Hong Kong; and (ii) structured short-term bank deposits of RMB500.0 million (31 December 2020: RMB400.0 million), representing principal-protected products issued by a PRC commercial bank.

流動資產淨值及淨資產

於二零二一年六月三十日，本集團錄得流動資產淨值及淨資產狀況分別為人民幣298.6百萬元(二零二零年十二月三十一日：人民幣294.4百萬元)及人民幣1,422.3百萬元(二零二零年十二月三十一日：人民幣1,407.5百萬元)。

流動資金及資本資源

財務資源

本集團於二零二一年六月三十日繼續維持強勁的財務狀況，現金及現金等價物達人民幣213.4百萬元(二零二零年十二月三十一日：人民幣179.7百萬元)。本集團繼續從經營活動產生穩定的現金流入，加上足夠的現金及銀行結餘，董事認為，本集團將有足夠和充足的流動資金及財務資源，以滿足本集團於報告期結束後至少未來十二個月的營運資金需求。

於二零二一年六月三十日，作為本集團現金管理活動的一部分，本集團作出投資(分類為按公平值計入損益的金融資產)合共人民幣570.5百萬元(二零二零年十二月三十一日：人民幣467.7百萬元)，主要包括(i)投資組合基金人民幣70.5百萬元(二零二零年十二月三十一日：人民幣67.7百萬元)，即一種投資組合基金，其相關投資組合包括現金及主要在香港上市的股份；及(ii)結構性短期銀行存款人民幣500.0百萬元(二零二零年十二月三十一日：人民幣400.0百萬元)，指由一家中國商業銀行發行的保本產品。

Management Discussion and Analysis

管理層討論及分析

As part of the Group's cash management policy to manage excess cash, the Group purchases investment products from financial institutions to achieve higher interest income without interfering with business operations or capital expenditures. The Group carefully balances the risks and returns associated with the investment products when making the investment decisions. The senior management of the Group is closely involved in scrutinising any decision of the Group to purchase investment products. The investment products should generally satisfy the following criteria, namely (i) its term should generally not exceed one year; (ii) it should not interfere with the Group's business operations or capital expenditures; (iii) it should be issued by a reputable bank with which the Group has a long-term relationship, preferably exceeding five years; and (iv) the underlying investment portfolio should generally be low risk.

作為本集團藉以管理超額現金的其中一項現金管理政策，本集團在不影響業務營運或資本支出的前提下，向金融機構購買投資產品，以獲取更高的利息收益。本集團在制定相關投資決策時，會謹慎衡量投資產品的風險與收益。本集團高級管理層密切參與審議本集團有關購買投資產品的一切相關決策。本集團選擇的投資產品通常須符合以下幾項標準，即：(i) 其收益週期一般不超過一年；(ii) 其將不影響本集團的業務營運或資本支出；(iii) 其應由與本集團有長期合作關係（最好超過5年）及具有良好信譽的銀行發行；及(iv) 相關投資組合通常應具低風險。

Cash Flow Analysis

The table below sets forth the information as extracted from the condensed consolidated statement of cash flow of the Group for the periods indicated:

現金流量分析

下表載列從本集團於所示期間簡明綜合現金流量表摘錄的資料：

		For the six months ended 30 June		
		截至六月三十日止六個月		
		2021	2020	
		二零二一年	二零二零年	
		Change	RMB'000	RMB'000
		變動	人民幣千元	人民幣千元
Net cash generated from operating activities	經營活動所得現金淨額	+492.2%	155,770	26,303
Net cash used in investing activities	投資活動所用現金淨額	+26.7%	(163,611)	(129,173)
Net cash generated from (used in) financing activities	融資活動所得(所用)現金淨額	N/A 不適用	41,989	(27,840)
Net increase (decrease) in cash and cash equivalents	現金及現金等價物增加(減少)淨額		34,148	(130,710)

Net cash generated from operating activities

經營活動所得現金淨額

During the Reporting Period, the net cash generated from operating activities amounted to RMB155.8 million (six months ended 30 June 2020: RMB26.3 million), representing a period-on-period increase of 492.2%, which is primarily attributable to our significantly improved adjusted EBITDA for the Reporting Period.

於報告期內，經營活動所得現金淨額為人民幣155.8百萬元（截至二零二零年六月三十日止六個月：人民幣26.3百萬元），同比增加492.2%，主要由於報告期內經調整EBITDA大幅改善。



Management Discussion and Analysis

管理層討論及分析

Net cash used in investing activities

During the Reporting Period, the net cash used in investing activities amounted to RMB163.6 million (six months ended 30 June 2020: RMB129.2 million), representing a period-on-period increase of 26.7%, which is primarily attributable to (i) an increase in purchase of financial assets at FVTPL during the current interim period for the purpose utilising idle cash balances for better investment returns; (ii) an increase investment income received financial assets at FVTPL and interest received as compared with same period last year; (iii) an increase in purchase of property, plant and equipment during the current interim period; and (iv) however, (i) to (iii) are partially offset by the decrease in deposits paid for acquisition of property, plant and equipment during the current interim period.

Net cash generated from (used in) financing activities

During the Reporting Period, the net cash generated from financing activities amounted to RMB42.0 million (six months ended 30 June 2020: net cash used in financing activities of RMB27.8 million), which is primarily attributable to the fact that (i) the Group raised new bank loans amounting to RMB30.0 million during the current interim period (six months ended 30 June 2020: nil); (ii) the Group has made net advances from the non-controlling shareholders of subsidiaries of RMB45.6 million (six months ended 30 June 2020: net advances of RMB2.0 million); and (iii) there was repayment of lease liabilities of RMB14.8 million (six months ended 30 June 2020: RMB13.4 million).

Significant Investment, Acquisition and Disposal

Save as disclosed in this report, the Group had no significant investment, acquisition or disposal during the Reporting Period.

Cash Management Activities

As part of the Group's cash management, the Group has from time to time purchased investment products, such as structured deposits, issued by a reputable PRC commercial bank usually with terms of less than six months and portfolio investment funds to achieve higher interest income without interfering with business operations or capital expenditures. The investment products are not rated by any credit rating agency but are classified as low-risk by the issuing bank and may involve liquid listed securities. The Group carefully balances the risks and returns associated with the investment products when making the investment decisions. The senior management of the Group is closely involved in scrutinising any decision of the Group to purchase investment products.

投資活動所用現金淨額

於報告期內，投資活動所用現金淨額為人民幣163.6百萬元(截至二零二零年六月三十日止六個月：人民幣129.2百萬元)，同比增長26.7%，主要由於(i)於本中期期間，增加購買按公平值計入損益的金融資產，以便利用閒置現金結餘獲得更好的投資回報；(ii)與去年同期相比，按公平值計入損益的金融資產所得投資收入及所得利息增加；(iii)於本中期期間，購買物業、廠房及設備增加；及(iv)然而，第(i)至(iii)項部分由本中期期間內購置物業、廠房及設備而支付的按金減少所抵銷。

融資活動所得(所用)現金淨額

於報告期間，融資活動所得現金淨額為人民幣42.0百萬元(截至二零二零年六月三十日止六個月：融資活動所用現金淨額人民幣27.8百萬元)，主要歸因於下列各項：(i)本集團於本中期期間籌集新銀行貸款人民幣30.0百萬元(截至二零二零年六月三十日止六個月：零)；(ii)本集團向附屬公司的非控股股東作出的墊款淨額為人民幣45.6百萬元(截至二零二零年六月三十日止六個月：墊款淨額人民幣2.0百萬元)；及(iii)償還租賃負債人民幣14.8百萬元(截至二零二零年六月三十日止六個月：人民幣13.4百萬元)。

重大投資、收購及出售

除本報告所披露者外，本集團於報告期內並無任何重大投資、收購或出售。

現金管理活動

作為本集團現金管理的一部份，本集團不時購買由一家聲譽良好的中國商業銀行發行期限通常少於六個月的投資產品(如結構性存款)及投資組合基金，在不影響業務營運或資本開支的前提下，以獲取更高的利息收益。投資產品未獲任何信貸評級機構評級，但由發行銀行分類為低風險，並可能涉及流通上市證券。本集團在制定相關投資決策時，會謹慎衡量投資產品的風險與收益。本集團高級管理層密切參與審議本集團有關購買投資產品的一切相關決策。

Management Discussion and Analysis

管理層討論及分析

Capital Expenditure

The Group regularly makes capital expenditure to expand its operations, maintain its medical facilities and improve its operating efficiency. Capital expenditure primarily consist of purchases of property, plant and equipment. The capital expenditure of the Group during the Reporting Period was RMB77.1 million (six months ended 30 June 2020: RMB43.1 million). The Group has financed its capital expenditures mainly through cash flows generated from its operating activities and bank loans.

USE OF PROCEED FROM THE INITIAL PUBLIC OFFERING

The Company's H shares were listed on the Hong Kong Stock Exchange on 8 November 2016. The Company's net proceeds from the initial public offering of its H shares amount to approximately RMB782.6 million (equivalently to approximately HK\$874.9 million) after deducting underwriting commissions and all related expenses. The net proceeds from the initial public offering have been and will be utilised in accordance with the purposes set out in the Prospectus.

Up to 30 June 2021, of the net proceeds from the initial public offering, (i) RMB73.6 million, representing approximately 9.4% of the net proceeds, has been utilised and used as general working capital; (ii) RMB134.7 million, representing approximately 17.2% of the net proceeds, has been utilised and used on expansion of our current operations and upgrading our hospital's facilities; and (iii) RMB158.8 million, representing approximately 20.3% of the net proceeds, has been utilised and used for acquisition and potential acquisition of businesses. As at 30 June 2021, out of the balance of the unutilised net proceeds of RMB415.4 million, part of such proceeds has been used to purchase certain financial products (classified as financial assets at FVTPL) to achieve higher interest income and capital return without interfering with our business operations or capital expenditure to earn better return on our excess cash balance, and the remaining balance has been kept at the bank accounts of the Group (included in bank balances and cash). As at the date of this report, the Company does not anticipate any material change to its plan on the use of proceeds as stated in the Prospectus.

資本開支

本集團定期作出資本開支以擴大營運、維持醫療設施並提高經營效率。資本開支主要包括購買物業、廠房及設備。本集團於報告期的資本開支為人民幣77.1百萬元(截至二零二零年六月三十日止六個月：人民幣43.1百萬元)。本集團主要通過經營活動所得現金流量及銀行貸款為資本開支提供資金。

首次公開發售所得款項用途

本公司H股於二零一六年十一月八日於香港聯交所上市。本公司於扣除包銷佣金及所有相關費用後，首次公開發售H股所得款項淨額約為人民幣782.6百萬元(相等於約874.9百萬元)。首次公開發售所得款項淨額已按照並將持續按照招股章程所載用途使用。

截至二零二一年六月三十日，首次公開發售所得款項淨額中(i)人民幣73.6百萬元(佔所得款項淨額約9.4%)已被動用並用於一般營運資金；(ii)人民幣134.7百萬元(佔所得款項淨額約17.2%)已被動用並用於擴大本集團現有業務及升級醫院設施；及(iii)人民幣158.8百萬元(佔所得款項淨額約20.3%)已被動用並用於業務收購及潛在收購。截至二零二一年六月三十日，尚未動用之所得款項淨額結餘為人民幣415.4百萬元，當中部份所得款項已被用於購買若干金融產品(分類為按公平值計入損益的金融資產)，從而獲得較高的利息收入及資本回報，在不干擾我們的業務營運或資本開支的情況下，就我們的超額現金結餘賺取更好的回報，以及餘額乃存於本集團的銀行賬戶(計入銀行結餘及現金)。於本報告日期，本公司預計招股章程所述所得款項用途計劃不會發生任何重大變動。



Management Discussion and Analysis

管理層討論及分析

The following table sets forth the intended purposes for the net proceeds from the initial public offering, the utilisation of such proceeds and the timeline of utilisation estimated by the management:

下表載列首次公開發售所得款項淨額的擬定用途，該等所得款項的動用情況及管理層估計的動用期限：

Purpose 用途	Net proceeds from the initial public offering intended for the purpose as disclosed in the Prospectus (RMB million) 招股章程所披露擬定 用途的首次公開發售 所得款項淨額 (人民幣百萬元)	Utilisation up to 30 June 2021 (RMB million) 截至二零二一年 六月三十日的 動用情況 (人民幣百萬元)	Unutilised amount (RMB million) 未動用金額 (人民幣百萬元)	Expected timeline for the utilisation of the unutilised amount ^{Note} 使用未動用 金額的預期期限 ^{附註}
Expansion of the Group's current operations and upgrading of hospital facilities 擴大本集團現有業務及升級醫院設施	70.4	8.5	61.9	By the end of 31 December 2021 於二零二一年十二月 三十一日前
Expansion of operating capacity and capability in multi-disciplinary specialised treatment and diagnosis and upgrade of medical facilities 擴大營運實力及多學科診治能力以及 升級醫療設施	281.7	126.2	155.5	By the end of 31 December 2021 於二零二一年十二月 三十一日前
Expansion of hospital management operations 擴大醫院管理營運	78.3	–	78.3	By the end of 31 December 2021 於二零二一年十二月 三十一日前
Expansion of healthcare operations in the PRC through selective mergers and acquisitions 通過選擇性併購擴大於中國的醫療業務	273.9	158.8	115.1	By the end of 31 December 2021 於二零二一年十二月 三十一日前
Working capital and other general corporate purposes 營運資金及其他一般公司用途	78.3	73.6	4.6	By the end of 31 December 2021 於二零二一年十二月 三十一日前
Total 總計	782.6	367.1	415.4	

Note: Such timeline is an estimation of the management only and is subject to change on account of the Group's operating conditions and market conditions from time to time. In particular, it should not be taken as an indication that any potential transaction is under negotiation and/or will materialise.

附註：有關期限僅為管理層的估計及可視乎本集團的營運狀況及不時的市況予以更改。尤其是，其不應被視為任何潛在交易正在磋商及／或任何潛在交易將會落實的跡象。

Management Discussion and Analysis

管理層討論及分析

INDEBTEDNESS

Bank Loans

In 2019, the Group obtained new bank loan facilities in the aggregate amount of RMB620.0 million for the purpose of funding the development of the Phase II medical facility and financing the operations of Kangxin Hospital, in which, up to 30 June 2021, RMB315.4 million has been drawn down. As at 30 June 2021, the Group had secured bank loans of carrying amount of RMB283.6 million (31 December 2020: RMB257.8 million). The principal agreements underlying such bank loan facilities include the following:

- (i) a RMB420.0 million fixed asset facility agreement (固定資產借款合同) with Industrial and Commercial Bank of China Limited, Chongqing Jiangbei Branch, pursuant to which RMB169.4 million has been drawn down in year 2019, RMB50.0 million has been drawn down in year 2020 and RMB30.0 million has been draw down during the Reporting Period. The bank loan carried an interest rate at the benchmark lending rate offered by the People's Bank of China (adjusted annually from the drawn down date) and is secured by shares pledged over the entire equity in Kangxin Hospital held by the Company and its non-controlling shareholder. As at 30 June 2021, the effective interest rate of the secured bank loan is 5.82% (31 December 2020: 5.84%) per annum. As at 30 June 2021, the carrying amount of the borrowing in respect of such arrangement amounted to RMB234.2 million (31 December 2020: RMB204.6 million); and

債項

銀行貸款

於二零一九年，本集團獲得新銀行貸款融資合共人民幣620.0百萬元，以為二期醫療設施的發展提供資金及為康心醫院運營撥資，其中截至二零二一年六月三十日已提取人民幣315.4百萬元。於二零二一年六月三十日，本集團有賬面值為人民幣283.6百萬元(二零二零年十二月三十一日：人民幣257.8百萬元)的有抵押銀行貸款。有關銀行貸款融資的主要合同包括以下各項：

- (ii) 與中國工商銀行股份有限公司重慶江北分行訂立的人民幣420.0百萬元的固定資產借款合同，據此，於二零一九年已提取人民幣169.4百萬元、二零二零年已提取人民幣50.0百萬元及報告期已提取人民幣30.0百萬元。銀行貸款利率按中國人民銀行提供的貸款基準利率計算，自提取日期起每年進行調整，以及銀行貸款以本公司及其非控股股東持有的康心醫院全部股權的股份作抵押。於二零二一年六月三十日，有抵押銀行貸款的實際年利率為5.82%(二零二零年十二月三十一日：5.84%)。於二零二一年六月三十日，有關該項安排的借款賬面值達人民幣234.2百萬元(二零二零年十二月三十一日：人民幣204.6百萬元)；及



Management Discussion and Analysis

管理層討論及分析

(ii) a RMB200.0 million financial leasing agreement (融資租賃合同) with Industrial and Commercial Bank of China Leasing Co., Ltd., pursuant to which RMB66.0 million has been drawn down in 2019 (six months ended 30 June 2021: nil). The loan carried an interest rate at the benchmark lending rate offered by the People's Bank of China plus 5%, which was fixed at the drawn down date. This agreement involves a sale and lease back arrangement over certain medical equipment assets of Kangxin Hospital, pursuant to which such assets have been transferred to the lender and leased back to Kangxin Hospital, with an option exercisable by Kangxin Hospital to purchase the assets at a nominal consideration upon the maturity of the lease. Despite that such arrangement assumes the legal form of a lease, the Group retains effective control over such assets; thus, the Group accounted for such arrangement as a secured loan at amortised cost at an effective interest rate of 6.74% (31 December 2020: 6.74%) per annum and repayable in quarterly variable instalments until September 2027. In addition, such assets have been pledged to the lender as security throughout the loan period. As at 30 June 2021, the carrying amount of the borrowing in respect of such arrangement amounted to RMB49.4 million (31 December 2020: RMB53.2 million). As at 30 June 2021, the property, plant and equipment with net book value of RMB38.9 million (31 December 2020: RMB45.5 million) had been pledged to secure the banking facility granted.

In connection with the bank loan facilities above, certain of our controlling shareholders, a non-controlling shareholder of a subsidiary and a related company controlled by certain of our controlling shareholders provided guarantees and undertakings in favour of the relevant lender. The financial assistance provided by certain of our controlling shareholders is exempted from the connected transaction requirements under Chapter 14A of the Hong Kong Listing Rules by virtue of Rule 14A.90 of the Hong Kong Listing Rules.

(iii) 與工銀金融租賃有限公司訂立的人民幣200.0百萬元的融資租賃合同，據此，於二零一九年已提取人民幣66.0百萬元（截至二零二一年六月三十日止六個月：無）。該貸款的利率在提取日已固定，為中國人民銀行所報基準貸款利率加5%。該合同涉及有關康心醫院若干醫療設備資產的售後租回安排，據此，相關資產已轉讓予借方並回租予康心醫院，康心醫院可選擇性按租賃到期時的名義代價購買該資產。儘管該項安排以租賃的合法形式進行，惟本集團仍保有該等資產的實際控制權；因此，本集團將該項安排視為一項有抵押貸款，按攤銷成本計量，實際年利率為6.74%（二零二零年十二月三十一日：6.74%），直至二零二七年九月可按季度分期償還。此外，相關資產已於貸款期間抵押予借方作為一項擔保。於二零二一年六月三十日，有關該安排的借款賬面值為人民幣49.4百萬元（二零二零年十二月三十一日：人民幣53.2百萬元）。於二零二一年六月三十日，賬面淨值為人民幣38.9百萬元（二零二零年十二月三十一日：人民幣45.5百萬元）的物業、廠房及設備已抵押作所授出銀行融資的擔保。

就上述銀行貸款融資而言，我們的多名控股股東、一間附屬公司的一名非控股股東及我們多名控股股東所控制的一間關聯公司已提供以相關借方為受益人的擔保及承諾。根據香港上市規則第14A.90條，多名控股股東提供的財務資助豁免遵守香港上市規則第14A章項下的關連交易規定。

Management Discussion and Analysis

管理層討論及分析

Contingent Liabilities

The Group is subject to legal proceedings and claims in the ordinary of business primarily arising from medical disputes brought by patients. Provision for medical disputes is made based on the status of potential and active claims outstanding as at the end of the relevant period, and primarily taking into account any judicial appraisal or court determination against the Group. As at 30 June 2021, the total stated claim amount of the Group's on-going medical disputes was approximately RMB5.5 million (31 December 2020: RMB6.8 million) and there were certain medical disputes without claim amount stated. Based on the Group's assessment, during the Reporting Period, approximately RMB3.0 million (six months ended 30 June 2020: RMB1.3 million) had been provided and included in accounts and other payables and provision of the Group.

As at 30 June 2021, the Group had no contingent liabilities or guarantees that would have a material impact on the financial position or operation of the Group.

Pledge of Assets

As at 30 June 2021, certain property, plant and equipment of the Group with net book value of RMB38.9 million (31 December 2020: RMB45.5 million) had been pledged to secure banking facilities granted to the Group.

Capital Commitments

The capital commitments of the Group were primarily attributable to construction costs relating to the expansion and renovation of the Group's medical facilities. As at 30 June 2021, the capital commitments in respect of property, plant and equipment contracted for but not provided in the consolidated financial statements were RMB223.3 million (31 December 2020: RMB255.5 million).

或然負債

本集團受制於法律訴訟及於日常業務中由病人提出的醫療糾紛索賠。醫療糾紛的撥備是根據有關期間結束時可能和尚未了結的進行中索賠個案狀況而作出，主要考慮本集團將面臨的任何司法判決或法院裁決。於二零二一年六月三十日，本集團尚未了結的醫療糾紛索賠總額約為人民幣5.5百萬元（二零二零年十二月三十一日：人民幣6.8百萬元），而有部份醫療糾紛未有列明索賠金額。根據本集團作出的評估，於報告期內，本集團已計提約人民幣3.0百萬元（截至二零二零年六月三十日止六個月：人民幣1.3百萬元）的撥備，並計入本集團的應付賬款及其他應付款項以及撥備中。

於二零二一年六月三十日，本集團並無會對本集團的財務狀況或經營產生重大影響的或然負債或擔保。

資產質押

於二零二一年六月三十日，本集團若干賬面淨值為人民幣38.9百萬元（二零二零年十二月三十一日：人民幣45.5百萬元）的物業、廠房及設備已被質押以擔保本集團獲授的銀行融資。

資本承擔

本集團的資本承擔主要歸因於與本集團醫療設施擴建及翻新有關的建築成本。於二零二一年六月三十日，本集團已訂約但未於綜合財務報表撥備之物業、廠房及設備的資本承擔為人民幣223.3百萬元（二零二零年十二月三十一日：人民幣255.5百萬元）。



Management Discussion and Analysis

管理層討論及分析

Financial Instruments

The Group's financial instruments primarily consisted of accounts and other receivables, financial assets at FVTPL, fixed bank deposits, bank balances and cash, restricted bank balances, accounts and other payables, amounts due to non-controlling shareholders of subsidiaries, bank loans and lease liabilities. The management of the Company manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

Exposure to Fluctuation in Exchange Rates

The proceeds of raised by the Company in its initial public offering of its H Shares are denominated in Hong Kong dollars. The Group deposits certain of its financial assets in Hong Kong dollars, and is mainly exposed to fluctuation in exchange rates of Hong Kong dollars against RMB. The Group is therefore exposed to foreign exchange risk.

The Group has not used any derivatives or financial instruments to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and will consider hedging significant foreign currency exposure should such need arise.

Gearing Ratio

As at 30 June 2021, the Group's gearing ratio (total interest-bearing bank loans divided by total equity and multiplied by 100%) was 19.9% (31 December 2020: 18.3%).

EMPLOYEES, REMUNERATION POLICIES AND TRAINING SCHEMES

The Group's comprehensive staff remuneration policy comprise basic salary determined with reference to the individual's position, seniority and length of service, performance bonus determined with reference to the metrics specific to the individual's job function and other benefits. The Group regularly benchmarks against available market data and adjusts its remuneration structure with a view to remaining competitive. As at 30 June 2021, the Group had a total of 3,538 (31 December 2020: 3,777) full-time staff.

金融工具

本集團的金融工具主要包括應收賬款及其他應收款項、按公平值計入損益的金融資產、定期銀行存款、銀行結餘及現金、受限制銀行結餘、應付賬款及其他應付款項、應付附屬公司非控股股東的款項、銀行貸款及租賃負債。本公司管理層管理和監控這些風險，以確保及時有效地採取適當措施。

匯率波動風險

本公司H股首次公開發售所募集的所得款項以港元計值。本集團以港元存放部份金額的金融資產，主要受港元兌人民幣匯率波動的影響。因此，本集團面臨外匯風險。

本集團並未應用任何衍生工具或金融工具對沖其貨幣風險承擔。管理層通過密切監測外幣匯率的變動來管理貨幣風險，並將考慮在有需要時就重大外幣承擔進行對沖。

資產負債比率

於二零二一年六月三十日，本集團之資產負債比率（計息銀行貸款總額除以總權益並乘以100%）為19.9%（二零二零年十二月三十一日：18.3%）。

僱員、薪酬政策及培訓計劃

本集團全面的員工薪酬政策包括參考個人職位、資歷及服務年期計算的基本工資、參考個人工作職能特有指標的績效花紅和其他福利。本集團定期以現有市場數據為基準，調整其薪酬架構，保持競爭力。於二零二一年六月三十日，本集團有合共3,538名（二零二零年十二月三十一日：3,777名）全職員工。

Management Discussion and Analysis

管理層討論及分析

The Group provides structured training and education programmes to enable its staff to consistently deliver high quality services. These programmes aim to equip the staff with a sound foundation of the medical principles and knowledge as well as practical skills in their respective practice area and foster a high standard of practice, organisation capability and vigilant attitude. Regular internal and external mandatory trainings are organised for medical staff to keep them abreast of the latest development in healthcare. From time to time, the Group identifies and sponsors its staff with high development potential to undertake further studies and professional training in prestigious academic institutions and participate in industry conventions. Medical teams also benefit from the experience and knowledge exchange during seminars and sharing sessions regularly held. The Group encourages medical staff to apply for professional and technical qualifications and enroll in specialised training programmes and assessments from time to time, including induction training for new employees, development training for young and middle-aged core talent, medical service quality training and management training for young core talent, with a view to ensuring that their relevant professional competencies meet the required standards. Through various training and education programmes, the Group also aims to foster a proactive risk reporting culture among staff, which is important in the early detection of clinical failure and damage control.

本集團提供系統培訓及教育計劃，以使員工能夠持續提供高質量的服務。該等計劃旨在裝備員工，使其具備彼等各自實踐領域的醫療原則及知識以及執業技能的堅實基礎，並培養高標準的實踐、組織能力及嚴謹態度。本集團為醫務人員組織定期的內部及外部強制性培訓，以使彼等了解醫療的最新發展。本集團會不時甄選出發展潛力大的員工及贊助彼等在著名學術機構進一步開展學習及專業培訓以及參加行業會議。醫療團隊亦從定期舉行的研討會及分享會上的經驗及知識交流中受益。本集團鼓勵醫務人員報考專業技術職稱及不定期接受內部人員專項培訓及考核，包括新員工入職培訓、中青年骨幹拓展培訓、醫療服務質量培訓以及青年幹部管理培訓等，以確保彼等之相關業務能力符合標準。通過各種培訓及教育計劃，本集團亦力圖在員工中培養主動風險報告文化，這對於及早發現臨床誤診及損害控制實屬重要。



INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2021 (six months ended 30 June 2020: nil).

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

EVENTS AFTER THE REPORTING PERIOD

There was no significant event after the Reporting Period.

REVIEW OF INTERIM REPORT

Audit Committee has reviewed the Group's interim results for the six months ended 30 June 2021 and has opined that applicable accounting standards and requirements have been complied with and that adequate disclosures have been made by the Company.

The Company's audit committee consists of three independent non-executive directors of the Company, Mr. Chan Sing Nun (the chairman of the audit committee), Mr. Yeung Ming Lai and Dr. Chen Keji. Among them, Mr. Chan Sing Nun has the appropriate professional qualifications (a certified public accountant accredited by the Hong Kong Institute of Certified Public Accountants).

The auditor of the Company has also reviewed the Group's interim results for the six months ended 30 June 2021 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

中期股息

董事會不建議派付截至二零二一年六月三十日止六個月的中期股息(截至二零二零年六月三十日止六個月：無)。

購回、出售或贖回本公司證券

於報告期內，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

報告期後事項

報告期後並無任何重大事項。

審閱中期報告

審核委員會已審閱本集團截至二零二一年六月三十日止六個月之中期業績，並認為本公司已遵守適用會計準則及要求並已作出充分披露。

本公司審核委員會由本公司三名獨立非執行董事，即陳星能先生(審核委員會主席)、楊銘澧先生及陳可冀醫生組成。其中陳星能先生具有適當的專業資格(由香港會計師公會認可的執業會計師)。

本公司核數師亦已按照香港會計師公會頒佈的香港審閱工作準則第2410號「由實體的獨立核數師執行中期財務資料審閱」審閱本集團截至二零二一年六月三十日止六個月之中期業績。

Corporate Governance Highlights

企業管治概覽

CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of corporate governance practices. The Board is of the opinion that the Company has complied with the applicable code provisions under the CG Code during the six months ended 30 June 2021.

The Board is committed to promoting good corporate governance to safeguard the interests of the Shareholders and believes that maintaining a high standard of corporate governance is essential to the success of the Company and would provide a practice enhancing greater accountability and transparency and meeting the expectations of the Group's stakeholders. The Company will continue to review and enhance its corporate governance to ensure that it will continue to meet the applicable requirements of the CG Code.

CHANGES IN INFORMATION OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVES

Save as disclosed in this report, there has been no change in information required to be disclosed pursuant to Rule 13.51B(1) of the Hong Kong Listing Rules since the date of the 2020 annual report of the Company.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE HONG KONG LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Hong Kong Listing Rules.

COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as a code of conduct of the Company for Directors' and Supervisors' securities transactions. Having made specific enquiry of all Directors and Supervisors, the Directors and the Supervisors have complied with the required standard set out in the Model Code during the six months ended 30 June 2021. Employees who are, or likely to be, in possession of unpublished inside information in relation to the Company or the Shares are prohibited from dealing in the Shares during the black-out period.

APPRECIATION

On behalf of the Board, I would like to take this opportunity to express our appreciation to the management team and staff of the Group for their contribution and also to extend my sincere gratitude to all our shareholders and business partners for their continuous support.

For and on behalf of the Board

Wang Junyang
Chairman

Dongguan, the PRC
31 August 2021

企業管治

本公司致力於維持高水平的企業管治常規。董事會認為，本公司於截至二零二一年六月三十日止六個月，已遵守企業管治守則之適用守則條文。

董事會致力推動良好的企業管治，以保障股東的利益，亦相信維持高水平的企業管治乃本公司的成功要素，有助建立高度問責及透明的常規，以達致本集團各利益相關者的期望。本公司將繼續審閱及提升其企業管治，確保其繼續符合企業管治守則的適用規定。

董事、監事及行政總裁資料的變更

除本報告所披露者外，自本公司之二零二零年年度報告日期以來，根據香港上市規則第13.51B(1)條，概無資料變更須予披露。

根據香港上市規則持續披露責任

本公司並無香港上市規則第13.20、13.21及13.22條項下的任何其他披露責任。

標準守則的合規

本公司已採納標準守則作為本公司董事和監事進行證券交易的行為守則。經向所有董事及監事作出具體查詢後，截至二零二一年六月三十日止六個月，董事及監事已遵守標準守則規定的所需標準。凡已經或可能管有未發佈有關本公司或股份內幕消息的僱員，一概不得於禁止交易期間買賣股份。

致謝

本人謹代表董事會藉此機會對本集團管理團隊及員工作出的貢獻表示感謝，同時對全體股東及業務夥伴的持續支持表示誠摯的感謝。

代表董事會

王君揚
主席

中國，東莞
二零二一年八月三十一日



DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS IN SECURITIES

As at 30 June 2021, the interests and short positions of the Directors, the Supervisors and the chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she were taken or deemed to have under such provisions of the SFO), or as recorded in the register maintained by the Company under section 352 of the SFO, or as notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were as follows:

(a) The Company

Name of Director 董事姓名	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class ⁽⁶⁾ 相同類別股份所佔概約百分比 ⁽⁶⁾	Approximate percentage of the Company's total issued share capital ⁽⁶⁾ 佔本公司已發行股本總額概約百分比 ⁽⁶⁾
Mr. Wang Junyang 王君揚先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽²⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽²⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Mr. Chen Wangzhi 陳旺枝先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Ms. Wang Aiqin 王愛勤女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Mr. Wong Wai Hung 王偉雄先生	Domestic Shares 內資股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	25,000,000 (Long Position) (好倉)	10%	7.48%

董事、監事及最高行政人員於證券之權益

於二零二一年六月三十日，本公司董事、監事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份及債權證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所的權益及淡倉（包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益及淡倉），或須列入由本公司按證券及期貨條例第352條存置之登記冊內，或根據標準守則須知會本公司及香港聯交所的權益及淡倉如下：

(a) 本公司

Other Information

其他資料

Notes:

- (1) Pursuant to a concert party agreement, each of Mr. Wang Junyang, Ms. Wang Aici, Mr. Chen Wangzhi and Ms. Wang Ai Qin has agreed to jointly control their respective interests in the Company and the decisions as to the business and operations of the Group shall be in accordance with the unanimous consent of all of them. Therefore, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (2) Kanghua Group (held as to 97.46% by Mr. Wang Junyang) held 197,500,000 Domestic Shares and Xingye Group (held as to 50% by Mr. Wang Junyang) held 25,000,000 Domestic Shares. As Mr. Wang Junyang controls more than one third of the voting power at the general meeting of each of Kanghua Group and Xingye Group, Mr. Wang Junyang is deemed to be interested in the same number of Shares in which each of Kanghua Group and Xingye Group is interested by virtue of the SFO.
- (3) Xingda Property (held as to 50% each by Mr. Chen Wangzhi and Ms. Wang Ai Qin) held 27,500,000 Domestic Shares. As each of Mr. Chen Wangzhi and Ms. Wang Ai Qin controls more than one third of the voting power at the general meeting of Xingda Property, each of Mr. Chen Wangzhi and Ms. Wang Ai Qin is deemed to be interested in the same number of Shares in which Xingda Property is interested by virtue of the SFO.
- (4) As Mr. Chen Wangzhi and Ms. Wang Ai Qin are husband and wife, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (5) Mr. Wong Wai Hung holds 34.0% in HH International (as defined below), which in turns holds 100% in Weishun Property (as defined below), which in turns holds 100% in Kangwei Industrial (as defined below), which in turns holds 37.5% in Xingye Group. Xingye Group held 25,000,000 Domestic Shares. As Mr. Wong Wai Hung controls more than one third of the voting power at the general meeting of Xingye Group, Mr. Wong Wai Hung is deemed to be interested in the same number of Shares in which Xingye Group is interested by virtue of the SFO.
- (6) The shareholding percentages are calculated on the basis of 250,000,000 Domestic Shares and 84,394,000 H Shares issued by the Company as at 30 June 2021.

附註：

- (1) 根據一項一致行動協議，王君揚先生、王愛慈女士、陳旺枝先生及王愛勤女士均同意共同控制其各自於本公司的權益，而就本集團業務及營運的決定應當作上述人士一致同意。因此，基於證券及期貨條例，上述各方視為於彼等合共持有的所有股份擁有權益。
- (2) 康華集團（王君揚先生持有97.46%）持有197,500,000股內資股，而興業集團（王君揚先生持有50%）持有25,000,000股內資股。由於王君揚先生於康華集團及興業集團各自的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王君揚先生被視為於康華集團及興業集團各自擁有的相同數目股份擁有權益。
- (3) 興達物業（陳旺枝先生及王愛勤女士分別各自持有50%）持有27,500,000股內資股。由於陳旺枝先生及王愛勤女士在興達物業的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，陳旺枝先生及王愛勤女士被視為於興達物業擁有的相同數目股份擁有權益。
- (4) 由於陳旺枝先生及王愛勤女士為夫妻，故基於證券及期貨條例，其各自被視為於彼等合共持有的所有股份中擁有權益。
- (5) 王偉雄先生持有浩享國際（定義見下文）34.0%，而浩享國際持有偉順物業（定義見下文）100%，而偉順物業持有康偉實業（定義見下文）100%，而康偉實業持有興業集團37.5%。興業集團持有25,000,000股內資股，由於王偉雄先生於興業集團的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王偉雄先生被視為於興業集團擁有的相同數目股份擁有權益。
- (6) 持股比例以本公司於二零二一年六月三十日發行的250,000,000股內資股及84,394,000股H股計算。



(b) Associated corporations of the Company

(b) 本公司相聯法團

Name of Director 董事姓名	Associated corporation 相聯法團	Nature of interest 權益性質	Approximate percentage interest in the associated corporation 佔相聯法團 權益概約百分比
Mr. Wang Junyang 王君揚先生	Kanghua Group 康華集團	Beneficial owner 實益擁有人	97.46%
Mr. Wang Junyang 王君揚先生	Xingye Group 興業集團	Beneficial owner 實益擁有人	50%
Mr. Wong Wai Hung 王偉雄先生	Xingye Group 興業集團	Interest in a controlled corporation ⁽ⁱ⁾ 於受控制法團的權益 ⁽ⁱ⁾	37.50%
Mr. Chen Wangzhi 陳旺枝先生	Xingda Property 興達物業	Beneficial owner; family interest of spouse 實益擁有人；配偶的家族權益	100%
Ms. Wang Ai Qin 王愛勤女士	Xingda Property 興達物業	Beneficial owner; family interest of spouse 實益擁有人；配偶的家族權益	100%

Note:

附註：

(i) Mr. Wong Wai Hung holds 34.0% in HH International (as defined below), which in turns holds 100% in Weishun Property (as defined below), which in turns holds 100% in Kangwei Industrial (as defined below), which in turns holds 37.5% in Xingye Group. As Mr. Wong Wai Hung controls more than one third of the voting power at the general meeting of Kangwei Industrial, Mr. Wong Wai Hung is deemed to be interested in the same amount of interest in Xingye Group in which Kangwei Industrial is interested by virtue of the SFO.

(i) 王偉雄先生持有浩享國際(定義見下文)34.0%，而浩享國際持有偉順物業(定義見下文)100%，而偉順物業持有康偉實業(定義見下文)100%，而康偉實業持有興業集團37.5%。由於王偉雄先生於康偉實業的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王偉雄先生被視為於康偉實業擁有的興業集團的相同權益擁有權益。

Save as disclosed above, as at 30 June 2021, to the knowledge of the Board, none of the Directors, the Supervisors or chief executives of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors, the Supervisors and chief executives of the Company were taken or deemed to have under such provisions of the SFO); (ii) recorded in the register kept by the Company pursuant to Section 352 of the SFO; or (iii) notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code.

除上文所披露者外，於二零二一年六月三十日，據董事會所知，概無本公司董事、監事及最高行政人員於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)之股份、相關股份及債權證中擁有任何(i)根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所的權益或淡倉(包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益及淡倉)；(ii)須列入由本公司按證券及期貨條例第352條存置之登記冊內的權益或淡倉；或(iii)根據標準守則須知會本公司及香港聯交所的權益或淡倉。

Other Information

其他資料

INTERESTS OF SUBSTANTIAL SHAREHOLDERS

As at 30 June 2021, according to the register kept by the Company pursuant to Section 336 of the SFO and so far is known to, or can be ascertained after reasonable enquiry by the Directors, the following person/entity had an interest or short position in the Shares and underlying Shares which would fall to be disclosed to the Company and the Hong Kong Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO, or be directly and indirectly interested in 5% or more of the nominal value of any class of share capital carrying rights to vote on all circumstances at general meetings of the Company:

(a) Interests in the Shares of the Company

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Mr. Wang Junyang 王君揚先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽²⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽²⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Ms. Wang Aici 王愛慈女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Kanghua Group 康華集團	Domestic Shares 內資股	Beneficial owner ⁽²⁾ 實益擁有人 ⁽²⁾	197,500,000 (Long position) (好倉)	79%	59.06%
Mr. Chen Wangzhi 陳旺枝先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家庭權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%

主要股東的權益

於二零二一年六月三十日，按照本公司根據證券及期貨條例第336條存置的登記冊，及就董事所知或經作出合理查詢後可確定，以下人士／實體於股份及相關股份中擁有根據證券及期貨條例第XV部第2及3分部之條文須向本公司及香港聯交所披露的權益或淡倉，或直接或間接擁有於本公司股東大會上在任何情況下有權投票的任何類別股本中面值5%或以上的權益：

(a) 於本公司股份的權益



Other Information 其他資料

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Ms. Wang Aiqin 王愛勤女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Xingda Property 興達物業	Domestic Shares 內資股	Beneficial owner ⁽³⁾ 實益擁有人 ⁽³⁾	27,500,000 (Long position) (好倉)	11%	8.22%
Xingye Group 興業集團	Domestic Shares 內資股	Beneficial owner ⁽⁵⁾ 實益擁有人 ⁽⁵⁾	25,000,000 (Long position) (好倉)	10%	7.48%
Mr. Wong Wai Hung 王偉雄先生	Domestic Shares 內資股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	25,000,000 (Long Position) (好倉)	10%	7.48%
HH International Investment Limited ("HH International") 浩享國際投資有限公司 (「浩享國際」)	Domestic Shares 內資股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	25,000,000 (Long Position) (好倉)	10%	7.48%
Dongguan Weishun Property Investment Co., Ltd. ("Weishun Property") 東莞市偉順物業投資有限公司 (「偉順物業」)	Domestic Shares 內資股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	25,000,000 (Long Position) (好倉)	10%	7.48%
Dongguan Kangwei Industrial Investment Co., Ltd. ("Kangwei Industrial") 東莞市康偉實業投資有限公司 (「康偉實業」)	Domestic Shares 內資股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	25,000,000 (Long Position) (好倉)	10%	7.48%

Other Information

其他資料

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
New China Asset Management (Hong Kong) Limited 新華資產管理(香港)有限公司	H Shares H股	Investment manager 投資經理	8,689,000 (Long position) (好倉)	10.30%	2.60%
Lin Lijun ("Mr. Lin") 林利軍(「林先生」)	H Shares H股	Interest in a controlled corporation ⁽⁶⁾ 於受控制法團的權益 ⁽⁶⁾	11,146,200 (Long position) (好倉)	13.21%	3.33%
LVC Assets Management Limited	H Shares H股	Interest in a controlled corporation ⁽⁶⁾ 於受控制法團的權益 ⁽⁶⁾	11,146,200 (Long position) (好倉)	13.21%	3.33%
LVC KH Investment L.P.	H Shares H股	Beneficial owner ⁽⁶⁾ 實益擁有人 ⁽⁶⁾	11,146,200 (Long position) (好倉)	13.21%	3.33%
Haitian (HK) Holdings Limited (formerly named as "Haitian (HK) Financial Development Limited") 海天(香港)控股有限公司 (前命名為「海天(香港)金融發展有限公司」)	H Shares H股	Beneficial owner 實益擁有人	5,052,600 (Long position) (好倉)	5.98%	1.51%
Zhan Yongxiang 詹永祥	H Shares H股	Beneficial owner 實益擁有人	5,021,966 (Long position) (好倉)	5.95%	1.50%
Mr. Wang Mingsong 王明松先生	H Shares H股	Interest in a controlled corporation ⁽⁷⁾ 於受控制法團的權益 ⁽⁷⁾	4,880,000 (Long position) (好倉)	5.78%	1.46%
Bo An Investments Pte. Ltd. ("Bo An Investments") 博安投資私人有限公司 (「博安投資」)	H Shares H股	Interest in a controlled corporation ⁽⁷⁾ 於受控制法團的權益 ⁽⁷⁾	4,880,000 (Long position) (好倉)	5.78%	1.46%
Huaxia International Company Limited ("Huaxia International") 華夏國際有限公司 (「華夏國際」)	H Shares H股	Beneficial owner ⁽⁷⁾ 實益擁有人 ⁽⁷⁾	4,880,000 (Long position) (好倉)	5.78%	1.46%



Notes:

- (1) Pursuant to a concert party agreement, each of Mr. Wang Junyang, Ms. Wang Aici, Mr. Chen Wangzhi and Ms. Wang Aiqin has agreed to jointly control their respective interests in the Company and the decisions as to the business and operations of the Group shall be in accordance with the unanimous consent of all of them. Therefore, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (2) Mr. Wang Junyang holds 97.46% and 50% in Kanghua Group and Xingye Group, respectively. As Mr. Wang Junyang controls more than one third of the voting power at the general meeting of each of Kanghua Group and Xingye Group, Mr. Wang Junyang is deemed to be interested in the same number of Shares in which each of Kanghua Group and Xingye Group is interested by virtue of the SFO.
- (3) Each of Mr. Chen Wangzhi and Ms. Wang Aiqin holds 50% in Xingda Property. As each of Mr. Chen Wangzhi and Ms. Wang Aiqin controls more than one third of the voting power at the general meeting of Xingda Property, each of Mr. Chen Wangzhi and Ms. Wang Aiqin is deemed to be interested in the same number of Shares in which Xingda Property is interested by virtue of the SFO.
- (4) As Mr. Chen Wangzhi and Ms. Wang Aiqin are husband and wife, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (5) Mr. Wong Wai Hung holds 34.0% in HH International, which in turns holds 100% in Weishun Property, which in turns holds 100% interest in Kangwei Industrial, which in turns holds 37.5% in Xingye Group. Xingye Group held 25,000,000 Domestic Shares. As Mr. Wong Wai Hung controls more than one third of the voting power at the general meeting of Xingye Group, each of Kangwei Industrial, Weishun Property, HH International and Mr. Wong Wai Hung is deemed to be interested in the same number of Shares in which Xingye Group is interested by virtue of the SFO.
- (6) Mr. Lin holds 100% in LVC Assets Management Limited, which in turn controls LVC KH Investment L.P. Each of Mr. Lin and LVC Assets Management Limited is deemed to be interested in the same number of Shares in which LVC KH Investment L.P. is interested by virtue of SFO.
- (7) Mr. Wang Mingsong holds 100% in Bo An Investments, which in turns holds 100% in Huaxia International. Each of Mr. Wang Mingsong and Bo An Investments is deemed to be interested in the same number of Shares in which Huaxia International is interested by virtue of the SFO.

附註：

- (1) 根據一項一致行動協議，王君揚先生、王愛慈女士、陳旺枝先生及王愛勤女士均同意共同控制其各自於本公司的權益，而就本集團業務及營運的決定應當作上述人士一致同意。因此，基於證券及期貨條例，上述各方視為於彼等合共持有的所有股份擁有權益。
- (2) 王君揚先生分別持有康華集團和興業集團97.46%及50%。由於王君揚先生於康華集團及興業集團各自的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王君揚先生被視為於康華集團及興業集團各自擁有的相同數目股份擁有權益。
- (3) 陳旺枝先生及王愛勤女士各自持有興達物業50%的股份。由於陳旺枝先生及王愛勤女士在興達物業的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，陳旺枝先生及王愛勤女士被視為於興達物業擁有的相同數目股份擁有權益。
- (4) 由於陳旺枝先生及王愛勤女士為夫妻，故基於證券及期貨條例，其各自被視為於彼等合共持有的所有股份中擁有權益。
- (5) 王偉雄先生持有浩享國際34.0%，而浩享國際持有偉順物業100%，而偉順物業持有康偉實業100%，而康偉實業持有興業集團37.5%。興業集團持有25,000,000股內資股，由於王偉雄先生於興業集團的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，康偉實業、偉順物業、浩享國際及王偉雄先生被視為於興業集團擁有的相同數目股份擁有權益。
- (6) 林先生持有LVC Assets Management Limited 100%，而LVC Assets Management Limited控制LVC KH Investment L.P.。基於證券及期貨條例，林先生及LVC Assets Management Limited各自被視為於LVC KH Investment L.P.擁有的相同數目股份擁有權益。
- (7) 王明松先生持有博安投資100%，而博安投資持有華夏國際100%。基於證券及期貨條例，王明松先生及博安投資各自被視為於華夏國際擁有的相同數目股份擁有權益。

Other Information

其他資料

(b) Substantial shareholders of other members of the Group

Name of shareholder 股東姓名／名稱	Name of member of the Group 本集團成員公司名稱	Nature of interest 權益性質	Approximate percentage interest held by the substantial shareholder 主要股東 持有權益 概約百分比
Kangdi Enterprise ⁽¹⁾⁽²⁾ 康帝實業 ⁽¹⁾⁽²⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	15%
Ms. Zhang Dandan ⁽¹⁾⁽³⁾ 張丹丹女士 ⁽¹⁾⁽³⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	15%
Ms. Wang Aier ⁽¹⁾⁽⁴⁾ 王愛兒女士 ⁽¹⁾⁽⁴⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	13%

Notes:

- (1) Pursuant to an entrusted management agreement, each of Kangdi Enterprise, Ms. Zhang Dandan and Ms. Wang Aier irrevocably vested their entire voting power at any general meeting of Renkang Hospital to the Company.
- (2) Kangdi Enterprise is held as to 50% by Mr. Wang Zhengren and as to 50% by Ms. Wang Keying, all of whom are members of the Wang Family and cousins of Mr. Wang Junyang.
- (3) Ms. Zhang Dandan is a member of the Wang Family and aunt-in-law of Mr. Wang Junyang.
- (4) Ms. Wang Aier is a member of the Wang Family and aunt of Mr. Wang Junyang.

(b) 本集團其他成員公司的主要股東

附註：

- (1) 根據委託管理協議，康帝實業、張丹丹女士及王愛兒女士各自均不可撤回地將其於仁康醫院任何股東大會的全部投票權歸屬於本公司。
- (2) 王正仁先生及王可瑩女士各自於康帝實業持有50%股權，其全部為王氏家族的成員及王君揚先生的表親。
- (3) 張丹丹女士是王氏家族成員及王君揚先生的孀母。
- (4) 王愛兒女士是王氏家族成員及王君揚先生的姑母。

Save as disclosed above, as at 30 June 2021, to the knowledge of the Directors, no other person had, or were deemed or taken to have interest or short position in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the registry kept by the Company pursuant to Section 336 of the SFO.

除上文所披露者外，於二零二一年六月三十日，據董事所知，概無其他人士於或被視作或當作於股份或相關股份中擁有根據證券及期貨條例第XV部第2及3分部之條文須向本公司披露，或記錄在本公司根據證券及期貨條例第336條存置的登記冊內的權益或淡倉。





TO THE BOARD OF DIRECTORS OF
GUANGDONG KANGHUA HEALTHCARE CO., LTD.
(a joint stock company incorporated in the People's Republic of China with limited liability)

致廣東康華醫療股份有限公司
董事會
(於中華人民共和國註冊成立的股份有限公司)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Guangdong Kanghua Healthcare Co., Ltd. (the "Company") and its subsidiaries (collectively referred to as the "Group") set out on pages 57 to 83, which comprise the condensed consolidated statement of financial position as of 30 June 2021 and the related condensed consolidated statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the six-month period then ended, and certain explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting" ("IAS 34") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

引言

本行已審閱載於第57至83頁的廣東康華醫療股份有限公司(「貴公司」)及其附屬公司(統稱「貴集團」)的簡明綜合財務報表，包括於二零二一年六月三十日的簡明綜合財務狀況表，以及截至該日止六個月期間的相關簡明綜合損益及其他全面收益表、權益變動表及現金流量表及若干說明附註。香港聯合交易所有限公司證券上市規則規定，就中期財務資料編製的報告須符合當中有關條文及國際會計準則委員會頒佈的國際會計準則第34號「中期財務報告」(「國際會計準則第34號」)。貴公司董事須負責根據國際會計準則第34號編製該等簡明綜合財務報表。本行的責任是根據本行的審閱對該等簡明綜合財務報表作出結論，並按照雙方所協定之委聘條款，僅向全體董事報告本行之結論。除此之外，本行之報告不可用作其他用途。本行不會就本報告的內容向任何其他人士負責或承擔任何責任。

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

審閱範圍

本行已根據香港會計師公會頒佈的《香港審閱委聘準則》第2410號「由實體的獨立核數師執行中期財務資料的審閱」進行審閱。審閱該等簡明綜合財務報表包括主要向負責財務及會計事務的人員作出查詢，並實施分析及其他審閱程序。審閱範圍遠較按照香港審計準則進行審核的範圍為小，故不能保證本行注意到在審核中可能發現的所有重大事項。因此，本行不會發表審核意見。

Report on Review of Condensed Consolidated Financial Statements

簡明綜合財務報表之審閱報告

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
31 August 2021

結論

根據本行的審閱工作，本行並未注意到任何事項，令本行相信簡明綜合財務報表在所有重大方面並無按照國際會計準則第34號編製。

德勤•關黃陳方會計師行
執業會計師
香港
二零二一年八月三十一日



Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

簡明綜合損益及其他全面收益表

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月		
		2021 二零二一年	2020 二零二零年	
		RMB'000 人民幣千元	RMB'000 人民幣千元	
		(unaudited) (未經審核)	(unaudited) (未經審核)	
	NOTES 附註			
Revenue	收益	3	871,485	760,987
Cost of revenue	收益成本		(741,640)	(687,813)
Gross profit	毛利		129,845	73,174
Other income	其他收入	4	15,750	15,796
Other expenses, gains and losses	其他開支、收益及虧損	5	2,596	(2,876)
Net reversal of impairment losses under expected credit loss model	預期信貸虧損模式項下之減值虧損撥回淨額		1,303	–
Impairment loss on goodwill	商譽減值虧損	11	–	(76,000)
Administrative expenses	行政開支		(103,441)	(123,246)
Finance costs	融資成本		(10,210)	(11,294)
Profit (loss) before taxation	除稅前溢利(虧損)	6	35,843	(124,446)
Income tax expenses	所得稅開支	7	(21,044)	(1,773)
Profit (loss) and total comprehensive income (expenses) for the period	期內溢利(虧損)及全面收入(開支)總額		14,799	(126,219)
Profit (loss) and total comprehensive income (expense) for the period attributable to:	下列各項應佔期內溢利(虧損)及全面收入(開支)總額:			
– owners of the Company	– 本公司擁有人		30,875	(106,324)
– non-controlling interests	– 非控股權益		(16,076)	(19,895)
			14,799	(126,219)
Earnings (loss) per share, basic (RMB cents)	每股基本盈利(虧損)(人民幣分)	9	9.2	(31.8)

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

At 30 June 2021

於二零二一年六月三十日

			At 30 June 2021 於二零二一年 六月三十日	At 31 December 2020 於二零二零年 十二月三十一日
		NOTES 附註	RMB'000 人民幣千元 (unaudited) (未經審核)	RMB'000 人民幣千元 (audited) (經審核)
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	10	997,601	976,272
Right-of-use assets	使用權資產	10	371,699	382,845
Goodwill	商譽	11	44,613	44,613
Deposits paid for acquisition of property, plant and equipment	收購物業、廠房及設備已付按金		94,457	91,218
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	13	70,546	67,663
			1,578,916	1,562,611
Current assets	流動資產			
Inventories	存貨		63,257	56,756
Accounts and other receivables	應收賬款及其他應收款項	12	278,175	248,679
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	13	500,000	400,000
Restricted bank balances	受限制銀行結餘		2,063	1,182
Fixed bank deposits	定期銀行存款		-	5,000
Bank balances and cash	銀行結餘及現金		213,392	179,673
			1,056,887	891,290
Current liabilities	流動負債			
Accounts and other payables and provision	應付賬款及其他應付款項及撥備	14	625,917	516,868
Amounts due to non-controlling shareholders of subsidiaries	應付附屬公司的非控股股東款項		64,439	18,856
Tax payables	應付稅項		17,666	22,907
Bank loans – due within one year	銀行貸款 – 一年內到期	15	15,740	7,574
Lease liabilities	租賃負債		34,485	30,685
			758,247	596,890
Net current assets	流動資產淨值		298,640	294,400
Total assets less current liabilities	總資產減流動負債		1,877,556	1,857,011



Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

At 30 June 2021
於二零二一年六月三十日

			At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Non-current liabilities	非流動負債			
Bank loans – due after one year	銀行貸款 – 一年後到期	15	267,857	250,256
Deferred tax liabilities	遞延稅項負債	16	22,013	21,945
Lease liabilities	租賃負債		165,385	177,308
			455,255	449,509
Net assets	資產淨值		1,422,301	1,407,502
Capital and reserves	資本及儲備			
Share capital	股本	17	334,394	334,394
Reserves	儲備		1,029,011	998,136
Equity attributable to owners of the Company	本公司擁有人應佔權益		1,363,405	1,332,530
Non-controlling interests	非控股權益		58,896	74,972
Total equity	權益總額		1,422,301	1,407,502

Condensed Consolidated Statement of Changes in Equity

簡明綜合權益變動表

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

		Attributable to owners of the Company 本公司擁有人應佔						Non-controlling interests 非控股權益	Total	
		Share capital 股本	Share premium 股份溢價	Capital reserve 資本儲備	Statutory reserve 法定儲備	Other reserve 其他儲備	Retained earnings 保留盈利	Sub-total 小計	Total 總計	
		RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	
		(note) (附註)								
At 1 January 2021 (audited)	於二零二一年一月一日 (經審核)	334,394	698,214	53,394	96,822	1,477	148,229	1,332,530	1,407,502	
Profit (Loss) and total comprehensive income (expense) for the period	期內溢利(虧損)及全面收入(開支)總額	-	-	-	-	-	30,875	30,875	14,799	
At 30 June 2021 (unaudited)	於二零二一年六月三十日 (未經審核)	334,394	698,214	53,394	96,822	1,477	179,104	1,363,405	1,422,301	
At 1 January 2020 (audited)	於二零二零年一月一日 (經審核)	334,394	698,214	53,394	88,927	-	181,496	1,356,425	1,457,558	
Loss and total comprehensive expense for the period	期內虧損及全面開支總額	-	-	-	-	-	(106,324)	(106,324)	(126,219)	
At 30 June 2020 (unaudited)	於二零二零年六月三十日 (未經審核)	334,394	698,214	53,394	88,927	-	75,172	1,250,101	1,331,339	

Note: Amount of RMB5,951,000 (31 December 2020: RMB5,633,000) included in the Group's retained earnings as at 30 June 2021 represents the profit generated from the private non-enterprise entities directly or indirectly held under Anhui Hualin (defined in Note 11). Under the PRC laws and regulations, the retained earnings of the private non-enterprise entity is not distributable.

附註：本集團於二零二一年六月三十日的保留盈利包含的人民幣5,951,000元（二零二零年十二月三十一日：人民幣5,633,000元），是指安徽樺霖直接或間接持有的私營非企業實體所產生的利潤（定義見附註11）。根據中國法律及法規，私營非企業實體的保留盈利是不可作分配的。



Condensed Consolidated Statement of Cash Flows

簡明綜合現金流量表

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Net cash generated from operating activities	經營活動所得現金淨額	155,770	26,303
Investing activities	投資活動		
Placement of restricted bank balances	存放受限制銀行結餘	(4,819)	(403,162)
Purchases of financial assets at fair value through profit or loss	購買按公平值計入損益的金融資產	(510,000)	(400,000)
Placement of fixed bank deposits	存放定期銀行存款	–	(70,000)
Purchase of property, plant and equipment	購買物業、廠房及設備	(68,901)	(43,097)
Deposits paid for acquisition of property, plant and equipment	收購物業、廠房及設備已付按金	(5,211)	(21,949)
Withdrawal of restricted bank balances	提取受限制銀行結餘	3,938	403,968
Proceeds from disposal of financial assets at fair value through profit or loss	出售按公平值計入損益的金融資產的所得款項	410,000	400,000
Investment income received from financial assets at fair value through profit or loss	按公平值計入損益的金融資產收取的投資收入	4,729	3,141
Withdrawal of fixed bank deposits	提取定期銀行存款	5,000	1,300
Interest received	已收利息	1,498	567
Proceeds from disposals of property, plant and equipment	出售物業、廠房及設備所得款項	155	59
Net cash used in investing activities	投資活動所用現金淨額	(163,611)	(129,173)
Financing activities	融資活動		
New bank loans raised	所籌集新銀行貸款	30,000	–
Repayments of lease liabilities	償還租賃負債	(14,784)	(13,358)
Interest paid	已付利息	(13,175)	(12,357)
Repayment of bank loan	償還銀行貸款	(5,635)	(4,125)
Repayments to non-controlling shareholders of subsidiaries	還款予附屬公司的非控股股東	(30,417)	(3,000)
Advances from non-controlling shareholders of subsidiaries	來自附屬公司的非控股股東的墊款	76,000	5,000
Net cash generated from (used in) financing activities	融資活動(所用)所得現金淨額	41,989	(27,840)
Net increase (decrease) in cash and cash equivalents	現金及現金等價物(減少)增加淨額	34,148	(130,710)
Cash and cash equivalents at beginning of the period	期初現金及現金等價物	179,673	223,880
Effect of foreign exchange rate changes	匯率變動影響	(429)	77
Cash and cash equivalents at end of the period, represented by bank balances and cash	期末現金及現金等價物，即銀行結餘及現金	213,392	93,247

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

1. GENERAL INFORMATION AND BASIS OF PREPARATION

廣東康華醫療股份有限公司 (Guangdong Kanghua Healthcare Co., Ltd.) (the “Company”) was established as a limited liability company in the People’s Republic of China (the “PRC”) and its overseas listed foreign invested ordinary shares (“H Shares”) are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”). The Company’s immediate and ultimate holding company is 東莞市康華投資集團有限公司 (Dongguan Kanghua Investment Group Co., Ltd.), a limited liability company established in the PRC. The addresses of the registered office and the principal place of business in Hong Kong of the Company are disclosed in the corporate information section to the interim report.

The Company and its subsidiaries (collectively referred as the “Group”) are principally engaged in provision of hospital services, provision of rehabilitation and other healthcare services, sale of pharmaceutical products and provision of elderly healthcare services in the PRC.

The condensed consolidated financial statements are presented in Renminbi (“RMB”), which is also the functional currency of the Company.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 (“IAS 34”) “Interim Financial Reporting” issued by the International Accounting Standards Board (“IASB”) as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange.

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for financial assets at fair value through profit or loss (“FVTPL”) which are measured at fair values at the end of each reporting period.

Other than additional accounting policies resulting from application of amendments to International Financial Reporting Standards (“IFRSs”), the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2021 are the same as those presented in the Group’s annual financial statements for the year ended 31 December 2020.

1. 一般資料及編製基準

廣東康華醫療股份有限公司(「本公司」)在中華人民共和國(「中國」)成立為一間有限責任公司及其境外上市外資普通股(「H股」)在香港聯合交易所有限公司(「香港聯交所」)主板上市。本公司的直接及最終控股公司為東莞市康華投資集團有限公司，一間於中國成立的有限責任公司。本公司註冊辦事處及香港主要營業地點地址披露於中期報告「公司資料」一節。

本公司及其附屬公司(統稱「本集團」)主要在中國從事提供醫院服務，提供康復及其他醫療服務、銷售藥品及提供老年醫療服務。

簡明綜合財務報表以人民幣(「人民幣」)計值，人民幣亦為本公司的功能貨幣。

簡明綜合財務報表乃根據國際會計準則委員會(「國際會計準則委員會」)頒佈的國際會計準則第34號(「國際會計準則第34號」)「中期財務報告」以及香港聯交所證券上市規則附錄十六的適用披露規定編製。

2. 主要會計政策

簡明綜合財務報表按歷史成本基準編製，惟按公平值計入損益(「按公平值計入損益」)的金融資產乃按各報告期末的公平值計量除外。

除因應用國際財務報告準則(「國際財務報告準則」)修訂本而導致的新增會計政策外，截至二零二一年六月三十日止六個月的簡明綜合財務報表採用的會計政策及計算方法與本集團截至二零二零年十二月三十一日止年度的年度財務報表所呈列者一致。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

Application of amendments to IFRSs

In the current interim period, the Group has applied the following amendments to IFRSs issued by the IASB, for the first time, which are mandatorily effective for the annual periods beginning on or after 1 January 2021 for the preparation of the Group's condensed consolidated financial statements:

Amendment to IFRS 16
國際財務報告準則第16號(修訂本)
Amendments to IFRS 9, IAS 39 and IFRS 7, IFRS 4 and IFRS 16
國際財務報告準則第9號、
國際會計準則第39號、
國際財務報告準則第7號、
國際財務報告準則第4號及
國際財務報告準則第16號(修訂本)

Covid-19-Related Rent Concessions
COVID-19相關租金寬減
Interest Rate Benchmark Reform – Phase 2
利率基準改革 – 第二階段

The application of the amendments to IFRSs in the current period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. REVENUE AND SEGMENT INFORMATION

The Group is principally engaged in (i) provision of hospital services; (ii) provision of rehabilitation and other healthcare services; (iii) sale of pharmaceutical products; and (iv) provision of elderly healthcare services.

Revenue

An analysis of the Group's revenue for the period is as follows:

2. 主要會計政策(續)

應用國際財務報告準則(修訂本)

於本中期期間，本集團已首次採納於二零二一年一月一日或之後開始之年度期間強制生效的由國際會計準則委員會頒佈的下列國際財務報告準則的修訂本，以編製本集團之簡明綜合財務報表：

於本期間應用國際財務報告準則的修訂本，對本集團本期間及過往期間的財務狀況及表現及/或該等簡明綜合財務報表所載披露事項並無重大影響。

3. 收益及分部資料

本集團主要從事(i)提供醫院服務；(ii)提供康復及其他醫療服務；(iii)藥品銷售；及(iv)提供老年醫療服務。

收益

本集團期內收益分析如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Recognised over time – output method:	按產出法隨時間確認：		
Hospital services:	醫院服務：		
– Inpatient healthcare services	– 住院醫療服務	487,392	467,957
– Outpatient healthcare services	– 門診醫療服務	281,633	226,472
– Physical examination services	– 體檢服務	52,321	27,162
Rehabilitation and other healthcare services:	康復及其他醫療服務：		
– Rehabilitation hospital services	– 康復醫院服務	19,723	22,143
– Rehabilitation centre services and other healthcare services	– 康復中心服務及其他醫療服務	24,524	9,315
Elderly healthcare services	老年醫療服務	5,166	1,636
		870,759	754,685
Recognised at a point in time:	於某一時間點確認：		
Sale of pharmaceutical products	藥品銷售	726	6,302
		871,485	760,987

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment information

Information reported to the executive directors of the Company, being the chief operating decision maker (the "CODM"), for the purposes of resource allocation and assessment of segment performance focuses on types of service provided.

The Group's operating segments are classified as (i) hospital services; (ii) rehabilitation and other healthcare services; (iii) sale of pharmaceutical products; and (iv) elderly healthcare services. The details of the Group's operating segments are as follows:

- | | |
|--|---|
| (i) Hospital services: | Provision of hospital services includes (i) inpatient healthcare services which generally refer to the treatment of patients who are hospitalised overnight or for an indeterminate period of time; (ii) outpatient healthcare services which generally refer to the treatment of patients who are hospitalised for less than 24 hours; and (iii) physical examinations services which generally refer to the clinical examination of individuals for signs of diseases and health advisory services. |
| (ii) Rehabilitation and other healthcare services: | Provision of rehabilitation services which generally refer to the provision of special care services to patients with permanent or long-term physical or mental disabilities. Other healthcare services include elderly healthcare and training services for the disabled. |
| (iii) Sale of pharmaceutical products: | Sale of pharmaceutical products to patients of the Group's hospitals and outside customers. |
| (iv) Elderly healthcare services: | Provision of elderly healthcare services, including assisted living, adult daycare, long-term care, residential care and hospice care to the aged patients. |

These operating segments also represent the Group's reportable segments. No operating segments identified by the CODM have been aggregated in arriving at the reportable segments of the Group.

3. 收益及分部資料(續)

分部資料

為進行資源分配及評估分部表現而向本公司執行董事(即主要經營決策者(「主要經營決策者」))呈報的資料側重於所提供服務的類型。

本集團的經營分部分為(i)醫院服務；(ii)康復及其他醫療服務；(iii)藥品銷售；及(iv)老年醫療服務。本集團經營分部的詳情如下：

- | | |
|-----------------|---|
| (i) 醫院服務： | 提供的醫院服務包括(i)住院醫療服務一般指為過夜或不定時入院的病人提供治療；(ii)門診醫療服務一般指為入院少於24小時的病人提供治療；及(iii)體檢服務一般指為個人提供有關疾病徵兆的臨床檢驗及保健諮詢服務。 |
| (ii) 康復及其他醫療服務： | 提供康復服務一般指向永久或長期身體或精神殘疾的患者提供特殊護理服務。其他醫療服務包括老年護理及殘疾人士訓練服務。 |
| (iii) 藥品銷售： | 向本集團醫院的患者及外部客戶銷售藥品。 |
| (iv) 老年醫療服務： | 提供老年醫療服務，包括生活輔助、成人日托、長期護理、住院護理及老年病人的臨終關懷。 |

該等經營分部亦代表本集團的可呈報分部。於釐定本集團的可呈報分部時，概無合併主要經營決策者確定的經營分部。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment revenues and results

The following is an analysis of the Group's revenue and results by operating segments:

For the six months ended 30 June 2021 (unaudited)

3. 收益及分部資料(續)

分部收益及業績

以下為按經營分部劃分的本集團收益及業績分析：

截至二零二一年六月三十日止六個月
(未經審核)

		Hospital services 醫院服務 RMB'000 人民幣千元	Rehabilitation and other healthcare services 康復及其他 醫療服務 RMB'000 人民幣千元	Sale of pharmaceutical products 藥品銷售 RMB'000 人民幣千元	Elderly healthcare services 老年 醫療服務 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
SEGMENT REVENUE	分部收益					
External revenue	外部銷售	821,346	44,247	726	5,166	871,485
Segment profit	分部溢利	127,786	981	116	962	129,845
Other income	其他收入					15,750
Other expenses, gains and losses	其他開支、收益及虧損					2,596
Net reversal of impairment losses under expected credit loss model	預期信貸虧損模式項下 之減值虧損， 撥回淨額					1,303
Administrative expenses	行政開支					(103,441)
Finance costs	融資成本					(10,210)
Profit before taxation	除稅前虧損					35,843

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment revenues and results (Cont'd)

For the six months ended 30 June 2020 (unaudited)

		Hospital services 醫院服務 RMB'000 人民幣千元	Rehabilitation and other healthcare services 康復及其他醫療服務 RMB'000 人民幣千元	Sale of pharmaceutical products 藥品銷售 RMB'000 人民幣千元	Elderly healthcare services 老年醫療服務 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
SEGMENT REVENUE	分部收益					
External revenue	外部銷售	721,591	31,458	6,302	1,636	760,987
Segment profit (loss)	分部溢利(虧損)	20,744	(23,907)	1,372	(1,035)	(2,826)
Other income	其他收入					15,796
Other expenses, gains and losses	其他開支、收益及虧損					(2,876)
Administrative expenses	行政開支					(123,246)
Finance costs	融資成本					(11,294)
Loss before taxation	除稅前虧損					(124,446)

There were no inter-segment sales during both periods.

The accounting policies of the operating segments are the same as the Group's accounting policies. Segment profit (loss) represents the profit earned (loss incurred) by each segment without allocation of other income, other expenses, gains and losses, net reversal of impairment losses under expected credit loss model, administrative expenses and finance costs. This is the measure reported to the CODM for the purposes of resource allocation and performance assessment.

Except as disclosed above, no other amounts are regularly provided to the CODM and therefore, no further analysis is presented.

3. 收益及分部資料(續)

分部收益及業績(續)

截至二零二零年六月三十日止六個月
(未經審核)

於兩個期間並無分部間銷售。

經營分部的會計政策與本集團會計政策相同。分部溢利(虧損)指各分部賺取的溢利(產生的虧損)，而並無分配其他收入、其他開支、收益及虧損、預期信貸虧損模式下的減值虧損撥回淨額、行政開支及融資成本。此乃就資源分配及表現評估而呈報予主要經營決策者的計量方式。

除上文所披露者外，並無其他金額定期提供予主要經營決策者，故並無呈列進一步分析。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

4. OTHER INCOME

4. 其他收入

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Bank and other interest income	銀行及其他利息收入	904	2,641
Investment income from financial assets at FVTPL	按公平值計入損益的金融資產的 投資收入	4,729	3,141
Rental income	租金收入	1,826	2,926
Government subsidies (note)	政府補貼(附註)	2,064	2,149
Others	其他	6,227	4,939
		15,750	15,796

Note: The government subsidies mainly represent the subsidies on costs incurred for operation of rehabilitation centres and hospitals, elderly healthcare centres, research and development projects and medical related seminars with no special and unfulfilled conditions attached.

附註：政府補貼主要指無附帶特殊及未履行條件的康復中心及醫院、老年醫療中心的運營、研發項目及醫療相關講座產生的成本的補貼。

5. OTHER EXPENSES, GAINS AND LOSSES

5. 其他開支、收益及虧損

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Fair value gain (loss) on financial assets at FVTPL	按公平值計入損益的金融資產的 公平值收益(虧損)	3,692	(2,581)
Net exchange (loss) gain	匯兌(虧損)收益淨額	(977)	1,312
Donations	捐款	(110)	(1,413)
Loss on disposals/write-off of property, plant and equipment	出售/撤銷物業、廠房 及設備的虧損	(9)	(194)
		2,596	(2,876)

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

6. PROFIT (LOSS) BEFORE TAXATION

6. 除稅前溢利(虧損)

		Six months ended 30 June 截至六月三十日止六個月	
		2021	2020
		二零二一年	二零二零年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Profit (loss) before taxation has been arrived at after charging:	除稅前溢利(虧損)經扣除下列項目後達致：		
Depreciation of property, plant and equipment	物業、廠房及設備折舊	55,585	54,191
Depreciation of right-of-use assets	使用權資產折舊	17,807	16,410
Research and development expenditure	研發開支	686	186
Short-term lease rentals in respect of rehabilitation centres and staff quarters	與康復中心及員工宿舍有關的短期租賃租金	2,071	133
Variable lease rentals in respect of hospitals	與醫院有關的可變租賃租金	5,771	3,274
Cost of inventories recognised as expenses (representing pharmaceutical products, consumables and others used, included in cost of revenue)	確認為開支的存貨成本(指所用藥品、耗材及其他，計入收益成本內)	397,972	372,164



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

7. INCOME TAX EXPENSES

7. 所得稅開支

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
PRC Enterprise Income Tax ("EIT")	中國企業所得稅(「企業所得稅」)		
Current tax	即期稅項	20,989	1,409
Overprovision of EIT in prior years	過往年度企業所得稅超額撥備	(17)	(172)
		20,972	1,237
Hong Kong Profits Tax	香港利得稅		
Underprovision in prior years	過往年度撥備不足	4	289
		20,976	1,526
Deferred tax charge (Note 16)	遞延稅項支出(附註16)	68	247
		21,044	1,773

Under the Law of the PRC on EIT (the "EIT Law") and Implementation Regulation of the EIT Law, the statutory income tax rate of the Company and its PRC subsidiaries is 25% for both periods.

根據中國企業所得稅法(「企業所得稅法」)及企業所得稅法實施條例,本公司及其中國附屬公司於兩個期間內的法定所得稅稅率為25%。

On 21 March 2018, the Hong Kong Legislative Council passed the Inland Revenue (Amendment) (No.7) Bill 2017 (the "Bill") which introduced the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HK\$2,000,000 of profits of the qualifying group entity will be taxed at 8.25% and profits above HK\$2,000,000 will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%.

於二零一八年三月二十一日,香港立法會通過《二零一七年稅務(修訂)(第7號)條例草案》(「該條例草案」),引入利得稅兩級制。該條例草案於二零一八年三月二十八日經簽署成為法律,並於翌日刊憲。根據利得稅兩級制,合資格集團實體首2,000,000港元溢利的稅率為8.25%,而超過2,000,000港元溢利的稅率為16.5%。不符合利得稅兩級制資格的集團實體之溢利繼續按16.5%統一稅率計算。

Accordingly, the Hong Kong Profits Tax of the qualifying group entity is calculated at 8.25% on the first HK\$2,000,000 of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK\$2,000,000.

因此,合資格集團實體首2,000,000港元估計應課稅溢利及2,000,000港元以上的估計應課稅溢利乃分別按8.25%及16.5%稅率計算香港利得稅。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

8. DIVIDENDS

No dividends were paid, declared or proposed during the current interim period (six months ended 30 June 2020: nil). The directors of the Company have determined that no dividend will be paid in respect of the current interim period (six months ended 30 June 2020: nil).

9. EARNINGS (LOSS) PER SHARE

The calculation of basic earnings (loss) per share attributable to the owners of the Company is based on the following data:

8. 股息

於本中期期間，本公司概無派付、宣派或建議派付股息（截至二零二零年六月三十日止六個月：無）。本公司董事已釐定概不會就本中期期間派付股息（截至二零二零年六月三十日止六個月：無）。

9. 每股盈利（虧損）

本公司擁有人應佔每股基本盈利（虧損）基於以下數據計算：

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Earnings (loss):	盈利（虧損）：		
Profit (loss) for the period attributable to the owners of the Company for the purpose of calculating basic earnings (loss) per share	用於計算每股基本盈利（虧損）的本公司擁有人應佔期內溢利（虧損）	30,875	(106,324)
		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 (unaudited) (未經審核)	2020 二零二零年 (unaudited) (未經審核)
Number of shares:	股份數目：		
Weighted average number of ordinary shares for the purpose of calculating basic earnings (loss) per share	用於計算每股基本盈利（虧損）的普通股加權平均數	334,394,000	334,394,000

No diluted earnings (loss) per share has been presented since there was no potential ordinary share in issue for both periods.

由於在兩個期間內沒有發行潛在普通股，故並無呈列每股攤薄盈利（虧損）。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT/RIGHT-OF-USE ASSETS

During the current interim period, the Group disposed of certain property, plant and equipment with an aggregate carrying amount of RMB164,000 (six months ended 30 June 2020: RMB253,000) for cash proceeds of RMB155,000 (six months ended 30 June 2020: RMB59,000), resulting in a loss on disposals/write-off of RMB9,000 (six months ended 30 June 2020: RMB194,000).

In addition, during the current interim period, the Group acquired property, plant and equipment and incurred expenditure on construction in progress of RMB32,724,000 and RMB44,354,000 (six months ended 30 June 2020: RMB26,124,000 and RMB35,110,000), respectively, for the purpose of upgrading and expanding the service capacity of the Group's hospital operations.

During the current interim period, the Group entered into new lease agreements for the use of properties in the PRC for 2 to 5 years (six months ended 30 June 2020: 3 to 5 years). The Group is required to make fixed monthly payments. On commencement of the leases, the Group recognised right-of-use assets and lease liabilities of RMB6,661,000 (six months ended 30 June 2020: RMB1,038,000) each relating to those new leases.

11. GOODWILL

As at 1 January 2021, the goodwill allocated to the cash-generating unit ("CGU") of 安徽樺霖醫療投資有限公司 (Anhui Hualin Medical Investment Co., Ltd.) ("Anhui Hualin") (the "Anhui Hualin CGU") ("Anhui Hualin's Goodwill") and 重慶康華眾聯心血管病醫院有限公司 (Chongqing Kanghua Zhonglian Cardiovascular Hospital Co., Ltd.) ("Kangxin Hospital") (the "Kangxin Hospital CGU") ("Kangxin's Goodwill") have the carrying amounts of RMB29,101,000 and RMB15,512,000 respectively. For the purpose of impairment assessment, the directors of the Company conducted reviews of Anhui Hualin CGU and Kangxin Hospital CGU containing the goodwill and determined that there is no impairment of the CGUs.

10. 物業、廠房及設備／使用權資產的變動

於本中期期間，本集團出售賬面總值為人民幣164,000元（截至二零二零年六月三十日止六個月：人民幣253,000元）的若干物業、廠房及設備，現金所得款項為人民幣155,000元（截至二零二零年六月三十日止六個月：人民幣59,000元），導致出售／撇銷虧損人民幣9,000元（截至二零二零年六月三十日止六個月：人民幣194,000元）。

此外，於本中期期間，本集團分別收購物業、廠房及設備及在建工程產生支出人民幣32,724,000元及人民幣44,354,000元（截至二零二零年六月三十日止六個月：人民幣26,124,000元及人民幣35,110,000元），以升級及擴大其醫院營運的服務能力。

於本中期期間，本集團訂立新租賃協議，以在中國使用物業2至5年（截至二零二零年六月三十日止六個月：3至5年）。本集團須按月支付固定費用。於租賃開始時，本集團確認均與該等新租賃有關的使用權資產及租賃負債人民幣6,661,000元（截至二零二零年六月三十日止六個月：人民幣1,038,000元）。

11. 商譽

於二零二一年一月一日，分配至安徽樺霖醫療投資有限公司（「安徽樺霖」）及重慶康華眾聯心血管病醫院有限公司（「康心醫院」）現金產生單位（「康心醫院現金產生單位」）的商譽（「康心商譽」）的賬面值分別為人民幣29,101,000元及人民幣15,512,000元。就減值評估而言，本公司董事對安徽樺霖現金產生單位及康心醫院現金產生單位所包括的商譽進行檢討，並釐定現金產生單位並無減值。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

11. GOODWILL (Cont'd)

The recoverable amount of the Anhui Hualin CGU has been determined based on a value in use calculation by reference to a valuation report prepared by an independent professional valuer. The calculation uses cash flow projections based on financial budgets approved by the management for the next five (31 December 2020: five) years. Cash flows beyond the five-year (31 December 2020: five-year) period are extrapolated using growth rate of 3.0% (31 December 2020: 3.0%). A pre-tax discount rate of 16.1% (31 December 2020: 17.5%) is used for this CGU and derived using risk-free rate, the market return and CGU specific factors.

The recoverable amount of the Kangxin Hospital CGU has been determined based on a value in use calculation by reference to a valuation report prepared by an independent professional valuer. The calculation uses cash flow projections based on financial budgets approved by the management for the next seven (31 December 2020: seven) years. Cash flows beyond the seven-year (31 December 2020: seven-year) period are extrapolated using growth rate of 3.0% (31 December 2020: 3.0%). A pre-tax discount rate of 14.9% (31 December 2020: 15.4%) is used for this CGU and derived using risk-free rate, the market return and CGU specific factors.

The key assumptions are growth rates and pre-tax discount rates which are estimated based on past practices and expectations of future changes in the market. After taken into consideration of the historical performance and most recent actual performance of the Anhui Hualin CGU and Kangxin Hospital CGU, the directors of the Company believe that any reasonably possible change in any of these assumptions would not cause the carrying amount of each cash generating unit to exceed its recoverable amount.

11. 商譽 (續)

安徽樺霖現金產生單位的可收回金額已根據使用價值計算，並參考獨立專業估值師編製的估值報告釐定。該計算使用基於管理層批准的未來五年（二零二零年十二月三十一日：五年）財務預算的現金流量預測。超過五年（二零二零年十二月三十一日：五年）期間的現金流量使用3.0%（二零二零年十二月三十一日：3.0%）的增長率推斷。使用無風險利率、市場回報及現金產生單位的特定因素得出的本現金產生單位使用16.1%（二零二零年十二月三十一日：17.5%）的稅前折現率。

康心醫院現金產生單位的可收回金額已根據使用價值計算，並參考獨立專業估值師編製的估值報告釐定。該計算使用基於管理層批准的未來六年（二零二零年十二月三十一日：七年）財務預算的現金流量預測。超過七年（二零二零年十二月三十一日：七年）的現金流量使用3.0%（二零二零年十二月三十一日：3.0%）的增長率推斷。使用無風險利率、市場回報及現金產生單位的特定因素得出的本現金產生單位使用14.9%（二零二零年十二月三十一日：15.4%）的稅前折現率。

主要假設是增長率及稅前貼現率，該等比率是根據過往慣例及市場未來變化的預期估算。經計及安徽樺霖現金產生單位及康心醫院現金產生單位的歷史表現及最近期實際表現，本公司董事認為，任何該等假設的任何合理可能變動將不會導致各現金產生單位的賬面值超過其可收回金額。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

12. ACCOUNTS AND OTHER RECEIVABLES

12. 應收賬款及其他應收款項

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Accounts receivables	應收賬款	236,739	212,400
Less: Allowance for credit loss	減：信貸虧損撥備	(6,381)	(7,694)
		230,358	204,706
Prepayments to suppliers	預付供應商款項	13,141	16,442
Interest receivables	應收利息	-	594
Others	其他	34,676	26,937
		278,175	248,679

The individual patients of the Group would usually settle payments by cash, credit cards or government's social insurance schemes. For credit card and mobile payments, the banks and counterparties will normally settle the amounts approximately 30 days after the transaction date. Payments by the PRC government's social insurance schemes will normally be settled by the local social insurance bureau or similar government departments which are responsible for the reimbursement of medical expenses for patients who are covered by the government's medical insurance schemes ranged from 30 to 180 days from the transaction date. Corporate customers will normally settle the amounts within 90 days after the transaction date by bank transfers.

The following is an aged analysis of accounts receivables, net of allowance for credit loss, presented based on the revenue recognition date at the end of the reporting period:

本集團的個人病人一般以現金、信用卡或政府社保計劃繳費。對於信用卡及移動支付，銀行及交易對手通常會在交易日期後約30天結算賬款。透過中國政府的社保計劃繳費，則通常須由當地社保局或負責向辦理政府醫療保險計劃的病人報銷醫療開支的類似政府部門，自交易日期起介乎30至180天內結清。公司客戶將一般於交易日期後90天內以銀行轉賬方式結算款項。

基於報告期末收益確認日期呈列的應收賬款（扣除信貸虧損撥備）的賬齡分析如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Within 30 days	30天以內	92,910	121,199
31 to 90 days	31至90天	88,910	36,124
91 to 180 days	91至180天	36,489	43,012
181 to 365 days	181至365天	8,773	2,992
Over 365 days	超過365天	3,276	1,379
		230,358	204,706

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

13. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS 13. 按公平值計入損益的金融資產

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Portfolio investment fund (note (i))	投資組合基金(附註(i))	70,546	67,663
Structured bank deposits (note (iii))	結構性銀行存款(附註(iii))	500,000	400,000
		570,546	467,663
Analysed for reporting purpose as:	就報告目的分析如下：		
Current assets	流動資產	500,000	400,000
Non-current assets	非流動資產	70,546	67,663
		570,546	467,663

Notes:

- (i) As part of the Group's cash management activities, the Group has a portfolio investment fund, the underlying portfolio of which includes a mixture of cash and shares that are primarily listed in Hong Kong. As at 1 January 2020, the portfolio investment fund was maintained by a discretionary fund manager and measured at fair value. During the year ended 31 December 2020, such portfolio investment fund was disposed of and part of the proceeds were rolled over to a new portfolio investment fund. At 30 June 2021, the Group currently does not expect any immediate use of the new portfolio investment fund in the short term and thus, the new portfolio investment fund is classified as non-current assets. The Group may at its discretion redeem the new fund subject to the relevant procedures, requirements and restrictions.
- (ii) The Group invested into structured deposits with banks in the PRC for guaranteed principal and variable investment returns. The majority of these structured deposits are with maturities of less than six months and the principal is generally renewed when matured.

附註：

- (i) 作為本集團現金管理活動的一部分，本集團設有投資組合基金，其相關投資組合包括現金及主要在香港上市之股份。於二零二零年一月一日，投資組合投資基金由全權委託基金經理維持，按公平值計量。截至二零二零年十二月三十一日止年度，該投資組合基金已被出售，部分所得款項已轉至新投資組合基金。於二零二一年六月三十日，本集團目前預期短期內不會即時使用新投資組合基金，因此，新投資組合基金被分類為非流動資產。本集團可酌情贖回新基金，惟須遵守相關程序、規定及限制。
- (ii) 本集團投資於中國銀行的結構性存款以保本及賺取可變投資回報。大部份結構性存款的到期日少於六個月，本金一般於到期時重續。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

14. ACCOUNTS AND OTHER PAYABLES AND PROVISION

14. 應付賬款及其他應付款項及撥備

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Accounts payables	應付賬款	281,249	256,802
Accrued expenses	應計開支	85,093	94,045
Receipts in advance (note)	預收款項(附註)	182,880	100,659
Payables for acquisition of property, plant and equipment	收購物業、廠房及設備應付款項	43,525	41,681
Other tax payables	其他應付稅項	2,273	3,070
Others	其他	27,918	17,655
Other payables	其他應付款項	341,689	257,110
Sub-total accounts and other payables	應付賬款及其他應付款項小計	622,938	513,912
Provision for medical dispute claims	醫療糾紛索償撥備	2,979	2,956
Total accounts and other payables and provision	應付賬款及其他應付款項及 撥備總額	625,917	516,868

Note: Included in the balance are advances from the PRC social insurance which represent operating cash of RMB142,471,000 (31 December 2020: RMB52,533,000) advanced from the PRC government for the daily operations of the hospitals operated by the Group.

附註：結餘包括中國社會保險的預付款，即自中國政府預付的人民幣142,471,000元(二零二零年十二月三十一日：人民幣52,533,000元)的經營現金，用於本集團所經營醫院的日常運營。

The credit period of accounts payables is from 30 to 90 days from the invoice date.

應付款項的信貸期為自發票日期起計30至90日。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

14. ACCOUNTS AND OTHER PAYABLES AND PROVISION (Cont'd)

The following is an aged analysis of accounts payables based on the date of receipt of goods:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Within 30 days	30天以內	70,451	72,662
31 to 90 days	31至90天	147,946	108,215
91 to 180 days	91至180天	28,413	42,749
181 to 365 days	181至365天	11,174	15,473
Over 365 days	超過365天	23,265	17,703
		281,249	256,802

14. 應付賬款及其他應付款項及撥備(續)

基於收貨日期的應付賬款的賬齡分析如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Within 30 days	30天以內	70,451	72,662
31 to 90 days	31至90天	147,946	108,215
91 to 180 days	91至180天	28,413	42,749
181 to 365 days	181至365天	11,174	15,473
Over 365 days	超過365天	23,265	17,703
		281,249	256,802

15. BANK LOANS

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Variable rate secured bank loan (note (a))	有抵押銀行貸款(浮動利率)(附註(a))	234,188	204,647
Fixed rate secured loan (note (b))	有抵押貸款(固定利率)(附註(b))	49,409	53,183
		283,597	257,830

15. 銀行貸款



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

15. BANK LOANS (Cont'd)

15. 銀行貸款 (續)

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
The carrying amounts of the loans are repayable*:	貸款賬面值於以下時間償還*：		
Within one year	一年內	15,740	7,574
Within a period of more than one year but not exceeding two years	一至兩年的期間內	26,391	21,897
Within a period of more than two years but not exceeding five years	兩至五年的期間內	80,952	73,549
Within a period of more than five years	超過五年的期間內	160,514	154,810
		283,597	257,830
Less: Amounts due within one year shown under current liabilities	減：流動負債項下所示於一年內到期的款項	(15,740)	(7,574)
Amounts shown under non-current liabilities	非流動負債項下所示款項	267,857	250,256

* The amount due are based on scheduled repayment dates set out in the loan agreements.

* 到期的款項乃根據貸款協議所載的計劃還款日期計算。

Notes:

附註：

(a) At 30 June 2021, the bank loan carried interest at the benchmark interest rate for loan offered by the People's Bank of China and adjusted annually from the drawn down date. The effective interest rate of the secured bank loan is 5.82% (31 December 2020: 5.84%) per annum. The main purpose of the loan is to finance the payment of phase 2 medical facility development of Kangxin Hospital and to settle certain amount due to a non-controlling shareholder of a subsidiary.

(a) 於二零二一年六月三十日，銀行貸款按自提取之日起每年調整的中國人民銀行提供的貸款基準利率計息。已抵押銀行貸款的實際年利率為5.82%（二零二零年十二月三十一日：5.84%）。貸款主要用於支付康心醫院第二階段醫療設施的開發，並結清若干應付一間附屬公司的一名非控股股東的款項。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

15. BANK LOANS (Cont'd)

Notes: (Cont'd)

(a) (Cont'd)

At 30 June 2021, the bank loan was secured with the key terms and securities pledged as follows:

- (i) financial guarantees provided by the Company, Mr. Wang Junyang, chairman of the Group, 東莞市東成石材有限公司, a company controlled by Dongguan Xingye Group Co., Ltd. and 東莞嘉德醫療投資有限公司 (collectively referred as the "Guarantors") with respective maximum amount of RMB500,000,000 (31 December 2020: RMB500,000,000); and
 - (ii) share pledges over the equity shares in Kangxin Hospital held by the Company and 東莞嘉德醫療投資有限公司.
- (b) The fixed rate secured loan represents a financing arrangement with Industrial and Commercial Bank of China Leasing Co., Ltd., an independent third party. Pursuant to the arrangement, the Group has transferred legal title of certain medical equipment to Industrial and Commercial Bank of China Leasing Co., Ltd., and shall then be leased back for use by the Group. Upon expiry of the lease term, the Group has an option to repurchase these medical equipment at a cash consideration of RMB1. At 30 June 2021, the carrying amount of these medical equipment is approximately RMB38,867,000 (31 December 2020: RMB45,517,000), and is guaranteed by the Guarantors.

The transfers of these medical equipment do not satisfy the requirements of IFRS 15 to be accounted for as a sale of assets. The Group continued to recognise the transferred assets and initially recognised a secured loan equal to the transfer proceeds. At 30 June 2021, the carrying amount of the borrowing in respect of such arrangements amounted to RMB49,409,000 (31 December 2020: RMB53,183,000). The loan carried effective interest rate of 6.74% (31 December 2020: 6.74%) per annum and would be settled with quarterly instalments until September 2027.

15. 銀行貸款 (續)

附註：(續)

(a) (續)

於二零二一年六月三十日，銀行貸款有擔保，主要條款及已抵押證券如下：

- (i) 由本公司、本集團主席王君揚先生、東莞市東成石材有限公司(一間由東莞市興業集團有限公司控制的公司)及東莞嘉德醫療投資有限公司(統稱「擔保人」)提供的財務擔保，各自最高金額為人民幣500,000,000元(二零二零年十二月三十一日：人民幣500,000,000元)；及
 - (ii) 對本公司及東莞嘉德醫療投資有限公司持有康心醫院的股權的股份質押。
- (b) 固定利率的有抵押貸款指與獨立第三方工銀金融租賃有限公司訂立的融資安排。根據該安排，本集團已將若干醫療設備的合法所有權轉讓予工銀金融租賃有限公司，其後將其租回以供本集團使用。租期屆滿後，本集團有權以現金代價人民幣1元購回該等醫療設備。於二零二一年六月三十日，該等醫療設備的賬面值約為人民幣38,867,000元(二零二零年十二月三十一日：人民幣45,517,000元)，並由擔保人提供擔保。

醫療設備轉讓不符合國際財務報告準則第15號規定並將作為出售資產入賬。本集團繼續確認已轉讓資產及初步確認等於轉讓所得款項的已抵押貸款。於二零二一年六月三十日，與有關安排相關的借款的賬面值為人民幣49,409,000元(二零二零年十二月三十一日：人民幣53,183,000元)。貸款的實際年利率為6.74%(二零二零年十二月三十一日：6.74%)，直至二零二七年九月可按季度分期償還。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

16. DEFERRED TAX LIABILITIES (ASSETS)

The following are the major deferred tax liabilities (assets) recognised and movements thereon during the current interim and preceding interim periods:

		Accelerated tax depreciation 加速稅項 折舊 RMB'000 人民幣千元	Pre-operating expenses written off 撇銷營業前 開支 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
At 31 December 2020 (audited)	於二零二零年十二月三十一日(經審核)	25,819	(3,874)	21,945
(Credit) charge to profit or loss (Note 7)	(計入)扣除損益(附註7)	(324)	392	68
At 30 June 2021 (unaudited)	於二零二一年六月三十日(未經審核)	25,495	(3,482)	22,013
At 1 January 2020 (audited)	於二零二零年一月一日(經審核)	26,032	(4,649)	21,383
(Credit) charge to profit or loss (Note 7)	(計入)扣除損益(附註7)	(299)	546	247
At 30 June 2020 (unaudited)	於二零二零年六月三十日(未經審核)	25,733	(4,103)	21,630

At 30 June 2021, the Group had unused tax losses of approximately RMB354,350,000 (31 December 2020: RMB254,047,000) available for offset against future profits. No deferred tax asset was recognised in respect of such tax losses due to unpredictable profit stream. The unused tax losses can be carried forward up to five years from the year in which the loss was originated, to offset future taxable profits.

At 30 June 2021, the Group has deductible temporary difference for pre-operating expenses written off amounted to approximately RMB13,930,000 (31 December 2020: RMB15,496,000). A deferred tax asset has been recognised in respect of the deductible temporary difference of RMB13,930,000 (31 December 2020: RMB15,496,000) at the end of the reporting period.

16. 遞延稅項負債(資產)

以下是於本中期及過往中期期間確認的主要遞延稅項負債(資產)及其變動:

於二零二一年六月三十日，本集團有未使用稅項虧損約為人民幣354,350,000元(二零二零年十二月三十一日：人民幣254,047,000元)可抵銷未來溢利。由於溢利流難以預測，因此並無就該等稅項虧損確認遞延稅項資產。未使用的稅項虧損可以自發生虧損之年度起最多五年結轉，以抵銷未來應課稅溢利。

於二零二一年六月三十日，本集團的可抵扣撇銷營業前的開支暫時性差額約為人民幣13,930,000元(二零二零年十二月三十一日：人民幣15,496,000元)。於報告期末，已就可抵扣暫時性差額為人民幣13,930,000元(二零二零年十二月三十一日：人民幣15,496,000元)確認遞延稅項資產。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

17. SHARE CAPITAL

17. 股本

	Number of domestic shares 內資股數目 '000 千股	Number of H shares H股數目 '000 千股	Share capital 股本 RMB'000 人民幣千元
At 1 January 2020 (audited), 31 December 2020 (audited) and 30 June 2021 (unaudited)	於二零二零年一月一日 (經審核)、二零二零年 十二月三十一日(經審核) 及二零二一年六月三十日 (未經審核)	250,000	84,394 334,394

18. CAPITAL COMMITMENTS

18. 資本承擔

	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Capital expenditure in respect of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements	於簡明綜合財務報表中已訂約 但未撥備的物業、廠房及設備的 資本開支 223,324	255,496



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

19. RELATED PARTY DISCLOSURES

In addition to the transactions, balances and commitments disclosed elsewhere in the condensed consolidated financial statements, the Group had entered into the following significant related party transactions:

19 關聯方披露

除簡明綜合財務報表其他章節所披露的交易、結餘及承擔外，本集團已訂立以下關聯方交易：

Name of related companies 關聯公司名稱	Relationship 關係	Nature of transactions 交易性質	As at/ For the six months ended 30 June 2021 於二零二一年 六月三十日/ 截至該日止 六個月	As at/ For the six months ended 30 June 2020 於二零二零年 六月三十日/ 截至該日止 六個月
			RMB'000 人民幣千元 (unaudited) (未經審核)	RMB'000 人民幣千元 (unaudited) (未經審核)
Kanghua Group 康華集團	Shareholder 股東	Interest expenses on lease liabilities 租賃負債之利息開支	4,362	4,953
		Lease liabilities 租賃負債	144,507	165,964
		Lease payment 租賃付款	21,247	17,841
Dongguan Tongli Enterprise Co., Ltd. 東莞市同力實業有限公司	Non-controlling shareholder of Dongguan Renkang Hospital Co., Ltd. 東莞仁康醫院有限公司的非控股股東	Interest expenses on lease liabilities 租賃負債之利息開支	836	949
		Lease liabilities 租賃負債	27,691	31,802
		Lease payment 租賃付款	3,303	2,983

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

19. RELATED PARTY DISCLOSURES (Cont'd)

Compensation of key management personnel

Key management personnel includes directors and supervisors. The remuneration of the key management personnel during the current interim period is as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (unaudited) (未經審核)
Fees	袍金	540	810
Salaries and allowances	薪金及津貼	938	968
Retirement benefit schemes contributions	退休福利計劃供款	30	17
		1,508	1,795

20. CONTINGENT LIABILITIES

The Group is involved as defendants in certain medical disputes arising from its normal business operations. Except for those disputes with provision made as disclosed in Note 14, the management of the Group believes that the final result of other medical disputes with total claims of RMB5,517,000 (31 December 2020: RMB6,792,000) as at 30 June 2021 will not have a material impact on the financial position or operations of the Group and the amount of outflow, if any, cannot be determined with sufficient reliability prior to judicial appraisals. Accordingly, no provision is made in this regard.

19 關聯方披露 (續)

主要管理人員薪酬

主要管理人員包括董事及監事。於本中期期間，主要管理人員的薪酬如下：

20. 或然負債

本集團作為被告牽涉其一般業務營運中產生的若干醫療糾紛。除附註14所披露就此等糾紛作出的撥備外，本集團管理層相信於二零二一年六月三十日，涉及總索賠人民幣5,517,000元（二零二零年十二月三十一日：人民幣6,792,000元）的其他醫療糾紛的最終結果將不會對本集團的財務狀況或營運造成重大影響，而流出金額（如有）無法於司法鑒定前充分可靠地釐定。因此，本集團並無就此作出撥備。



Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

21. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Other than the financial assets carried at fair value as detailed in the following table, the directors of the Company consider that the carrying amounts of other financial instruments that are recorded at amortised cost in the condensed consolidated financial statements approximate their fair values.

	Fair value as at 30 June 2021 於二零二一年 六月三十日 的公平值 RMB'000 人民幣千元	Fair value as at 31 December 2020 於二零二零年 十二月三十一日 的公平值 RMB'000 人民幣千元
--	---	---

Portfolio investment fund

70,546

67,663

投資組合基金

Structured bank deposits

500,000

400,000

結構性銀行存款

21. 金融工具的公平值計量

除下表所詳述按公平值列賬的金融資產外，本公司董事認為，按攤銷成本於本簡明綜合財務報表中入賬的其他金融工具的賬面金額與其公平值相若。

Fair value hierarchy	Valuation techniques and key inputs
公平值 架構	估值技巧及 主要輸入數據

Level 2 Quoted price from a financial institution

第二級 報價來自金融機構

Level 2 Quoted price from financial institutions

第二級 報價來自金融機構

There was no transfer between Level 2 and other Levels in both periods.

於兩個期間內，第二級及其他級別之間並無轉撥。

Definitions

釋義

Adjusted EBITDA 「經調整EBITDA」	the earnings before accounting for bank and other interest income, interest expenses, taxes, depreciation and amortisation, fair value gain/loss and investment income from financial assets at FVTPL, exchange gain/loss and impairment of goodwill 除銀行及其他利息收入、利息開支、稅項、折舊及攤銷、按公平值計入損益的金融資產公平值收益／虧損、投資收入、匯兌收益／虧損前的盈利及商譽減值
Anhui Hualin 「安徽樺霖」	Anhui Hualin Medical Investment Co., Ltd. (安徽樺霖醫療投資有限公司), a limited liability company established in the PRC on 19 December 2016 with 57% of its equity interest being held by Dongguan Kanghua Medical Rehabilitation Investment Company Limited (東莞康華康復醫療投資有限公司), our wholly-owned subsidiary and 43% held by Hefei Haihua Enterprises Management Consulting Partnership (Limited Partnership) (合肥海樺企業管理諮詢合夥企業(有限合夥)), an Independent Third Party 安徽樺霖醫療投資有限公司，於二零一六年十二月十九日在中國成立的有限公司，其57%的股權由我們的全資附屬公司東莞康華康復醫療投資有限公司持有，及43%由獨立第三方合肥海樺企業管理諮詢合夥企業(有限合夥)持有
Anhui Hualin Group 「安徽樺霖集團」	Anhui Hualin together with the entities the results of which are consolidated into its financial statements 安徽樺霖連同業績合併到其財務報表中的實體
Audit Committee 「審核委員會」	the audit committee of the Board 董事會審核委員會
Board of Directors or Board 「董事會」	the board of Directors of the Company 本公司董事會
CG Code 「企業管治守則」	the Corporate Governance Code contained in Appendix 14 to the Hong Kong Listing Rules 香港上市規則附錄十四所載的《企業管治守則》
Company 「本公司」	Guangdong Kanghua Healthcare Co., Ltd. (廣東康華醫療股份有限公司), a joint stock limited liability company established under the laws of the PRC, the H Shares of which are listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 3689) 廣東康華醫療股份有限公司，一家根據中國法律成立的股份有限公司，其H股於香港聯交所主板上市(股份代號：3689)
Controlling Shareholders 「控股股東」	has the meaning ascribed under the Hong Kong Listing Rules and unless the context otherwise requires, refers to Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group, Xingye Group, Mr. Chen Wangzhi, Ms. Wang Ai Qin and Xingda Property as a group of Controlling Shareholders of the Company, and each of them, a "Controlling Shareholder" 具有香港上市規則所賦予的涵義，除非文義另有所指，指王君揚先生、王愛慈女士、康華集團、興業集團、陳旺枝先生、王愛勤女士及興達物業作為一組本公司控股股東，而彼等各自為一名「控股股東」
Director(s) 「董事」	the director(s) of the Company 本公司董事



Domestic Share(s) 「內資股」	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded on any stock exchange 本公司股本中每股面值為人民幣1.00元並以人民幣認購或入賬列為繳足股本的普通股，並且是目前未在任何證券交易所上市或交易的非上市股份
Group or we or our 「本集團」或「我們」	the Company and its subsidiaries 本公司及其附屬公司
H Share(s) 「H股」	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Hong Kong Stock Exchange 本公司普通股股本中每股面值人民幣1.00元的境外上市外資普通股，於香港聯交所主板上市
HK\$ or Hong Kong dollars 「港元」	Hong Kong dollars, the lawful currency of Hong Kong 港元，香港法定貨幣
Hong Kong 「香港」	the Hong Kong Special Administrative Region of the PRC 中國香港特別行政區
Hong Kong Listing Rules 「香港上市規則」	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time 《香港聯合交易所有限公司證券上市規則》，經不時修訂、補充或以其他方式修改
Hong Kong Stock Exchange 「香港聯交所」	The Stock Exchange of Hong Kong Limited 香港聯合交易所有限公司
Huaxin Building 「華心樓」	refers to the complex (華心樓) at Kanghua Hospital which was commissioned to provide VIP healthcare services 康華醫院華心樓，獲分派提供貴賓醫療服務
Independent Third Party(ies) 「獨立第三方」	Any entity or person who is not a connected person of our Company within the meaning ascribed thereto under the Hong Kong Listing Rules 根據香港上市規則，歸因於香港上市規則賦予的涵義，並非本公司關連人士的任何實體或人士
Kangdi Enterprise 「康帝實業」	Dongguan Kangdi Enterprise Co., Ltd. (東莞市康帝實業有限公司), a limited liability company established in the PRC on 25 July 2014 with 50% of its equity interest held by Mr. Wang Zhengren (王政仁) and 50% by Ms. Wang Keying (王可瑩), all of whom are members of the Wang Family, being cousins of Mr. Wang Junyang. Kangdi Enterprise holds a 15% equity interest in Renkang Hospital 東莞市康帝實業有限公司，一家於二零一四年七月二十五日在中國成立的有限公司，其股權由王政仁先生及王可瑩女士各持有50%，彼等均為王氏家族的成員及王君揚先生的堂兄弟姐妹。康帝實業於仁康醫院持有15%的股權

Definitions

釋義

Kanghua Group 「康華集團」	Dongguan Kanghua Investment Group Co., Ltd. (東莞市康華投資集團有限公司), a limited liability company established in the PRC on 29 March 2002 and one of the Controlling Shareholders holding approximately 59.06% interest in the Company. It is owned as to 97.46% by Mr. Wang Junyang and as to 2.54% by Ms. Wang Aici. Kanghua Group, Mr. Wang Junyang, Ms. Wang Aici, Xingye Group, Mr. Chen Wangzhi, Ms. Wang Aiqin and Xingda Property are acting together as a group of Controlling Shareholders 東莞市康華投資集團有限公司，一家於二零零二年三月二十九日在中國成立的有限公司及我們其中一名控股股東，持有本公司約59.06%權益，其分別由王君揚先生及王愛慈女士擁有97.46%及2.54%。康華集團、王君揚先生、王愛慈女士、興業集團、陳旺枝先生、王愛勤女士及興達物業作為一組控股股東一致行動
Kanghua Hospital 「康華醫院」	Dongguan Kanghua Hospital Co., Ltd. (東莞康華醫院有限公司), a limited liability company established in the PRC on 15 September 2005 and a wholly-owned subsidiary of the Company 東莞康華醫院有限公司，一家於二零零五年九月十五日在中國成立的有限公司，且為本公司的全資附屬公司
Kangxin Hospital 「康心醫院」	Chongqing Kanghua Zhonglian Cardiovascular Hospital Co., Ltd. (重慶康華眾聯心血管病醫院有限公司), a limited liability company established in the PRC on 10 June 2014 and a non-wholly owned subsidiary of the company 重慶康華眾聯心血管病醫院有限公司，一家於二零一四年六月十日在中國成立的有限責任公司及本公司非全資附屬公司
Model Code 「標準守則」	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 to the Hong Kong Listing Rules 香港上市規則附錄十所載《上市發行人董事進行證券交易標準守則》
O&G 「婦產科」	obstetrics and gynaecology 婦產科
PRC or China 「中國」	the People's Republic of China 中華人民共和國
PRC Company Law 「中國公司法」	the Company Law of the People's Republic of China (中華人民共和國公司法), as amended and adopted by the Standing Committee of the Twelfth National People's Congress on 28 December 2013 and effective on 1 March 2014, as amended, supplemented and otherwise modified from time to time 《中華人民共和國公司法》，由第十二屆全國人民代表大會常務委員會於二零一三年十二月二十八日修訂並通過，自二零一四年三月一日起生效，經不時修訂、補充及以其他方式修改
Prospectus 「招股章程」	the prospectus of the Company dated 27 October 2016 本公司日期為二零一六年十月二十七日的招股章程



Renkang Hospital 「仁康醫院」	Dongguan Renkang Hospital Co., Ltd. (東莞仁康醫院有限公司), a limited liability company established in the PRC on 23 August 2005 with 57% of its equity interest being held by the Company, 15% by Kangdi Enterprise, 15% by Ms. Zhang Dandan and 13% by Ms. Wang Aier, respectively 東莞仁康醫院有限公司，一家於二零零五年八月二十三日在中國成立的有限公司，其股權分別由本公司、康帝實業、張丹丹女士及王愛兒女士持有57%、15%、15%及13%
Reporting Period 「報告期」或「報告期間」	the six months ended 30 June 2021 截至二零二一年六月三十日止六個月
RMB 「人民幣」	the lawful currency of the PRC 中國法定貨幣
SFO 「證券及期貨條例」	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong), as amended, supplemented or otherwise modified from time to time 香港法例第571章《證券及期貨條例》(經不時修訂、補充或以其他方式修改)
Share(s) 「股份」	share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, including the Domestic Share(s) and the H Share(s) 本公司股本中每股面值人民幣1.00元的股份，包括內資股及H股
Shareholder(s) 「股東」	holder(s) of the Share(s) 股份持有人
subsidiary or subsidiaries 「附屬公司」	has the meaning ascribed thereto in the Companies Ordinance (Chapter 622 of the laws of Hong Kong) 具有香港法例第622章《公司條例》賦予該詞的涵義
substantial shareholder(s) 「主要股東」	has the meaning ascribed thereto in the Hong Kong Listing Rules 具有香港上市規則賦予該詞的涵義
Supervisor(s) 「監事」	the members of the Supervisory Committee 監事會成員
Supervisory Committee 「監事會」	the Company's supervisory committee established pursuant to the PRC Company Law 本公司根據中國公司法設立的監事會

Definitions

釋義

Tongli Enterprise	Dongguan Tongli Enterprise Co., Ltd. (東莞市同力實業有限公司), a limited liability company established in the PRC on 23 June 2003 with 43% of its equity interest being held by Ms. Wang Aiqin, 29% by Ms. Wang Aici, 15% by Ms. Zhang Dandan (張丹丹) and 13% by Ms. Wang Aier (王愛兒), respectively, all of whom are members of the Wang Family, being aunts of Mr. Wang Junyang. Pursuant to a nominee arrangement among the Wang Family, (i) Ms. Wang Aici (an aunt of Mr. Wang Junyang) agreed to hold 16% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Junyang; (ii) Ms. Wang Aiqin (an aunt of Mr. Wang Junyang and the spouse of Mr. Chen Wangzhi) agreed to hold 15% and 6.5% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Junyang and Mr. Chen Wangzhi, respectively; and (iii) Ms. Wang Aiqin agreed to hold 15% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Wencheng (王文成)
「同力實業」	東莞市同力實業有限公司，一家於二零零三年六月二十三日在中國成立的有限公司，其股權分別由王愛勤女士、王愛慈女士、張丹丹女士及王愛兒女士持有43%、29%、15%及13%，彼等均為王氏家族的成員及王君揚先生的姑母或姨母。根據王氏家族中的代名人安排，(i) 王愛慈女士(王君揚先生的姑母)同意代表王君揚先生持有其於同力實業16%權益；(ii) 王愛勤女士(王君揚先生的姑母及陳旺枝先生的配偶)同意代表王君揚先生及陳旺枝先生分別持有其於同力實業15%權益及6.5%權益；及(iii) 王愛勤女士同意代表王文成先生持有其於同力實業15%權益
Wang Family	The family members of the founder of the Group, the late Mr. Wang Jincheng (王金城), including (i) his children; (ii) his siblings; (iii) the spouses of his siblings; and (iv) the children of his siblings
「王氏家族」	本集團創辦人已故王金城先生的家庭成員，包括(i) 其子女；(ii) 其兄弟姊妹；(iii) 其兄弟姊妹的配偶；及(iv) 其兄弟姊妹的子女
Xingda Property	Dongguan Xingda Property Investment Co., Ltd. (東莞市興達物業投資有限公司), a limited liability company established in the PRC on 14 December 2001 and one of the Controlling Shareholders holding approximately 8.22% interest in the Company. It is owned as to 50% each by Mr. Chen Wangzhi and Ms. Wang Aiqin. Xingda Property, Mr. Chen Wangzhi, Ms. Wang Aiqin, Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group and Xingye Group are acting together as a group of Controlling Shareholders
「興達物業」	東莞市興達物業投資有限公司，一家於二零零一年十二月十四日在中國成立的有限公司及我們其中一名控股股東，持有本公司約8.22%權益，其由陳旺枝先生及王愛勤女士各擁有50%。興達物業、陳旺枝先生、王愛勤女士、王君揚先生、王愛慈女士、康華集團及興業集團作為一組控股股東一致行動
Xingye Group	Dongguan Xingye Group Co., Ltd. (東莞市興業集團有限公司), a limited liability company established in the PRC on 15 April 1997 and one of the Controlling Shareholders holding approximately 7.48% interest in the Company. It is owned as to 50% by Mr. Wang Junyang, as to 37.5% by Dongguan Kangwei Industrial Investment Co., Ltd. (東莞市康偉實業投資有限公司) and as to 12.5% by Ms. Wang Aici, respectively. Xingye Group, Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group, Mr. Chen Wangzhi, Ms. Wang Aiqin and Xingda Property are acting together as a group of Controlling Shareholders
「興業集團」	東莞市興業集團有限公司，一家於一九九七年四月十五日在中國成立的有限公司及我們其中一名控股股東，持有本公司約7.48%權益，其由王君揚先生、東莞市康偉實業投資有限公司及王愛慈女士分別擁有50%、37.5%及12.5%。興業集團、王君揚先生、王愛慈女士、康華集團、陳旺枝先生、王愛勤女士及興達物業作為一組控股股東一致行動
%	percentage ratio
%	百分比比率





廣東康華醫療股份有限公司
Guangdong Kanghua Healthcare Co., Ltd.*

